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Miguel Angel Arévalo-González, Nayra Pérez-Delgado, Carmen Mora-Fernández and 
Juan F. Navarro-González
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Abstract: With this Editorial, we are hereby presenting to the reader the Special Issue on “Clinical
Research on Diabetic Complications”. Chronic complications of diabetes mellitus have a major
impact on the life of subjects with the disease, resulting in decreased quality of life and increased
morbidity and mortality. This Special Issue includes contributions addressing different clinical
aspects of the natural history, prevention and prediction, and characterization and management of
diabetes-related complications.
Keywords: diabetic macroangiopathy; cardiovascular disease; heart disease; cerebrovascular disease;
peripheral artery disease; diabetic foot disease; diabetic microangiopathy; diabetic retinopathy;
diabetic kidney disease; diabetic neuropathy
Diabetes mellitus is associated with the development of chronic complications as a result of
long-term exposure to hyperglycemia [1]. Diabetes-related complications are roughly divided between
those affecting macrovessels (macroangiopathy or macrovascular complications), and those affecting
microvessels (microangiopathy or microvascular complications). However, we currently know that we
should have a more holistic view, beyond the traditional classification into micro- and macrovascular
complications, as diabetes may affect any specific tissue or cell type. We have several articles of the
latter concept in this Special Issue (e.g., diabetes-related cognitive impairment). The great burden
of diabetes-related complications entails preventing or delaying its appearance as a main goal of
diabetes management [2].
We have several articles dealing with diabetic macroangiopathy. One of the main pieces of
research of this Special Issue, an article by Lin et al., deals with a very relevant topic in the field of
cardiovascular disease prevention in diabetes. The authors performed a systematic literature search and
a meta-analysis of randomized controlled trials of aspirin use for primary prevention of cardiovascular
disease that points to a favorable balance between the risks and benefit of the use of this preventive
treatment in individuals with diabetes. In another paper, Castelblanco et al. performed a study
using ultrasound tissue characterization of carotid atherosclerotic plaques in which they found that
plaques from type 1 diabetic subjects have a different pattern, with increased calcium plaque content,
from that of non-diabetic individuals. Further, in another study by the same group, the circulating
concentrations of soluble CD36, a potential cardiovascular risk biomarker, was only weakly associated
with type 2 diabetes but not with type 1 diabetes. In addition, the work of Li et al. found that the
increased arterial stiffness in prediabetes is mainly associated to postprandial glucose (i.e., subjects with
impaired glucose tolerance). The proof-of-concept study of Donate-Correa and colleagues showed the
potential involvement of the FGF23/Klotho system on the pathogenesis of diabetic foot disease. Finally,
regarding diabetes-related cardiovascular disease, in a review paper García-Carro and colleagues
wrote an overview of the current strategies and mechanisms of therapies that have demonstrated reno-
and cardioprotective effects.
J. Clin. Med. 2019, 8, 2193; doi:10.3390/jcm8122193 www.mdpi.com/journal/jcm1
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Two original articles contribute to greater insight in the field of diabetic microangiopathic
complications. First, Cabré et al. showed that the measurement of dermal electrochemical conductance
may be a useful tool to screen diabetic peripheral neuropathy. Further, a paper by Granado-Casas et al.
showed that in subjects with type 1 diabetes, those with retinopathy had a poorer quality of life in the
absence of other major diabetic complications.
As pointed out above, diabetes may have a deleterious effect on any cell type. A clear example of
this is the impact of diabetes on cognitive function, indicating the metabolic damage on the central
nervous system. We have several original articles addressing this issue. In a study by Simó-Servat et al.,
the authors found gaze fixation abnormalities in subjects with type 2 diabetes (T2D) associated with
cognitive status; they concluded that microperimetry to measure parameters of fixation may be a
method to detect prodromal stages of dementia. Further, Ogama et al. found that subjects with type 2
diabetes and sarcopenia, among those with cognitive impairment, showed higher glucose variability.
Finally, Kim and coworkers provide us with a very interesting piece of work where they describe
that the use of dipeptidyl peptidase-IV inhibitors, compared to sulfonylureas, in elderly subjects with
type 2 diabetes is associated with a lower risk of dementia in real-world settings.
The rest of the articles of this Special Issue also address relevant questions. A pilot study by
Ciudin et al. show the potential of a genetic tool to predict the response to bariatric surgery of subjects
with type 2 diabetes. In search of new biomarkers, Del Coco et al. describe a new metabolic serum
signature associated with the progression and burden of complications of type 2 diabetes. Finally,
Wu et al. use a nationwide database to show that individuals treated with hemodialysis from Taiwan
hold a lower risk of developing type 2 diabetes.
To conclude, we should underline that we are far from the optimal knowledge of diabetes-related
complications. We need much more research efforts to provide clinicians with new tools to prevent
and manage chronic diabetic complications.
Conflicts of Interest: The author declares no conflicts of interest.
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Abstract: Introduction: The aim of this pilot study was to assess genetic predisposition risk scores
(GPS) in type 2 diabetic and non-diabetic patients in order to predict the better response to bariatric
surgery (BS) in terms of either weight loss or diabetes remission. Research Design and Methods:
A case-control study in which 96 females (47 with type 2 diabetes) underwent Roux-en-Y gastric
by-pass were included. The DNA was extracted from saliva samples and SNPs were examined and
grouped into 3 GPS. ROC curves were used to calculate sensitivity and specificity. Results: A highly
sensitive and specific predictive model of response to BS was obtained by combining the GPS in
non-diabetic subjects. This combination was different in diabetic subjects and highly predictive of
diabetes remission. Additionally, the model was able to predict the weight regain and type 2 diabetes
relapse after 5 years’ follow-up. Conclusions: Genetic testing is a simple, reliable and useful tool for
implementing personalized medicine in type 2 diabetic patients requiring BS.
Keywords: diabetes; obesity; bariatric surgery
1. Introduction
Obesity represents a major public health problem and it is associated with a significant economic
burden on the health systems of developed countries, mainly due to the associated co-morbidities.
Among these co-morbidities, type 2 diabetes (T2D) is one of the most important.
Bariatric surgery (BS) is a successful treatment for morbid obesity and leads to a dramatic
improvement in obesity-related comorbidities [1]. The remission rate of T2D after BS is around 60–70%
after 1 year of follow-up [2]. Therefore, there is a significant proportion of non-responders to BS in
terms of diabetes remission. Additionally, after 5 years, there is about a 20–35% relapse of T2D after
Y-de-Roux gastric by-pass (RYGB) [3–5]. A score based on clinical variables for the pre-operative
prediction of T2D remission following RYGB surgery (DiaRem) was proposed [6]. However, this model
has several limiting factors [7] and it has not been generally adopted in clinical practice. At present,
there are no reliable predictors of T2D remission and relapse after BS.
In recent years, interest in the genetic influence on the response of different treatments for obesity
has increased. Two retrospective studies [8,9] showed that several single nucleotide polymorphisms
J. Clin. Med. 2019, 8, 964; doi:10.3390/jcm8070964 www.mdpi.com/journal/jcm3
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(SNPs) were associated with a poor response to BS. However, in these studies the discrimination
capacity of the GPS was not significant, and the role of T2D in the response to BS and the impact of
these genetic factors on diabetes remission were not evaluated.
On this basis, the aim of the present study was to evaluate whether genetic markers can be used
for the prediction of adequate weight loss and diabetes remission after BS.
2. Material and Methods
A single-center, retrospective observational pilot study in a third-level university hospital
(Vall d´Hebron University Hospital, Barcelona, Spain) was conducted following the Strengthening
the Reporting of Observational Studies in Epidemiology guidelines. The study comprised patients
that underwent RYBG surgery between January 2010 and December 2012. The inclusion criteria were
women, stable weight in the prior 6 months before BS, and minimum of 5 years of follow-up after
BS. In order to avoid heterogeneity and given that the vast majority of the patients under bariatric
surgery were women, we decided to rule out the inclusion of men in this pilot study. The patients
were informed about the study and they all signed the written informed consent form.
The exclusion criteria were male, marked mobility problems, a different BS technique apart
from RYBG, and severe psychiatric or eating disorders. For the genetic study, a sample of saliva was
collected. The characteristics of RYBG were food loop length: 150–180 cm, and bilio-pancreatic loop
length: 120 cm, gastric pouch 30 cc3. The technique was the same in all cases, performed by the same
surgical team in our hospital.
Excess body weight (EBW) was defined as the amount of weight that was in excess of the ideal
body weight (IBW). The percentage of excess weight loss (EWL) was calculated according to the
formula: %EWL = (weight before BS (kg) −weight after BS (kg)/EBW(kg)) × 100. The post-BMI weight
regain was defined as a 10% regain of the minimal weight after BS. The minimal weight after BMI was
achieved at 2 years follow-up for all of the patients.
Diabetes remission was defined according to American Diabetes Association (ADA) criteria [10].
Relapse of T2D was defined as one or more of the following conditions: (a) restarting diabetes
medication; (b) one or more HbA1c measures ≥ 6.5%; and/or (c) one or more fasting glucose measures
≥ 126 mg/dL [11].
The study was approved by the Local Ethics Committee and registered at Clinical.Trials.gov,
NCT02405949.
2.1. Genotyping and Sequencing
The DNA was extracted from saliva samples and processed by GoldenGate® Genotyping Assay
for VeraCode. The genetic predisposition was assessed using Nutri inCode (NiC) (Ferrer inCode) and
selecting the 57 SNPs associated with susceptibility to diabetes, obesity, appetite regulation, weight
loss in response to hypocaloric diet, and the response to BS. The details about the SNPs are reflected
in the Supplementary Materials. The selected SNPs were grouped into three genetic predisposition
risk scores (GPS): diabetes remission, weight loss in non-diabetic subjects, and weight loss in subjects
with diabetes.
2.2. Statistical Analysis
In order to assess the best predictive GPS, patients were distributed into 4 subgroups according
to the BS response (%EWL) and the presence of T2D: (1) %EWL < 40% without diabetes (n = 15);
(2) %EWL < 40% with diabetes (n = 16); (3) %EWL > 75% without diabetes (n = 35); and (4) T2D and
%EWL > 75% with diabetes (n = 31). Univariate and multivariate logistic regressions were used to
establish associations. Akaike Information Criterion (AIC)-based backward selection was used to
remove insignificant terms from an initial model containing all the candidate predictors. The calibration
of the model’s adequacy was determined by the Hosmer–Lemeshow test. The area under the ROC
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curve (AUROC) was used for evaluating the prediction performance of the models. The cut-offs for
the developed algorithms were selected as the point which maximizes the Youden index.
3. Results
The clinical characteristics of the patients included in the study are shown in Table 1. Apart from
age, we did not find any significant differences between diabetic and non-diabetic subjects before
BS. The diabetic treatment received by subjects with diabetes is displayed in Figure 1. No other
medication apart from AINEs occasionally and vitamin supplements as per protocol after bariatric
surgery (ciancobalamin 1000 mcg/month, colecalciferol 25.000–100.000 UI/month) were administered.
Table 1. Baseline characteristics of the patients included in the study.
Non-Diabetic Patients Type 2 Diabetic Patients p
N 50 47
Age (years) 48.0 (37.5; 55.0) 52.0 (46.0; 58.8) 0.0016
Initial BMI (Kg/m2) 45.2 (43.0; 48.5) 42.5 (40.1; 46.4) 0.008
2 y post-BS BMI (Kg/m2) 31.8 (26.1; 35.6) 30.9 (26.8; 35.7) n.s.
5 y post-BS BMI (Kg/m2) 32.63 (21; 52.14) 33.68 (21; 46.43) n.s.
Hypertension (%) 48.3 49.5 n.s.
Dyslipidemia (%) 43.2 45.7 n.s.
Sleep apnea (%) 27.2 29.7 n.s.
In the subgroup of the non-diabetic patients, the multivariate logistic regression equation for
predicting positive weight loss response (%EWL > 75%) after the BS (NiC-Bariatric-ND) includes
SNPs associated with weight loss in response to a hypocaloric diet and SNPs associated to appetite
regulation. The model showed an AUROC of 0.763 (95% CI 0.605 to 0.920; p < 0.001), a sensitivity of
86.49%, and a specificity of 57.14%. The calibration of the adequacy of the model determined by the
Hosmer–Lemeshow test was 0.679.
The continuous variables were median (1st quartile; 3rd quartile) and the categorical data were
percentages. BMI: body mass index. EWL: excess of weight loss. BS: bariatric surgery. Hypertension
was defined by increased systolic (≥140 mmHg) or increased diastolic (≥90 mmHg) blood pressure or by
the use of antihypertensive drugs, according to current guidelines. Dyslipidemia was defined by the use
of lipid-lowering drugs, decreased values of HDL cholesterol (men< 0.9 mmol/L, women < 1.0 mmol/L)



















Figure 1. The diabetic treatment received before BS by the subjects with diabetes included in the study.
SU: sulphonylurea, iDPPIV: DPPIV enzyme inhibitor, GLP-1AR: GLP-1 receptor agonists.
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Weight regain after 5 years’ follow-up was seen in 9.6% of the patients. The model to identify
the patients who had presented weight regain after 5 years’ follow-up showed an AUROC of 0.834
(95% CI 0.705 to 0.923; p < 0.0001), a sensitivity of 100%, and a specificity of 70.21%. The calibration of
the adequacy of the model determined by the Hosmer–Lemeshow test was 0.5148.
In T2D patients, the multivariate logistic regression equation for the prediction of weight loss
response (%EWL > 75%) after BS (NiC-Bariatric-D) included SNPs associated with weight loss in
response to hypocaloric diet, SNPs associated to response to BS [9], and SNPs associated to response to
lifestyle interventions [11]. The model showed an AUROC of 0.929 (95% CI 0.850 to 0.99; p < 0.001),
a sensitivity of 87.10% and a specificity of 93.33%. The calibration of the model’s adequacy determined
by the Hosmer–Lemeshow test was 0.291. Weight regain in subjects with diabetes was observed in
17.5% of them. The model to identify patients with diabetes who will regain weight after a follow-up of
5 years after bariatric surgery showed in this case an AUROC of 0.781 (95% CI 0.623 to 0.896; p < 0.04),
a sensitivity of 71.43%, and a specificity of 84.85%. The calibration of the model’s adequacy determined
by the Hosmer–Lemeshow test was 0.8664. Figure 2 shows the AUROC corresponding to weight regain
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Figure 2. The predictive capacity of the genetic score for weight regain after 5 years’ follow-up in the
whole (A) population, non-T2D subjects (B), and T2D patients (C).
Diabetes remission was seen in 73.91% of the type 2 diabetic patients included in the study
(66.67% in the group of %EWL < 40% and 77.42% in the group of %EWL > 75%). Diabetes relapse was
seen in 25% of the patients.
The multivariate logistic regression equation for the prediction of diabetes remission and relapse
after BS (NiC-Bariatric-DR) included SNPs associated with obesity, SNPs associated with weight loss
in response to hypocaloric diet, SNPs associated with appetite regulation, and SNPs associated with
genetic predisposition to diabetes. This prediction model showed an AUROC of 0.868 (95% CI 0.709
to 0.976; p < 0.0001) for diabetes remission, with a sensitivity of 76.47% and a specificity of 83.33%.
In our population, the AEROC for DiaRem was lower than obtained by genetic testing, (0.69 versus
0.86), and when both scores were combined, the AUROC was 0.87, with a sensitivity of 88.49% and a
specificity of 80% (Figure 3).
Figure 3. The predictive capacity of the DiARem score and the combination between DiARem and
genetics in our study population. The AUROC for DiaRem was lower than obtained by genetic test
(0.69 versus 0.86), and when both scores were combined the AUCROC was 0.87, with a sensitivity of
88.49% and a specificity of 80.00%.
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Regarding diabetes relapse after 5 years, the model based showed an AUROC of 0.833 (95% CI
0.682 to 0.932; p < 0.0001), with a sensitivity of 90.00 and a specificity of 80.00 (Figure 4). The calibration
of the adequacy of the model determined by the Hosmer–Lemeshow test was 0.280.
Figure 4. The predictive capacity of the genetic score for T2D relapse after 5 years’ follow-up.
4. Discussion
Bariatric surgery provides adequate and sustainable weight loss and T2D remission, but 15–20%
of the subjects do not reach these targets [12]. A recent study [13] showed a high inter-individual
variability of the EWL response at mid-term after BS and that poor EWL could be illustrated by
two different patterns: poor sustained weight loss or pronounced weight regain. At present, there
are no reliable biomarkers for individual response to BS. Due to the increasing availability of BS
around the world and the alarming prevalence of obesity and its associated co-morbidities such
as T2D, the discovery of biomarkers that will permit us to identify the best candidates for BS are
urgently needed.
In the present study, we developed genetic-based algorithms for the prediction of %EWL after
BS and for T2D remission with high sensitivity and specificity. Still et al. [8] proposed a genetic score
to predict the %EWL after BS, showing a non-statistically significant AUROC, a sensitivity of 48.39,
and a specificity of 73.33. In addition, this score did not take into the account the presence of diabetes.
Regarding diabetes remission after BS, we analyzed for comparison purposes the predictive
capacity of DiARem scores [8] in our study population. In our population, the AUROC for DiaRem
was lower than obtained by genetic test (0.69 versus 0.86), and when both scores were combined,
the AUCROC was 0.87, with a sensitivity of 88.49% and a specificity of 80.00%. This finding supports
the use of genetic testing in clinical practice.
It is worth mentioning that in diabetic patients, the rate of remission was not significantly different
between the group with %EWL < 40% and the group with %EWL > 75% (p = 0.674). In addition,
previous data showed that about 30% of T2D patients that are able to discontinue the medication after
BS will present a relapse within the first 5 years [3–5]. Some studies found weak correlation between
weight regain, younger age or lower BMI before BS as predictors of T2D relapse after BS [5,14], while
other studies found no association [3]. Therefore, at present, there are no reliable predictors of T2D
relapse after BS. In our study, the proposed score showed a high predictive value of T2D relapse after
BS, thus, underlying the potential key role of genetic testing in precision medicine in order to assure
better outcomes after BS. Interestingly, in our study, in the subgroup of T2D patients, the inclusion of
SNPs associated to response to BS did not improve the prediction scores, suggesting that these genes
are not critical or do not intervene in the remission and relapse of T2D. This finding suggests that the
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physiopathology of diabetes remission and relapse after RYGB might not be related with the %EWL in
this population.
Overall, these results are intriguing and point to a genuine genetic background in the mechanisms
involved in diabetes remission and relapse after BS, perhaps related to insulin resistance.
In conclusion, in this pilot study we have developed highly sensitive and specific genetic predictive
scores of responses to BS in terms of weight loss and T2D remission and the long-term sustainability of
these effects. These results would allow us not only to implement a more effective and personalized
BS, but also to optimize healthcare resources. However, further studies with a larger sample size to
confirm this pilot study are needed.
Supplementary Materials: The supplementary materials are available online at http://www.mdpi.com/2077-0383/
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Abstract: Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia
associated with alterations in carbohydrate, lipid, and protein metabolism. The prognosis of T2DM
patients is highly dependent on the development of complications, and therefore the identification
of biomarkers of T2DM progression, with minimally invasive techniques, is a huge need. In the
present study, we applied a 1H-Nuclear Magnetic Resonance (1H-NMR)-based metabolomic approach
coupled with multivariate data analysis to identify serum metabolite profiles associated with T2DM
development and progression. To perform this, we compared the serum metabolome of non-diabetic
subjects, treatment-naïve non-complicated T2DM patients, and T2DM patients with complications in
insulin monotherapy. Our analysis revealed a significant reduction of alanine, glutamine, glutamate,
leucine, lysine, methionine, tyrosine, and phenylalanine in T2DM patients with respect to non-diabetic
subjects. Moreover, isoleucine, leucine, lysine, tyrosine, and valine levels distinguished complicated
patients from patients without complications. Overall, the metabolic pathway analysis suggested that
branched-chain amino acid (BCAA) metabolism is significantly compromised in T2DM patients with
complications, while perturbation in the metabolism of gluconeogenic amino acids other than BCAAs
characterizes both early and advanced T2DM stages. In conclusion, we identified a metabolic serum
signature associated with T2DM stages. These data could be integrated with clinical characteristics to
build a composite T2DM/complications risk score to be validated in a prospective cohort.
Keywords: branched-chain amino acids; metabolomics; NMR spectroscopy; type 2 diabetes mellitus
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1. Introduction
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia associated
with impairments in carbohydrate, lipid, and protein metabolism [1]. DM is classified in two main
categories: type 1, due to cellular-mediated autoimmune pancreatic islet β-cells destruction which
occurs in 5–10% of cases, and type 2 (T2DM), due to insulin resistance (IR) with a defect in compensatory
insulin secretion, which affects 90% of diabetic patients [2]. Environmental and lifestyle changes in
association with populations aging account for the rapid global increase in T2DM prevalence and
incidence in recent decades [3]. A comprehensive summary of factors contributing to T2DM risk
includes not only obesity and related aspects of diet quality and quantity, but also sedentary lifestyle
and lack of physical activity, exposure to noise or fine dust, short or disturbed sleep, smoking, stress,
depression, and a low socioeconomic status [4]. Chronic hyperglycemia leads to many long-term
complications, such as cardiovascular disease (CVD), cerebrovascular disease, peripheral vascular
disease, neuropathy, retinopathy, and renal failure, resulting in increasing disability, reduced life
expectancy, and increased health costs [5]. The prognosis of patients with T2DM is highly dependent
on the development of complications; the prevalence of patients with cardiovascular complication is
growing exponentially and most T2DM patients die as a result of cardiovascular causes.
Despite the recently introduced therapies to manage T2DM, the progressive nature of IR and the
inability of β-cells to cope with increased insulin demand still obligate insulin therapy for selected
clusters of patients to achieve and maintain adequate glycemic control [6–8].
Because of the risks and benefits of treatments, the care of patients with T2DM involves complex
decision-making [9]. Therefore, the identification of biomarkers of metabolic worsening in T2DM is of
clinical relevance.
Recently, several metabolomic techniques were applied to the identification of metabolic
signatures associated with T2DM [10–17]. Data in this research field were extensive, revealing
new diagnostic/prognostic disease biomarkers [14], or metabolic markers of response to targeted
therapies [15,16]. Metabolomics also provided tools for patient’s stratification and recognizable
metabolic patterns associated with organ dysfunction [17]. These studies focused on the diagnostic
value of metabolic signatures in prospective cohorts, while the metabolic comparison of T2DM patients
at different stages of the disease was less investigated. To do this, we took advantage of a selected
cohort of T2DM patients that we characterized in our previous works [18–23].
Here, we aimed to identify, by a 1H-Nuclear Magnetic Resonance (1H-NMR)-based metabolomic
approach coupled with multivariate data analysis, a serum metabolic signature associated with T2DM
development and progression. The study design is characterized by the comparison of opposite
phenotypes: non-diabetic subjects and two subsets of T2DM patients—T2DM patients at an early stage
of the disease (without complications and treatments) and at a late stage (with diabetic complications
on insulin monotherapy).
2. Materials and Methods
2.1. Patient Samples
Enrolled patients were accurately selected from a large cohort of Italian T2DM patients and control
subjects, recruited from the Italian National Research Center on Aging (INRCA), Ancona. All subjects
provided written informed consent, which was approved by the INRCA’s Ethics Committee. The
inclusion criteria for T2DM patients and the clinical information collected from each subject were as
described by Testa et al. [24].
We selected 26 T2DM patients and seven control subjects with comparable age, body mass index
(BMI), lipid plasma profile, and gender distribution. All studied subjects consumed a Mediterranean
diet. Subjects were considered as controls if at the time of blood collection they did not have T2DM
and any major acute and/or chronic age-related diseases such as acute myocardial infarction, chronic
heart failure, Alzheimer’s disease, or cancer. Among the 26 T2DM patients, we selected 13 patients
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without complications and 13 patients with documented complications on insulin monotherapy at the
time of blood collection. The presence/absence of diabetic complications was established as follows:
(1) retinopathy was defined as dilated pupils detected on funduscopic and/or
fluorescence angiography;
(2) incipient nephropathy was a urinary albumin excretion rate >30 mg/24 h and normal
creatinine clearance;
(3) chronic renal failure was defined as an estimated glomerular filtration rate <60 mL/min per
1.73 m2, based upon the four-variable modification of diet in renal disease (MDRD) formula;
(4) neuropathy was established by electromyography;
(5) ischemic heart disease was diagnosed by clinical history and/or ischemic electrocardiographic
alterations; these patients had had ST- or non-ST-elevation myocardial infarction, which was
defined as a major adverse cardiac event (MACE);
(6) Peripheral vascular disease, including arteriosclerosis obliterans and cerebrovascular disease,
was diagnosed based on history, physical examination, and Doppler imaging.
Each patient could be affected by more than one complication (Table 1).
Table 1. Number and type of complications in T2DM-C patients.
Number








Chronic renal failure 4/13
Lower limb arteriopathy 5/13
Mace 5/13
Uncomplicated patients were recruited within one month of diagnosis and had not received
any specific pharmacological treatment for diabetes at the time of the blood collection. Other drugs
prescribed to diabetic patients are shown in the Table 2. To avoid possible bias due to different
treatments, T2DM patients taking glucose-lowering drugs others from insulin were excluded.
Table 2. Drug treatment prescribed to T2DM patients.
T2DM-NC T2DM-C
ACE inhibitors 1 8
Diuretics - 5
Vasodilators - 4
Beta blockers - 4
Antiarrhythmic drugs - 2
Calcium channel blockers - 3
Statins 1 1
Antiplatelet drugs - 5
NSAIDs - 7
Proton-pump inhibitors 1 2
CNS agents 2 2
Abbreviations: ACE = angiotensin-converting-enzyme; Abbreviations: NSAIDs = nonsteroidal anti-inflammatory
drugs; CNS = central nervous system.
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2.2. Laboratory Assays
Overnight fasting venous blood samples were collected from 08:00 to 10:00 h. Blood
concentration of glycosylated hemoglobin (HbA1c) was measured by a G8 HPLC analyzer (TOSOH
BIOSCIENCE, Tokyo, Japan). Plasminogen activator inhibitor-1 (PAI-1) antigen was quantified with an
immune-enzymatic method (Biopool, Sweden). Total and high-density lipoprotein (HDL) cholesterol,
triacylglycerols (TAG), fasting insulin, fasting glucose, fibrinogen, apolipoprotein AI and B (ApoAI
and ApoB), and creatinine were measured using commercially available kits on an automated clinical
chemistry COBAS Modular Platform (C module) analyzer (Roche-Hitachi, Basel, Switzerland). Highly
sensitive C-reactive protein (hsCRP) was determined by the particle-enhanced immune-turbidimetric
assay (CRP High Sensitive, Roche-Hitachi) on a COBAS analyzer. The homeostasis model assessment
(HOMA) index was calculated as glucose (mg/100 mL)*insulin (uIU/mL)/405. BMI was calculated
as weight divided by height squared (kg/m2). α-Fucosidase and β-galactosidase were quantified
as described by Spazzafumo et al. [25]. Insulin growth factor 1 (IGF1) level was quantified with a
commercially available ELISA kit.
2.3. Sample Preparation and NMR Measurements
Serum samples were stored at a temperature of −80 ◦C until the NMR measurements were
performed. Prior to NMR analysis, serum samples were thawed and an aliquot of 200 μL was mixed
with 400 μL saline buffer solution (in 100% D2O containing TSP as a chemical shift reference, δ = 0 ppm,
NaCl 0.9%, 50 mM sodium phosphate buffer and pH 7.4) to minimize the pH variation and transferred
in a 5 mm NMR tube [26]. All measurements were performed on a Bruker Avance III 600 Ascend NMR
spectrometer (Bruker, Ettlingen, Germany), operating at 600.13 MHz for 1H observation, equipped
with a TCI cryoprobe (Triple Resonance inverse Cryoprobe) incorporating a z-axis gradient coil and
automatic tuning-matching (ATM). Experiments were acquired at 300 K in automation mode after
loading individual samples on a Bruker Automatic Sample Changer, interfaced with the IconNMR
software (Bruker). For each sample, two types of 1D 1H-NMR experiments were recorded: a standard
(ZGCPPR Bruker standard pulse sequence) spectrum, with pre-saturation and composite pulse for
selection, and a Carr–Purcell–Meiboom–Gill (CMPG) spin-echo sequence, with 32 transients, 16 dummy
scans, 5 s relaxation delay, size of FID (free induction decay) of 64 K data points, spectral width
of 12,019.230 Hz (20.0276 ppm), an acquisition time of 1.36 s, a total spin-spin relaxation delay of
1.2 ms, and solvent signal saturation during the relaxation delay. The resulting FIDs were multiplied
by an exponential weighting function corresponding to a line broadening of 0.3 Hz before Fourier
transformation, automated phasing, and baseline correction. Moreover, peak assignments were carried
out using 2D NMR experiments (1H-1H J-resolved, 1H-1H COSY, Correlation Spectroscopy, 1H-13C
HSQC Heteronuclear Single Quantum Correlation, 1H-13C HMBC, Heteronuclear Multiple Bond
Correlation) and by comparison with published data [26,27].
2.4. Metabolic Pathway Analysis
The most relevant metabolic pathways potentially involved in the metabolomic study were
identified using MeTPA MetaboAnalyst software [28]. The purpose is to investigate if certain metabolic
pathways are significantly different for the two groups of patients, when compared with control
subjects and also whit each other. Metabolites of interest previously quantified by selected distinctive
unbiased NMR signals were used as the input matrix for the metabolic pathway analysis. The pathway
impact is calculated as the sum of the importance measures of the matched metabolites normalized by
the sum of the importance measures of all metabolites in each pathway [29].
2.5. Statistical Analysis
All clinical parameters were computed with Excel (Microsoft 7) and presented as mean ± SD. The
comparison among the data was made using one-way repeated measures ANOVA. Further comparisons
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were made by using paired-sample t-test. The SPSS/PC computer program (SPSS, Chicago, IL, USA)
was used to perform all statistical analyses. Statistical significance was set at p ≤ 0.05.
The metabolic profile of serum samples from controls and T2DM patients at different stages were
analyzed by NMR. The 1H-NMR Carr–Purcell–Meiboom–Gill (CPMG) spectra were processed using
Topspin 3.5 and Amix 3.9.13 (Bruker, Biospin, Italy), both for simultaneous visual inspection and the
successive bucketing process. The full NMR spectra (in the range 9.0–0.5 ppm) were segmented in
fixed rectangular buckets of 0.04 ppm width and successively integrated. The spectral region between
5.10 and 4.7 ppm was discarded because of the residual peak of water. The total sum normalization
was applied to minimize small differences due to sample concentration and/or experimental conditions
among samples. The data set (bucket table) resulted in a matrix, made of 204 variables, corresponding
to the bucketed 1H-NMR spectra values (in columns), measured for each sample (in rows). Multivariate
statistical analysis was performed using MetaboAnalyst software [28]. Unsupervised principal
component analysis (PCA), and partial least squares/supervised orthogonal partial least squares
discriminant analysis (PLSDA and OPLSDA, respectively) were applied to examine the intrinsic
variation in the data, and also to screen out potential biomarkers [30]. In particular, OPLSDA analysis
focuses the predictive information in one component, so that the first OPLS component shows the
between-class difference. The remaining systematic information is transferred in higher components,
thus facilitating interpretation. Two parameters, R2 and Q2, describe the goodness of the statistical
models. The former (R2) explains the total variations in the data, whereas the latter (Q2, calculated
via 10-fold cross-validation, CV) provides an estimate of the predictive ability of the models [31].
By 1H-NMR spectroscopy, metabolites of interest were quantified by analyzing the integrals of selected
distinctive unbiased NMR signals [32–34]. Results, represented as mean intensities and standard
deviation of the selected NMR signals, were validated by one-way ANOVA with Tukey’s honestly
significant difference (HSD) post-hoc test. To better visualize data, a heatmap was performed on
metabolites and samples, using Euclidean for distance measure and Ward for the clustering algorithm.
Then, to identify the potential biomarkers associated with T2DM disease in patients with complications
(T2DM-C), the receiver operating characteristic (ROC) curve was applied, using the Biomarker Analysis
module of the MetaboAnalyst software. Multivariate ROC curve exploratory analysis was used to
identify the promising biomarkers with high sensitivity and high specificity. The ROC curves were
generated using Monte–Carlo cross validation (MCCV) algorithm and linear Support Vector Machines
(SVM) clustering to evaluate the feature importance of the selected metabolites [35]. Both univariate
and multivariate statistical analyses were performed using MetaboAnalyst software [28].
3. Results
3.1. Clinical Characteristics
Three different selected groups of subjects were included for this investigation: non-diabetic
subjects, referred as the control group (CG) and two different groups of T2DM patients, with or without
complications and insulin treatment. Patients with complications on insulin monotherapy were
indicated as T2DM-C; patients without complications and treatments were indicated as T2DM-NC.
Clinical characteristics of CG and T2DM groups are summarized in Tables 1 and 3. There was no
significant difference in age (range 60–68 years) and BMI between groups. All subjects were overweight
as confirmed by BMI values exceeding 25, with prevalence in android obesity as indicated by the
waist to hip ratio (WHR). Fasting plasma glucose level was significantly higher in both T2DM groups
compared to CG and significantly different (p < 0.05) between T2DM groups. In both T2DM groups,
HbA1c and HOMA were higher than in CG, especially in T2DM-C (p < 0.001 and p < 0.005, respectively,
T2DM-C vs. CG). It is important to note that insulin treatment holds plasma insulin levels to values
not significantly different from that of other groups, so that metabolic changes we measured in our
study cannot be related to defects in insulin secretion.
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Table 3. Clinical information for control group (CG) and type 2 diabetes mellitus (T2DM) patients
(T2DM-NC and T2DM-C) enrolled in the study. (T2DM-C: patients with complications on insulin
monotherapy; T2DM-NC: without complications).
CG T2DM-NC T2DM-C
Number of subjects (n) 7 13 13
Male gender (n, %) 4, 57.1% 8, 61.5% 7, 53.8%
Age (years) 63 ± 2 64 ± 3 64 ± 4
BMI (kg/m2) 26.94 ± 3.05 28.78 ± 4.05 29.31 ± 3.82
WHR 0.90 ± 0.07 0.94 ± 0.06 0.94 ± 0.06
Fasting glucose (mg/dL) 93 ± 6.2 165 ± 59.4 ***,b 247 ± 65.0 ***,a
HbA1c (%) 5.68 ± 0.38 6.92 ± 0.90 ***,b 8.87 ± 1.73 ***,a
Fasting insulin (mU/L) 5.2 ± 1.6 9.2 ± 7.8 8.5 ± 4
hsCRP (mg/L) 2.4 ± 2.1 3.5 ± 3.1 3.9 ± 2.8
PAI-1 (ng/mL) 18.9 ± 5.7 24.7 ± 11 16 ± 8*
Creatinine (mg/dL) 0.81 ± 0.17 0.91 ± 0.19 1.33 ± 0.70 *
Azotemia (mg/dL) 38 ± 7.9 38 ± 9.7 b 54 ± 30 **,a
Ferritin (ng/mL) 111 ± 71 236 ± 177 ** 140 ± 113
Total cholesterol (mg/dL) 237 ± 25 230 ± 36 215 ± 43
HDL cholesterol (mg/dL) 59 ± 11 58 ± 15 51 ± 14
LDL cholesterol (mg/dL) 141 ± 24 136 ± 36 116 ± 34
Triglycerides (mg/dL) 106 ± 46 142 ± 128 160 ± 95
ApoB (mg/dL) 109 ± 2 112.8 ± 30 105.1 ± 30
IGF1 (ng/mL) 32.7 ± 6.5 38.5 ± 9.7 32.9 ± 5.8
β-Galactosidase (nM/ml/h) 5.47 ± 1.73 3.77 ± 3.11 6.65 ± 3.87
α-Fucosidase (nM/ml/h) 374 ± 179 328 ± 208 389 ± 219
HOMA-IR 1.2 ± 0.4 2.9 ± 2.0 * 4.3 ± 1.9 ***
eGRF (ml/min) 89.7 ± 28.1 82.8 ± 14.7 60.5 ± 25.3 *
Disease duration (years) n/a n/a 22 ± 12
Values are given as the mean ± SD. p values were obtained by ANOVA and post-Tukey. *, ** and *** refer to a p-value
< 0.05, 0.005 and < 0.001, respectively, for the type 2 diabetes mellitus (T2DM) classes versus control group (CG).
Different letters represent significant differences among different T2DM groups. T2DM-C = T2DM patients with
complications and insulin treatment; T2DM-NC = T2DM patients without complications and treatment; BMI = body
mass index; WHR = waist to hip ratio; PAI-1 = plasminogen activator inhibitor-1; IGF1 = Insulin growth factor;
HOMA-IR =Homeostatic Model Assessment for Insulin Resistance; eGRF = estimated glomerular filtration rate;
ApoB = apolipoprotein B; hsCRP = highly sensitive C-reactive protein.
PAI-1, azotemia and creatinine were significantly increased in T2DM-C. No significant changes
in IGF1, β-galactosidase, and α-fucosidase levels were observed between groups. All patients were
hyperlipidemic, with no significant differences in their plasma total cholesterol, low-density lipoprotein
(LDL), HDL, ApoB, and TAG levels. Ferritin level was significantly higher in T2DM-NC compared to
CG (Table 3).
3.2. 1H-NMR Analysis of Serum Samples
Typical 1H-NMR CMPG (600 MHz) spectra of serum, obtained from CG and T2DM samples are
reported in Figure 1. Resonance assignments were performed according to the literature [36] and
further confirmed by 2D NMR spectra. A complex pattern of signals ascribable to aromatic molecules
(1), sugar moieties, and aliphatic metabolites (2) was shown (Figure 1), with some of the identified
metabolites reported for each different group. Although the NMR spectra appeared similar among
different serum samples, there were striking differences in peak intensities for the different groups.
The 1H-NMR spectra were dominated by high-intensity signals of sugars (α and β glucose) and
some high molecular weight metabolites, such as lipoproteins (very low and low density lipoprotein,
VLDL/LDL). As expected, a significant increase in sugar content was observed in T2DM patients
(with or without complications) compared to the CG. Small molecules, as branched-chain amino
acids (leucine, isoleucine, valine), aliphatic and aromatic amino acids (alanine, arginine, glutamine,
glutamate, methionine, glycine, phenylalanine, tyrosine), organic acids (lactate, formate, pyruvate,
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citrate, acetate, acetoacetate, β-hydroxybutyrate), osmolytes (choline, TMA-N-oxide), and others,
including methyl-histidine, N-acetyl-glycoproteins, dimethylamine (DMA), trimethylamine (TMA)
and creatinine were also identified [27].
Figure 1. Representative 1H CPMG (Carr–Purcell–Meiboom–Gill) NMR spectra of serum isolated from
different groups of diabetic (T2DM-NC, T2DM-C) and control (CG) patients. Aromatic, and sugar and
aliphatic regions with some identified metabolites were visualized.
3.3. Multivariate Analysis of NMR Data
Multivariate data analysis was applied to the NMR spectra for reducing the complexity and
the volume of the data. After the pre-processing of the NMR spectra, including the bucketing
process and total sum normalization to minimize small differences due to sample concentration and/or
experimental conditions among samples [36], both unsupervised (PCA) and supervised (PLSDA,
OPLSDA) multivariate statistical methods were applied. As a first attempt, PCA analysis was
conducted to display natural groupings of samples without imposing any preconception about class
membership, allowing the general trend display and the identification of potential outliers among
samples. Supervised statistical methods, such as PLSDA and OPLSDA analyses, were also applied in
order to search for discriminating features and potential biomarkers, responsible for the separation
between groups. In particular, pairwise multivariate (PCA, PLSDA, OPLSDA) analyses were obtained
comparing the CG vs. T2DM-NC (Figure 2) and the CG vs. T2DM-C groups (Figure 3). Moreover,
T2DM patients were also compared with each other (T2DM-C vs. T2DM-NC, Figure 4). The PCA score
plot obtained for CG and T2DM-NC (Figure 2A) revealed a good separation between the two groups,
especially along the first principal component PC1 (PC1 and PC2 accounted for 51.3% and 23% of
the total variance, respectively). A clear separation between the two groups was observed also in the
corresponding PLSDA (Figure S1A in Supplementary Materials) and OPLSDA score plots (Figure 2B).
The PLSDA model was obtained, with the first two components explaining 50% and 23.5% of the total
variance, R2 = 0.86 and Q2 = 0.78, and the corresponding OPLSDA score plot was obtained with the first
predictive and orthogonal components, accounting for 17.8% and 53% of the total variance, respectively.
The variables (bucket reduced NMR signals) responsible for the CG and T2DM-NC separation were
observed in the corresponding VIP plot (p < 0.05) (Figure S1B in Supplementary Materials). In addition
to a relative higher α and β-glucose content that characterized T2DM-NC patients with respect to CG,
a relative decrease of alanine, creatine/creatinine, glutamine, glutamate, leucine, lysine, methionine,
N-acetylglycoproteins, phenylalanine, and tyrosine was observed in T2DM-NC patients with respect
to the CG (Figure 2C). Moreover, the quantitative variation in discriminating metabolites among the
observed groups was calculated by the integration of specific signals, identified by the NMR-based
multivariate analysis (Table 4). Results, reported as the mean and standard deviation of integrals for
each group, were validated by one-way ANOVA with the HSD post-hoc test. The level of statistical
17
J. Clin. Med. 2019, 8, 720
significance was at least at p-values < 0.05 with 95% confidence level. PCA, PLSDA, and OPLSDA
analyses were also performed for CG and T2DM-C patients (Figure 3). PCA analysis showed an
even better separation than that observed comparing CG and T2DM-NC, between CG and T2DM-C
patients (PC1 and PC2 accounted for 73.7% and 10.5% of the total variance, respectively) (Figure 3A).
This result appeared more evident when PLSDA (with the first two components explaining 73.6%
and 9.3% of the total variance, R2 = 0.85 and Q2 = 0.72) and OPLSDA (with the first predictive and
orthogonal components accounting for 22.9% and 48.6%) analyses were applied to the data (Figure S2
in Supplementary Materials and Figure 3B, respectively). Together with the expected higher level of
sugars, several metabolites, such as alanine, carnitine, citrate, creatine, glutamate, glutamine, isoleucine,
leucine, lactate, lysine, methionine, N-acetyl-glycoproteins, phenylalanine, tyrosine and valine were
also quantified and statistically validated as significantly reduced in T2DM-C patients compared to the
CG (Figure 3C and Table 4).
Figure 2. PCA and OPLSDA score scatter plots distinguishing between CG and T2DM-NC. (A) PCA
(PC1/PC2, 51.3% and 23% of the total variance, respectively); (B) OPLSDA (obtained with the first
predictive and orthogonal components, accounting for 17.8% and 53% of the total variance, respectively)
analyses of NMR data; (C) metabolites significantly changed between T2DM-NC and CG patients.
PCA = principal component analysis; OPLSDA= orthogonal partial least squares discriminant analysis.
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Figure 3. PCA and OPLS-DA score scatter plots distinguishing between CG and T2DM-C. (A) PCA
(PC1/PC2, 73.7% and 10.5% of the total variance, respectively); (B) OPLSDA (obtained with the
first predictive and orthogonal components, accounting for 22.9% and 48.6% of the total variance,
respectively) analyses of NMR data; (C) metabolites significantly changed between T2DM-C and
CG patients.
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Figure 4. PCA and OPLS-DA score scatter plots distinguishing between T2DM-NC and T2DM-NC.
(A) PCA (PC1/PC2, 35.8% and 25.2% of the total variance, respectively); (B) OPLSDA (obtained with
the first predictive and orthogonal components, accounting for 13.9% and 57.9% of the total variance,
respectively) analyses of NMR data; (C) metabolites significantly changed between T2DM-C and
T2DM-NC patients.
Finally, T2DM patients were also compared with each other (T2DM-C vs. T2DM-NC). The
statistical models obtained appeared well descriptive but weakly predictive, showing a partial overlap
of samples (Figure 4). In fact, PCA model (Figure 4A) was built with PC1 and PC2 accounting for 35.8%
and 25.2% of the total variance, while in the PLSDA score plot (Figure S3 in Supplementary Materials)
the first two components explained 33.5% and 24.5% of the total variance, respectively (R2 = 0.46 and
Q2 = −0.27); the OPLSDA score plot was obtained with the first predictive and orthogonal components
accounting for 13.9% and 57.9% (Figure 4B). Metabolites showing a significant variation between
the two groups were carnitine, isoleucine, leucine, lactate, lysine, N-acetylglycoproteins, tyrosine,
and valine (Figure 4C and Table 4).
The metabolites listed in Table 4 were also used as input variables in order to investigate the
distance of any type of samples, obtaining a heatmap (Figure 5). Moreover, to identify the potential
biomarkers associated with T2DM disease, a multivariate ROC curve analysis was also performed
on selected metabolites, considering the T2DM-C patients compared to controls (GC) (Figure 6).
An overview of all ROC curves (created from six different biomarker models using different number
of features) and predictive accuracies with different features are shown in Figure 6A,B, respectively.
Considering the first top metabolites (selected frequency >~0.7%), the obtained AUC value was 0.999,
with a 0.938–1 confidence interval (CI). Moreover, from the variable importance in projection (VIP) plot
(Figure 6C) and prediction of T2DM-C patients and controls using MCCV analysis (Figure 6D), the most
discriminating metabolites in descending order of importance were indicated. In addition to glucose,
also leucine, glutamate, lysine, valine, and isoleucine resulted the top five important metabolites,
based on their frequency selection during cross-validation (Figure 6C). In conclusion, the ROC curves
analysis allowed to obtain a general overview of significant alterations of biomarkers in T2DM patients
with complications. In particular, BCAAs such as leucine, valine, and isoleucine resulted significant in
this analysis.
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Figure 5. Heatmap visualization of group averages based on 17 biomarkers. Heatmap visualization
based on 17 metabolites. Rows: biomarkers; columns: samples. Red: GC; green and blue: T2DM-C
and T2DM-NC patients, respectively. Color key indicates metabolite values: dark blue: lowest; dark
red: highest.
Figure 6. Comparison of variables based on ROC curve. (A) Multivariate receiver operating
characteristic (ROC) analysis, showing the feature numbers the AUCs and the confidence intervals of
the six models; (B) predictive accuracies with different features based on the ROC curves; (C) percentage
selected frequency of metabolites based on ROC curves, with the variable importance in projection (VIP)
plot indicating the most discriminating metabolite in descending order of importance; (D) prediction of
T2DM-C patients and controls using Monte–Carlo cross validation (MCCV) analysis.
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3.4. Metabolic Pathway Analysis
A metabolic pathway analysis using the MeTPA (Metabolomics Pathway Analysis) software [37]
was performed in order to identify the most relevant pathways potentially involved in the observed
changes of T2DM serum metabolites. Based on the observed quantitative variation for the identified
metabolite content found in CG and T2DM patients at different stages, according to the p-value
and the impact value (Tables S1–S3 in Supplementary Materials), at least six potential target
pathways resulted altered in T2DM-NC patients (Figure 7A). These pathways included alanine,
aspartate and glutamate metabolism, D-glutamine and D-glutamate metabolism, lysine degradation,
aminoacyl-tRNA biosynthesis, and carbohydrate metabolism (starch and sucrose metabolism,
glycolysis, or gluconeogenesis). The same metabolic pathways, with a different significance, appear to
be compromised in T2DM-C patients with respect to CG (Figure 7B), with the exception of pathways
involving carbohydrate metabolism. Finally, when the analysis was conducted by comparing the two
diabetic groups, phenylalanine and branched-chain amino acid (BCAA) metabolism resulted perturbed
and discriminant of the two diabetic stages (Figure 7C).
Figure 7. Summary of metabolic analysis conducted by MetPA. (A) CG vs. T2DM-C. (a) Alanine,
aspartate, and glutamate metabolism; (b) aminoacyl-tRNA biosynthesis; (c) lysine degradation; (d)
d-glutamine and d-glutamate metabolism. (B) CG vs. T2DM-NC. (a) Alanine, aspartate and glutamate
metabolism; (b) aminoacyl-tRNA biosynthesis; (c) lysine degradation; (d) d-glutamine and d-glutamate
metabolism; (e) starch and sucrose metabolism; (f) glycolysis or gluconeogenesis. (C) T2DM-NC
vs. T2DM-C. (a) Alanine, aspartate and glutamate metabolism; (b) d-glutamine and d-glutamate
metabolism; (c) lysine degradation; (d) phenylalanine metabolism; (e) aminoacyl-tRNA biosynthesis;
(f) valine, leucine and isoleucine biosynthesis; (g) valine, leucine and isoleucine degradation. (D)
Schematic diagram of the metabolic pathways supposed to be altered in T2DM detected by 1H NMR
analysis. Arrows (↑ ↓) represented the increase or decrease of metabolites in the serum.
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4. Discussion
T2DM is a metabolic disorder characterized by chronic hyperglycemia due to the resistance of
target tissues to the metabolic action of insulin and dysfunction of pancreatic β cells. According to the
most recent guidelines, individuals with T2DM are considered at high to very-high cardiovascular
risk, depending on the presence or not of established complications [38]. Insulin therapy is used
for the treatment of T2DM when the progression of the disease overcomes the effectiveness of oral
hypoglycemic drugs [39]. Due to the paucity of metabolic markers of disease progression and the
suboptimal performance of risk equations, the characterization of biomarkers that can indicate specific
and temporal metabolic and vascular disturbances in the progression of T2DM is an active field
of investigation. Metabolomics has gained growing applications in the identification of circulating
biomarkers thus contributing to the diagnosis, prognosis and risk estimation of diseases [40]. In the
present study, the serum metabolic profiling of control and T2DM groups was investigated to explore
the metabolic response to diabetic complications leading to the identification of a metabolic signature
that might serve as predictor of disease progression.
To do this, we profiled a well-characterized diabetic cohort of patients who showed hyperglycemia,
with increased levels of HbA1c and HOMA index with respect to CG closely matched for age and
BMI. Among T2DM patients, retinopathy, nephropathy, and neuropathy were the most frequent
observed complications. Analysis of clinical data revealed that a set of few metabolites including
PAI-1, azotemia, and creatinine were increased in the T2DM-C group and potentially related to disease
complications. Moreover, an increased ferritin level was observed in T2MD-NC patients compared to
the CG (Table 3). This was consistent with previous studies that described a functional correlation
between PAI-1, ferritin, and type II diabetes [41,42]. These conventional clinical and biochemical
parameters clearly distinguished T2DM patients from CG but do not allow the detection of specific
alterations useful for the clinical discrimination of T2DM patient cohorts. Application of metabolomics
to these datasets has led to a broader evaluation of a large set of serum metabolites associated with each
class of patients. As a result of disease complexity [43], several metabolites were identified in T2DM,
most of which were involved in amino acid metabolism (Figure 7D). This result is in agreement with
previously reported metabolomic studies highlighting the association of serum amino acids alteration
with metabolic disorders, and T2DM [44–47].
More in detail, MetPA software analysis of NMR data showed a significant perturbation of alanine,
glutamine and glutamate metabolism in both T2DM groups (T2DM-C and T2DM-NC) of patients
(Figure 5, Tables S1–S3). Multivariate analyses pointed out a decreased serum level of these amino
acids in both groups of diabetic (T2DM-C and T2DM-NC) with respect to control patients. This result
confirms previous studies that identified alanine and glutamine as consistently associated with an
increased risk of developing T2DM [36,48]. Alanine, glutamine, and glutamate are gluconeogenic
amino acids precursors for glucose synthesis. Therefore, decreased serum level of these amino acids
could be associated to a major hepatic utilization for glucose synthesis in agreement with previous
reports of increased gluconeogenesis from amino acids in T2DM patients [49–51]. Indeed, our metabolic
pathway analysis clearly suggests the involvement of the gluconeogenesis pathway, particularly at the
earliest T2DM stage (Figure 7). Moreover, the reduced amount of serum lactate, measured in T2DM-C
compared with T2DM-NC patients, could be seen as a consequence of the higher alanine utilization for
glucose synthesis. In this case, pyruvate is shunted towards alanine and away from lactate synthesis.
The multivariate analysis performed on serum metabolic profiles also showed and allowed to
quantify significant differences in the levels of isoleucine, lysine, tyrosine, and valine in T2DM-C with
respect to CG patients and between the two diabetic groups (Table 4). Leucine, isoleucine, and valine
are essential amino acids also known as BCAAs. Indeed, MetPA analysis highlighted a compromised
BCAA metabolism as a discriminant of the two diabetes stages (Figure 7C). Thus, the strong decrease
in BCAA serum level observed in the advanced with respect to T2DM early stage could be considered
as a time-dependent perturbation of BCAA metabolism. Moreover, ROC curve analysis validated the
clinical relevance of BCAAs as potential biomarkers in the diagnosis of T2DM complications (Figure 6).
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In recent years, BCAA metabolism was found to be significantly altered in patients with several
diseases including diabetes [52]. Both human and animal studies demonstrated a functional correlation
between BCAA metabolism and a higher susceptibility to IR in T2DM patients [53–57]. Here, we showed
lower levels of BCAA in T2DM patients compared to CG, raising questions regarding the mechanisms
regulating BCAA metabolism in our cohort. In this context, we speculate that IR levels and disease
complications may have a major impact on this result, as corroborated by other studies that utilize
functional and NMR approaches. For instance, lower plasma levels, with respect to healthy controls,
of BCAAs in T2DM patients were indicated as a first sign of kidney dysfunction [56]. Further, the
decreased serum levels of BCAAs that we observed in T2DM are in line with the results of Shin et al. [57]
who demonstrated that alteration in hypothalamic insulin signaling can decrease plasma BCAA levels
by inducing the hepatic activity of branched-chain α-keto acid dehydrogenase, a rate-limiting enzyme
in the BCAA degradation pathway. Overall, this indication well correlated with the HOMA-IR values
that we measured in the diabetic patients with respect to CG, with the highest value of IR measured in
the complicated T2DM patients (Table 3). Moreover, a higher BCAA level has been found in retinal
Müller cells from diabetic compared to euglycemic rats [58]. This study demonstrated that BCAAs
competitively inhibited glutamate transamination and induced glutamate excitotoxicity and neuronal
cell death, providing an early sign of retinopathy. This data well correlated with the high occurrence
(more than 90% of subjects) of retinopathy that we measured among T2DM-C patients (Table 1).
Moreover, increased muscle BCAA oxidation has been reported to improve muscle glucose uptake in
metabolic syndrome by enhancing the recycling of glucose via the glucose-alanine cycle [59].
Serum levels of lysine decreased from control subjects to T2DM patients at an early stage and
to T2DM complicated patients. Interestingly, recent work reported a therapeutic effect of lysine
administration in T2DM patients to counteract the production of glycated lysozyme [60]. Protein
glycation is a well-established process associated with long-term hyperglycemia characterizing many
pathophysiological conditions such as cancer, inflammation, metabolic dysfunctions and aging [61].
We also found that tyrosine serum level significantly decreased in both groups of diabetic patients
with respect to CG and also differentiated T2DM-C from T2DM-NC patients (Table 4). It is important
to note that a previous work, conducted on rat liver, demonstrated that insulin was capable to increase
the activity of the tyrosine aminotransferase enzyme. Thus, by activating the transamination of
tyrosine to p-hydroxyphenylpyruvate the serum level of tyrosine was reduced [62]. On the basis of
these data, the high fasting insulin level measured in diabetic subjects (Table 3) could be linked to
the decreased tyrosine serum level in diabetic patients. Importantly, it has been also reported that
circulating tyrosine level could be correlated with the risk of developing various major complications
of diabetes [56]. Moreover, other studies described an association of a low tyrosine level with the
impairment of kidney function, which itself could predict future microvascular events [63,64]. Tyrosine
is also linked to catecholamine synthesis, a mechanism that may be involved in the development of
T2DM complications [65]. Increasing evidence suggested a correlation among tyrosine levels, obesity,
and insulin concentration in both diabetic and non-diabetic subjects [65]. Moreover, tyrosine has
been identified as the only metabolite significantly associated with HOMA in obesity-independent
models [66,67].
The serum level of patients in the advanced T2DM stage was also characterized by a lower level
of carnitine with respect to T2DM-NC. L-carnitine, primarily synthesized in the liver and kidneys
from lysine and methionine, has an essential role in the transfer of activated long-chain fatty acids into
the mitochondria where β-oxidation takes place [68]. Considering that impaired fatty acid transport
inside mitochondria can result in triglyceride cytosolic accumulation in and IR [69], we can consider
the reduced serum carnitine level measured in complicated T2DM patients closely associated to the
highest HOMA-IR of these subjects.
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5. Conclusions
Results from the present study identified a set of metabolites discriminating control from T2DM
groups. We also demonstrated that specific metabolic alterations characterize T2DM groups at the
systemic level with main differences in amino acids pathways. If this result reflects a way to decrease
the pathological state by activating compensatory mechanisms or is a mere consequence of deranged
metabolic pathways is yet to be understood. In this context, the metabolism of gluconeogenic amino
acids and BCAAs may have a role. On the basis of these results, considering that BCAAs are essential
amino acids introduced with the diet, changes in dietary habit, not only as carbohydrate intake,
have to be taken into account for the prevention of T2DM complications. Finally, if this metabolic
change represents the pathological basis for the onset of complications increasing, for instance, the risk
of developing cancer should be also considered and evaluated. Our data will represent the basis
for future studies involved patients affected by tumors related to metabolic dysfunctions such as
hepatocellular carcinoma.
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Abstract: The aim of this study was to determine whether plasma concentrations of sCD36 (soluble
CD36) are associated with the presence of type 1 or type 2 diabetes. Plasma levels of sCD36 were
analysed in 1023 subjects (225 type 1 diabetes (T1D) patients, 276 type 2 diabetes (T2D) patients, and
522 non-diabetic control subjects) using an enzyme-linked immunosorbent assay (ELISA). Multinomial
and logistic regression models were performed to evaluate associations with sCD36 and its association
with diabetes types. There were no significant differences in sCD36 (p = 0.144) among study groups,
neither in head-to-head comparisons: non-diabetic versus T1D subjects (p = 0.180), non-diabetic
versus T2D subjects (p = 0.583), and T1D versus T2D patients (p = 0.151). In the multinomial model,
lower sCD36 concentrations were associated with older age (p < 0.001), tobacco exposure (p = 0.006),
T2D (p = 0.020), and a higher-platelets count (p = 0.004). However, in logistic regression models
of diabetes, sCD36 showed only a weak association with T2D. The current findings show a weak
association of circulating sCD36 with type 2 diabetes and no association with T1D.
Keywords: sCD36; type 1 diabetes mellitus; type 2 diabetes mellitus
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1. Introduction
CD36 belongs to the class B scavenger receptor family, it is a transmembrane glycoprotein
of 88-kDa expressed in a wide variety of cell types [1]. CD36 recognises many types of ligands,
such as oxidised low-density lipoprotein (oxLDL), advanced glycation products, free fatty acids,
or apoptotic cell surfaces [2–5]. This multivariate ligand recognition allows it to exert several
functions, depending on the cell type. Among others, CD36 internalise modified lipoproteins (e.g.,
oxidised LDL), which facilitates cholesterol accumulation in macrophages or the regulation of fatty
acid uptake through the plasma membrane and the subsequent metabolism [6,7]. CD36 expression
or function are involved in angiogenesis, macrophage and platelet activation, lipid metabolism,
and inflammation [8–11], which influences susceptibility to certain metabolic diseases, such as obesity,
insulin resistance, impaired glucose tolerance, and fatty liver disease [7,12,13]. CD36 has been reported
to be associated with type 2 diabetes (T2D) [14]. In monocytes and macrophages, CD36 is up-regulated
by hyperglycaemia, insulin resistance, and oxLDL [8,10,15–17]. Moreover, oxLDL concentrations are
elevated in type 2 diabetes [18,19].
The soluble form of CD36 (sCD36) was first described to be associated with metabolic syndrome
in a small group of subjects: sCD36 was elevated in T2D patients compared with both lean (5-fold)
and obese (2- to 3-fold) non-diabetic subjects [20]. Moreover, it has been described to be associated
with insulin resistance, impaired glucose tolerance, and fatty liver in non-diabetic subjects [21–23].
Other studies have found discordant results concerning the circulating concentrations of sCD36 in
patients with T2D, resulting in no difference [24,25], or increased concentrations in T2D diabetic
subjects with chronic kidney disease [26], compared to non-diabetic subjects. However, a recent study
found no association of sCD36 with glucose or additional factors that were described in previous
studies to be associated with its concentrations [24]. To our knowledge, no studies have assessed
sCD36 concentrations in patients with type 1 diabetes (T1D).
The aim of the current study was to assess whether the circulating concentrations of sCD36 are
associated with diabetes, T1D or T2D, compared with a non-diabetic control group, all of them without
previous cardiovascular events and free from chronic kidney disease. Taken together, the findings
show a weak association of circulating sCD36 with T2D and no association with T1D.
2. Experimental Section
2.1. Subjects
One thousand and twenty-three patients were recruited from the University Hospitals Arnau
de Vilanova (Lleida, Spain) and Germans Trias i Pujol (Badalona, Spain) to participate in this study.
Subjects with T1D (n = 225) and T2D (n = 276) were selected from two previous studies [27,28].
The control group (n = 522) was selected from a population-based study in our region (subjects without
diabetes on the basis of values of HbAc1 <6.5% and glucose <126 mg/dL) [29]. Additionally, 50 subjects,
22 T2D patients and 28 non-diabetic subjects, were recruited at the University Hospital Germans Trias i
Pujol to perform the sub-study using flow cytometric analysis. The inclusion criteria for the four groups
were as follows: age range 20–85 years, absence of established chronic kidney disease (defined as
calculated glomerular filtration rate <60 mL/min and/or urine albumin/creatinine ratio >299 mg/g), and
absence of known clinical cardiovascular events or associated revascularization procedures, including
coronary heart disease, cerebrovascular disease, or peripheral vascular disease (including the diagnosis
of diabetic foot disease).
Blood samples were collected in the fasting state, and blood tests were performed using
standard laboratory methods [28]. Urine tests were performed in diabetic patients following standard
laboratory methods. Subjects were considered to have hypertension or dyslipidaemia if they were
under anti-hypertensive or lipid-lowering agent treatment, respectively. Blood samples for sCD36
measurements were collected in the fasting state with EDTA tubes, processed immediately after
extraction, and stored at−80 ◦C at the biobanks of the participant centres until determination. Peripheral
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blood samples for flow cytometric and real-time PCR assays were collected on the same condition
and processed after one hour on a shaker plate. Local ethics committees of both participating centres
approved the study (12/2009 and P11/11) which followed the Declaration of Helsinki. All participants
provided written informed consent before inclusion.
2.2. Determination for sCD36 by ELISA
Plasma concentrations of human sCD36 were measured using a commercially available ELISA
kit (Nordic BioSite, Täby, Sweden), in accordance with the manufacturer’s instructions. Appropriate
dilutions of patient samples were measured in duplicates. Briefly, standards and samples were pipetted
into the wells and incubated for 2 h on the plate shaker at room temperature (RT). After washing
4 times, a detection antibody was added and incubated for 2 h on the plate shaker at RT. Following
washing 4 times, a streptavidin conjugated with Horseradish Peroxidase solution was added to the
wells and incubated for 50 min on the plate shaker at RT and protected from light. After washing
4 times, 50 μL substrate solution (TMB-tetramethylbenzidine) was added to the wells and incubated
for 20 min at RT protected from light. The colour development was stopped with 50 μL of stop solution.
Absorbance was read at 450 nm using SpectraMax 340PC384 (Molecular Devices, LLC, Sunnyvale,
California, USA). The results were analysed using a log–log curve fit. The calibration was performed
with recombinant human CD36 in the concentration range 1.95–250 ng/mL. For sCD36 concentrations
lower than the detection limit, a value of 0.05 ng/mL was assigned (in the non-diabetic control group,
n = 64/522; T1D, n = 41/225; T2D, n = 24/276). Intra-assay and inter-assay precision coefficients of the
ELISA assay were 4%–6% and 8%–12% respectively, as determined by the manufacturer.
2.3. Consistency Test of sCD36 Determination
Due to the variability found in the concentrations of sCD36 in the published articles, we wanted
to rule out that this was a consequence of differences in pre-analytical conditions. We designed
an experiment to compare sCD36 assessed by ELISA (Nordic BioSite, Täby, Sweden) that included
96 samples from 14 volunteers. Plasma samples were processed at different centrifugation velocities:
1500× g (following our protocol), 1850× g and 3000× g (velocities used in other studies) [20,30].
Moreover, it was assessed whether the number of freeze-thaw cycles affected the sCD36 concentration.
Samples without previous thaw, as used in our protocol, and with three freeze-thaw cycles, as requested
by the in-house ELISA found in the literature, were evaluated [31].
2.4. Flow Cytometric Analysis
The analysis of CD36 by flow cytometry included 50 subjects, 22 T2D patients and 28 non-diabetic
subjects. Peripheral blood samples were collected in the fasting state into vacutainers (BD Bioscience, San
Jose, CA, USA) containing EDTA. Erythrocytes were lysed with ammonium chloride (BD Pharm Lyse™,
San Jose, CA, USA), then the cells were washed with phosphate buffered saline (PBS), and incubated
with monoclonal antibodies against CD36 (Miltenyi Biotec, Bergisch Gladbach, Germany), CD3,
and CD14 (BD Biosciences, San Jose, CA, USA). Thereafter, flow cytometric analysis was carried out on
a Fortessa SORP flow cytometer (BD Biosciences, San Jose, CA, USA), using sample acquisition and
analysis software FACSDiva v6.2 (BD Biosciences, San Jose, CA, USA).
2.5. Real-Time PCR
The analysis of CD36 mRNA included the above-mentioned 50 subjects (22 T2D patients and
28 without diabetes). Erythrocytes were lysed with ammonium chloride (BD Pharm Lyse™), then the
cells were washed with PBS and disrupted with QUIzol Lysis Reagent (Quiagen, Hilden, Germany),
and total RNA was extracted using the miRNA Mini Kit (Quiagen, Hilden, Germany). Total RNA
(1 μg) was reverse-transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche,
Basel, Switzerland). Each reaction was then amplified in a LightCycler® 480 PCR system using
SYBR Green I Master (Roche, Basel, Switzerland). The primer pairs used were: forward primer
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5′->3′ (GAGAACTGTTATGGGGCTAT) and reverse primer 5′->3′ (TTCAACTGGAGAGGCAAAGG).
Gene expression values were normalized to the expression levels of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
2.6. Statistical Analyses
Descriptive statistics of mean (standard deviation) or median (interquartile range) were estimated
for quantitative variables while, for qualitative variables, absolute and relative frequencies were
used. The differences between groups T1D, T2D, and control group, were assessed by Student’s
t-test, ANOVA, the Mann–Whitney test, or the Kruskal–Wallis test. Regarding the differences in
qualitative variables, this was assessed by the Chi-squared test or Fisher’s exact test. Tukey’s correction
was used to account for multiple tests. Correlations were assessed by Spearman’s rank correlation
coefficient. Associations between qualitative variables and sCD36 concentration were tested with
the T test. Multinomial logistic regression models of sCD36 quartile were performed to study the
variables associated with their levels, first quartile was used as reference. In these models, variables of
the bivariate analysis with a p value <0.2 and clinical relevance were used. Logistic regression models
of T1D versus non-diabetic and T2D versus non-diabetic were performed. For the models of diabetes,
a non-diabetic age- and sex-matched group from the non-diabetic participants (n = 522) were selected
for T1D (n = 314) and T2D (n = 247). In all models, the goodness-of-fit assumption was tested by the
Hosmer–Lemeshow test. Logistic regression models were checked by receiver-operating characteristic
(ROC) curves and DeLong’s test to correlated ROC curves. Estimates of odds ratios was reported with
corresponding 95% confidence intervals and statistical significance was established as a p-value <0.05.
The R statistical software, version 3.3.1, and SPSS software (version 22, IBM, SPSS, Chicago, IL, USA)
were used for all of the analyses.
3. Results
A total of 1023 individuals, clinically well-characterised (225 type 1 diabetic patients, 276 type 2
patients, and 522 non-diabetic subjects), were included in the study. In the overall study population,
the mean age was 50 years, and up to 45.4% were men. The age in the different groups of participants
ranged between 23 and 77 years in patients with T1D, between 40 and 75 years in patients with T2D,
and between 27 and 84 years in the non-diabetic control group. There were significant differences
among the three study groups for all studied variables, except for tobacco exposure. All the clinical
characteristics can be found in Table 1.
3.1. Circulating sCD36 in the Study Groups
There were no significant differences in the median plasma concentrations of sCD36 among the
three study groups (p = 0.144). In head-to-head comparisons, concentrations of sCD36 were not
different between non-diabetic and T1D subjects (2.84 ng/mL versus 3.66 ng/mL; p = 0.180), non-diabetic
and T2D subjects (2.84 ng/mL versus 2.62 ng/mL; p = 0.583), or T1D and T2D (3.66 ng/mL versus
2.62 ng/mL; p = 0.151). In addition, there were no significant differences in sCD36 levels divided in
quartiles among the three groups (p = 0.062) (Table 1).
Furthermore, despite median, sCD36 concentrations were similar in women and men with T2D
(2.99 ng/mL versus 2.15 ng/mL; p = 0.374), or T1D (3.69 ng/mL versus 3.58 ng/mL; p = 0.812), median
sCD36 concentrations were significantly higher in women in the non-diabetic group (3.40 ng/mL versus
2.36 ng/mL; p = 0.047). In addition, sCD36 concentrations tended to be increased in T2D statin users
(1.88 ng/mL versus 3.53 ng/mL; p = 0.084) and tended to be decreased in T1D statin users (4.53 ng/mL
versus 2.70 ng/mL; p = 0.145).
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Table 1. Clinical and anthropometrical characteristics of the study groups.












N = 522 N = 225 N = 276
Sex, Men 212 (40.6%) 109 (48.4%) 143 (51.8%) 0.006 0.086 0.009 0.509
Age, years 49 (39–59) 44 (38.0–51.0) 59 (51–66) <0.001 <0.001 <0.001 <0.001
BMI, Kg/m2 25.5 (23.4–28.3) 25.6 (22.6–28.1) 30.2 (27.9–34.7) <0.001 0.557 <0.001 <0.001
Waist, cm 94.0 (85.0–102) 88.0 (80.0–97.0) 104 (97.5–112) <0.001 <0.001 <0.001 <0.001
Alcohol mg/day 2.86 (0–12.3) 2.37 (0–7.19) 1.53 (0–9.92) 0.030 0.095 0.055 0.685
Tobacco 270 (51.7%) 116 (51.6%) 149 (54.0%) 0.805 1.000 0.977 0.977
Hypertension 81 (16%) 55 (24.4%) 153 (55.4%) <0.001 0.009 <0.001 <0.001
sBP, mmHg 121 (110–132) 128 (116–138) 139 (127–150) <0.001 <0.001 <0.001 <0.001
dBP, mmHg 76.0 (70–83) 75.0 (68.5–80) 76.0 (70–84) 0.020 0.026 0.889 0.028
Dyslipidaemia 115 (22.6%) 96 (42.7%) 129 (46.7%) <0.001 <0.001 <0.001 0.412
Antiplatelet - 63 (28%) 99 (35.9%) <0.001 - - 0.076
Statins 114 (22.4%) 96 (42.7%) 116 (42%) <0.001 <0.001 <0.001 0.958
Glucose, mg/dL 90 (84–96) 159 (107–208) 148 (117–182) <0.001 <0.001 <0.001 0.619
HbA1c, % 5.5 (5.2–5.8) 7.40 (7.00–7.9) 7.60 (6.80–8.5) <0.001 <0.001 <0.001 0.230
Creatinine mg/dL 0.79 (0.70–0.93) 0.78 (0.65–0.87) 0.79 (0.68–0.93) 0.011 0.009 0.567 0.046
eGFR 86.2 (77.4–97.6) 95.2 (82.7–108) 86.8 (77.5–100) <0.001 <0.001 0.383 <0.001
ALT U/L 17 (13–23) 17 (13.8–21) 19 (16–28) <0.001 0.719 <0.001 <0.001
Triglycerides, mg/dL 87 (67.0–125) 65 (53–86) 118 (84.8–166) <0.001 <0.001 <0.001 <0.001
Total-C, mg/dL 196 (175–226) 180 (164–201) 184 (163–206) <0.001 <0.001 <0.001 0.180
HDL, mg/dL 57 (48–68) 62.5 (53–74) 48 (40–58) <0.001 <0.001 <0.001 <0.001
LDL, mg/dL 119 (100–142) 101 (84.5–116) 108 (88.4–129) <0.001 <0.001 <0.001 0.003
Haemoglobin, g/dL 14.2 (13.3–15.2) 14 (13.1–14.9) 13.7 (12.9–14.7) <0.001 0.031 <0.001 0.098
Haematocrit, % 42.4 (3.58) 41.5 (3.51) 41.1 (3.54) <0.001 0.003 <0.001 0.545
Platelets, 109/L 233 (203–273) 223 (197–256) 226 (188–274) 0.019 0.027 0.078 0.759
Diabetes duration, years - 21 (15–29) 8 (4–13.5) <0.001 - - <0.001
sCD36, ng/mL 2.84 (0.56–9.06) 3.66 (0.69–18.7) 2.62 (0.66–7.57) 0.144 0.180 0.583 0.151
sCD36 Quartiles 2 0.062 0.259 0.259 0.036
(<−0.562) 134 (25.7%) 53 (23.6%) 64 (23.2%)
(−0.562,1.05) 127 (24.3%) 49 (21.8%) 80 (29%)
(1.05,2.24) 133 (25.5%) 51 (22.7%) 77 (27.9%)
(>2.24) 128 (24.5%) 72 (32.0%) 55 (19.9%)
1 Mean (SD) or median (Interquartile range) for continuous variables and frequency (percentage) for categorical
variables; 2 Soluble CD36 in quartiles was Ln transformed. BMI, body mass index; sBP, systolic blood pressure; dBP,
diastolic blood pressure; ALT, alanine aminotransferase; eGFR; estimated glomerular filtration rate (MDRD4_IDMS
equation); HDL, high-density lipoprotein; LDL, low-density lipoprotein.
3.2. Associations of Circulating sCD36 in the Study Groups
When considering all three groups together, age, body mass index (BMI), systolic blood pressure,
triglycerides, and haematocrit were negatively correlated with sCD36 (p-values between p < 0.05 and
p < 0.01). Moreover, in the control group, age, BMI, systolic blood pressure, triglycerides, glucose,
and HbA1c were negatively correlated. The number of platelets was positively correlated with sCD36
(p-values between p < 0.05 and p < 0.01) (Figure S1). Finally, glucose was positively correlated with
sCD36 in T1D (p < 0.05). In the T2D group, sCD36 was not correlated with any of the analysed variables
(Figure 1).
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Figure 1. Correlation analysis of circulating sCD36 and clinical variables in type 1 diabetes (T1D)
(red–blue) and type 2 diabetes (T2D) (green–orange) groups. Spearman’s correlation is significant at
the 0.05 *, 0.01 **, and 0.001 *** levels (2-tailed). BMI, Body mass index; sBP, systolic blood pressure;
dBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (MDRD4_IDMS equation);
ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c,
glycated haemoglobin; DM duration, diabetes duration.
On the other hand, in patients with T2D, significantly higher sCD36 concentrations were found in
antiplatelet users (p = 0.039) and in patients with dyslipidaemia (p = 0.048). Significantly lower sCD36
concentrations were found in T1D diabetes patients with tobacco exposure (p = 0.005). In non-diabetic
subjects, significantly lower sCD36 concentrations were found in subjects with hypertension (p < 0.001),
dyslipidaemia (p = 0.044), and statin users (p = 0.035) (Table 2).
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3.3. Multinomial Logistic Regression Models of sCD36
We generated multinomial logistic regression models for sCD36 quartiles of the whole study
group. Additionally, to avoid model meddling because of the group characteristics, we analysed T1D,
T2D, and non-diabetic control groups separately. First quartile (Q1) was taken as a referent group and
was compared with the other groups, defined as second (Q2), third (Q3), and quarter (Q4) quartile,
respectively. In the whole group, the variables independently associated with sCD36 concentrations
were: older age with all quartiles of sCD36 (Q2: OR = 0.978, p = 0.014; Q3: OR = 0.980, p = 0.024,
and Q4: OR = 0.967, p < 0.001), tobacco exposure with Q4 (OR = 0.581, p = 0.006); T2D with all quartiles
of sCD36 (Q2: OR = 2.072, p = 0.006; Q3: OR = 1.852, p = 0.020, and Q4: OR = 1.925, p = 0.020); and Q3
of platelets with the Q2 (OR = 1.858, p = 0.020) and Q4 (OR = 2.204, p = 0.004) (Table S1).
In the multinomial model for T1D, the variables independently associated with sCD36
concentrations were: tobacco exposure with Q3 (OR 0.289, p = 0.009), and Q4 (OR = 0.352, p = 0.015),
higher BMI with Q3 (OR = 1.125, p = 0.044), and higher glomerular filtration rate (eGFR) with Q2
(OR = 0.968, p = 0.013) (Table S2).
In the multinomial model of T2D, MPV (mean platelet volume) was associated with Q2 (OR = 0.581,
p = 0.027) and Q3 (OR = 0.561, p = 0.023), insulin treatment was associated with Q2 (OR = 5.838,
p = 0.033), treatment with oral anti-diabetic agents was associated with Q3 (OR = 4.108, p = 0.029),
and antiplatelet treatment was associated with Q3 (OR2.694, p = 0.026) (Table S3).
Finally, in the non-diabetic group, the variables independently associated with sCD36
concentrations were: higher levels of HbA1c with all quartiles (Q2: OR = 0.243, p < 0.001; Q3:
OR = 0.260, p < 0.001; and Q4: OR = 0.299, p = 0.002), older age and higher triglycerides with Q4
(OR = 0.975, p = 0.039 and OR = 0.994, p = 0.019 respectively), and Q3 of platelets with Q2 of sCD36
(OR = 2.414, p = 0.029), Q2 of platelets with Q3 of sCD36 (OR = 0.443, p = 0.031) and Q3 and Q4 of
platelets with Q4 of sCD36 (OR = 4.318, p < 0.001 and OR = 2.635, p = 0.026, respectively) (Table S4).
3.4. Association of sCD36 with Type 1 and Type 2 Diabetes
The multiple logistic regression model of the non-diabetic control group versus T1D showed
that the variables independently associated with the presence of T1D were: older age (OR = 0.969,
p = 0.003), the presence of hypertension (OR = 2.020, p = 0.007), presence of dyslipidaemia (OR = 3.127,
p < 0.001), higher haematocrit (OR = 0.862, p < 0.001), and the Q4 of platelets (OR = 0.472, p = 0.008)
(Figure 2a). The ROC curve showed non-discriminative power when sCD36 was added to the model
(Figure S2a).
In the logistic regression model of the non-diabetic controls versus T2D, we observed that the
variables independently associated with the presence of T2D were: female gender (OR = 0.294,
p < 0.001), hypertension (OR = 2.746, p < 0.001), dyslipidaemia (OR = 1.822, p = 0.011), high BMI
(OR = 1.234, p < 0.001), higher haematocrit (OR = 0.763, p < 0.001), Q2 and Q3 of platelets (OR = 0.405,
p = 0.004 and OR = 0.483, p = 0.024 respectively), and Q2 and Q3 of sCD36 (OR = 2.479, p = 0.006 and
OR = 2.078, p = 0.032, respectively) (Figure 2b). The models with and without sCD36 showed that the
addition of sCD36 concentrations did not provide additional discriminative power to the model area
under the ROC curve of 0.844, p < 0.001 versus 0.851, p < 0.001 (Figure S2b).
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Figure 2. Logistic regression models for presence of diabetes. (a) T1D versus non-diabetic group
(Hosmer and Lemeshow test p-value = 0.789); (b) T2D versus non-diabetic (Hosmer and Lemeshow
test p-value = 0.686). Tobacco, tobacco exposure.
3.5. Flow Cytometric Analysis of CD36 and Real-Time PCR
Flow cytometric analysis was used to detect the expression of CD36 in circulating mononuclear
cells from T2D patients and non-diabetic control subjects. In the recruited group, the mean age was
55 years, and up to 46% were men. No significant differences were found in the expression of CD36
scavenger receptor either in monocytes, or in leukocyte population between T2D patients and the
non-diabetic group (Figure S3). Regarding mRNA expression, no differences in CD36 expression were
found between T2D patients and the non-diabetic control group (Figure S4).
3.6. Consistency Test in sCD36 Assessment
In the assay of sCD36, performed in healthy volunteers, we did not find differences in sCD36
among the different centrifugation forces or among the number of freeze-thaw cycles. Paired plasma
samples prepared by 1500× g, 1850× g, and 3000× g gave nearly identical results and a good correlation
within each assay. Moreover, in the assays that compared samples with three, or without, freeze-thaw
cycles, there were no differences in the results of the three different centrifugation forces, which were
highly correlated (Table S5).
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4. Discussion
In the present study, we did not observe differences in plasma sCD36 concentrations between
patients with T1D, T2D, and non-diabetic control subjects, all of them with normal renal function
and free from advanced late diabetic complications, including macrovascular disease. Overall, there
was an association between sCD36 plasma concentrations and cardiovascular risk factors such as
hypertension, dyslipidaemia, tobacco exposure, age, sex, and BMI. In the current study, we measured
most of the variables that have been previously described to be associated with sCD36. These factors
included the use of several medications, age, sex, systolic and diastolic blood pressure, tobacco
exposure, BMI, HDL, LDL, total cholesterol, triglycerides, haematocrit, haemoglobin, platelets, serum
creatinine, blood glucose, and HbA1c. In addition, we have assessed for the first time, the contribution
of all of these factors together in a large group of subjects with and without diabetes. Importantly, we
found increased sCD36 in patients with T2D that had dyslipidaemia or that were antiplatelet users.
As dyslipidaemia and the use of antiplatelet drugs is relatively frequent in T2D, this could have led to
spuriously elevated sCD36 in previous studies in patients with T2D.
Regarding the correlations between sCD36 concentrations and clinical variables, such
as components of the metabolic syndrome among them insulin resistance, there is a large
variability [20,21,23,24,32,33]. In the non-diabetic group, sCD36 concentrations were negatively
correlated with glucose and HbA1c, and positively correlated with the number of platelets, as already
described in the literature. However, we found a negative correlation of sCD36 with age, BMI,
and triglycerides, in contrast to the reported findings of a previous study [21,32,34]. Interestingly,
and in accordance with the findings of another study, we found no significant correlations between
sCD36 with all variables analysed in T2D [24]. This may explain, at least in part, that our results
are discordant with some of the previous studies that found an association of sCD36 with insulin
resistance, components of the metabolic syndrome, and the risk of T2D [20,32,35]. An additional
reason for these differences may lie in the diverse characteristics of the study populations, which
include differences in age, duration of diabetes, metabolic syndrome components, the presence of
complications, and the use of antidiabetic medications. The characteristics of our population study
faithfully reflects the characteristics of the Spanish population [36]. Regarding medication, and in
contrast to the findings reported, we did not find differences in sCD36 concentrations between diabetic
patients with or without statin medication [26]. Furthermore, the number of subjects with diabetes
in our study was larger than that in previous studies and included patients with T1D for the first
time. Previous studies with a lower number of subjects found higher levels of sCD36 in subjects
with T2D [20,21,35]. However, in a subsequent study with 200 T2D patients, although these subjects
exhibited higher sCD36 concentrations, the only characteristics that predicted sCD36 were diabetes
duration and markers of platelet activation [34]. The latter findings are in line with ours.
To our knowledge, this is the first study that addresses the potential association of sCD36 with
diabetes as a primary study objective. We did not find a clear association of sCD36 concentrations
with T2D, the evaluation of the ROC curve shows that sCD36 does not contribute additional power
to the predictive model. In fact, we did find a weak association of sCD36 with T2D, which may
partly be due to the clinical and metabolic characteristics, among them waist circumference, which is
an indirect measure of insulin resistance. In order to demonstrate that insulin resistance per se may
be an associated factor to sCD36, direct measurements of insulin resistance should have been used.
Regarding T1D, we found no association with sCD36. Patients with T1D showed younger age and had
a high-frequency of hypertension and dyslipidaemia. Since sCD36 concentrations were not related to
T1D, this may indicate indirectly that hyperglycaemia, which is a common feature in patients with
either T1D or T2D, is not one of the main factors contributing to plasma sCD36 concentrations. Our
findings are in line with some recent studies that found no association of sCD36 with diabetes or its
associated metabolic disturbances in middle-aged subjects with metabolic syndrome [24], or patients
with early-onset coronary artery disease [25]. Another study found that baseline sCD36 did not
predict diabetes independently of fasting glucose and insulin in a non-diabetic population [22]. In
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that study, the addition of sCD36 in a multivariate model of diabetes prediction had no impact on
diabetes prediction.
CD36 signalling responds to ox-LDL, and on the one hand, reduces macrophage motility and
probably induces the trapping of macrophages in the arterial intima, which promotes atherosclerosis.
On the other hand, it induces chronic inflammation and contributes to insulin resistance common
in obesity and dyslipidaemia, both associated to metabolic disorders [37,38]. However, this does
not seem to be consistently associated with its circulating levels. Regarding the determination
of circulating sCD36, there is a lack of well-characterized or standardized methods to assess its
concentrations [30]. Despite this scarcity, as reported previously [30], the pre-analytical procedures do
not explain the variability of the results reported in different studies. Differences between studies may
be explained by several factors: (a) regarding the heterogeneous origin of CD36 particles in the plasma
of patients [39,40], our data show no differences in the CD36 surface expression from monocytes and
leukocytes of peripheral blood among patients with T2D under antidiabetic treatment and non-diabetic
subjects. (b) Although hyperglycaemia was shown to influence CD36 mRNA expression increasing the
de novo CD36 synthesis in monocytes from healthy subjects [41], we did not find differences in the CD36
mRNA expression of monocytes and leukocytes from peripheral blood between non-diabetic subjects
and patients with T2D under anti-diabetic treatment. (c) In poorly-controlled patients, lower plasma
levels of glycated CD36 and higher levels of non-glycated CD36 have been described in comparison
with well-controlled diabetic patients [39], and this fact may account also for differences with different
assays. (d) Another condition that could influence the concentration of CD36 is the number of
microparticles to which it is associated, e.g., CD36 associated with platelet-derived microparticles may
be increased in proportion to these cell particles in non-diabetic subjects [40,42]. Actually, our findings
showed that increased circulating platelet numbers are independently associated with a moderate and
a high-sCD36 concentration in non-diabetic subjects.
Our study has some limitations. First, although we adjusted for risk factors known to be associated
with diabetes in our analyses, the possibility that some other confounding factors play a role may
have been incompletely accounted for in plasma sCD36. Second, we did not validate our assay
with tests from other manufacturers. Third, the cross-sectional design precludes conclusions about
causality, and therefore prospective studies are needed to establish the usefulness of the sCD36 plasma
concentration as a predictive factor for T1D and T2D. Finally, as we did not measure insulin resistance
in the study subjects, this precludes the assessment of the impact of this metabolic variable on plasma
sCD36 concentration.
5. Conclusions
Circulating plasma sCD36 concentrations do not appear to be a biomarker of T1D or T2D. However,
our study does not completely rule out the possibility that sCD36 may constitute a biomarker of
cardiovascular events in diabetes and other populations. The follow-up of the cohorts with and without
diabetes subjects may help to clarify this question.
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Abstract: Background: Evidence of low-dose aspirin as the primary prevention strategy for
cardiovascular disease (CVD) in diabetes are unclear. This study was designed to evaluate the
effect of low-dose aspirin use for the primary prevention of CVD in diabetes. Methods: We collected
randomized controlled trials of low-dose aspirin for the primary prevention of CVD in adults
with diabetes lasting at least 12 months from Medline, Embase, and the Cochrane Library up to
10 November 2018. Two reviewers extracted data and appraised the reporting quality according to
a predetermined protocol (CRD4201811830). This review was conducted using Cochrane standards,
trial sequential analysis, and the Grading of Recommendation. The primary outcomes were major
adverse cardiovascular events (MACE, including non-fatal myocardial infarction, ischemia stroke,
and cardiovascular death) and an incidence of major hemorrhage (major intracranial hemorrhage and
major gastrointestinal bleeding). Results: In this primary prevention (number = 29,814 participants)
meta-analysis, low-dose aspirin use reduced the risk of MACE by 9% and increased the risk of major
hemorrhage by 24%. The benefits were only observed in subjects of age ≥ 60 years while reducing the
same risk of MACE. In efficacy, it reduced the risk of stroke but not myocardial infarction. No increase
in all-cause mortality or cardiovascular death was observed. Conclusions: We suggested the use of
low-dose aspirin as the primary prevention strategy for CVD in diabetes, particularly in an older
population. The absolute benefits were largely counterbalanced by the bleeding hazard.
Keywords: aspirin; primary prevention; diabetes mellitus; meta-analysis; trial sequential analysis
1. Introduction
The leading cause of mortality and morbidity in diabetes is cardiovascular disease (CVD) [1].
Additionally, diabetes patients have a twofold increased risk of CVD (including coronary heart disease,
stroke, and vascular deaths). It has been well established that aspirin shows benefits in reducing the
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cardiovascular morbidity and mortality as secondary prevention in subjects of diabetes [2]. Although
there is no strong evidence for a specific dosage, low-dose aspirin use (81 or 100 mg/day) is common in
clinical practice. Higher doses do not increase efficacy but increase the risk of bleeding [3]. However,
the role of aspirin in the primary prevention of CVD in subjects of diabetes remains inconclusive [4].
The Antithrombotic Treatment Trialists’ Collaboration in 2009 demonstrated that aspirin had no
significant effect in diabetic patients. However, this previous consensus was controversial because of
an apparent sex and age-related bias [5]. American Diabetes Association 2019 suggested that low-dose
aspirin use (75–162 mg/day) was appropriate as the primary prevention strategy in diabetic patients
aged more than 50 years old or individual with one additional cardiovascular risk factor and no
increased risk of major bleeding [6]. The European Guidelines on CVD prevention do not support this
prevention strategy because the evidence for it is weak [7]. Therefore, the appropriate therapy strategy
for aspirin is still unclear.
There have been many large trials to detect the true effect of aspirin use; they all included diabetes
patients without previous cardiovascular disease. A Study of Cardiovascular Events in Diabetes
(ASCEND: 15,480 diabetic participants under 100 mg of aspirin once daily and placebo, median
follow-up of 7.4 years), showed that individuals using aspirin had a 12% reduction in risk of major
adverse cardiovascular events (MACE) but had a 29% increase in bleeding risk compared with a placebo
group [8]. Another large trial, namely, the Aspirin in Reducing Events in the Elderly (ASPREE: 2057
diabetes patients with 100 mg aspirin once daily and placebo, median follow-up of 4.7 years) revealed
a non-significant 10% reduction in the risk of MACE and a non-significant 30% increase in bleeding
risk [9]. The other large study, namely the Japanese Primary Prevention of Atherosclerosis with
Aspirin for Diabetes (JPAD2: 2160 diabetic participants with 81 or 100 mg daily and placebo, median
follow-up of 10.3 years), which was a randomized, open-label, standard care-controlled trial, revealed
no statistically significant benefit in cardiovascular events [10]. These large randomized control trials
indicated that aspirin may have a positive effect on the prevention of CVD, but the increased bleeding
risk should be considered. Furthermore, these results were compatible with results from the previous
meta-analysis, which also showed inconsistent results about the role of aspirin in primary prevention
of CVD and risk for bleeding among subjects with diabetes [11–15]. The possible explanation for this
discrepancy may be attributable to several factors, such as dose of aspirin, age, gender, or ethnic factors.
The dosage of aspirin used in previous studies ranged from 100 mg every other day to 650 mg per
day, which may have led to a selection bias and affected the results of the meta-analysis. Given the
practical problem of aspirin use in diabetes, we aimed to focus on low-dose aspirin use in diabetes
for primary prevention in this investigation. Owing to the recent publication of large randomized
control trials, including JPAD2, ASCEND, and ASPREE trials, we aimed to effectively summarize
the eligible evidence and promote the proper dissemination of this important clinical information.
To accomplish this goal in our meta-analysis, we used the GRADE profiler guideline development
tool software to assess the overall certainty of the evidence in this topic area. Statistical methods were
used to evaluate the benefits and disadvantages of aspirin use in diabetes and to make an objective
conclusion regarding its use as the primary prevention method for CVD in diabetic patients.
2. Experimental Section
2.1. Data Sources and Searches
We performed a systematic literature search in electronic datasets (i.e., PubMed, Embase,
and Cochrane central) for randomized controlled trials (RCTs) that evaluated low-dose aspirin
as the primary prevention strategy in diabetes (additional search details are listed in Table S2).
We also conducted manual screening for references from original articles, conference abstracts,
and previous systematic reviews to identify eligible trials. We followed the Preferred Reporting Items
for Systematic Reviews and Meta Analyses (PRISMA) guidelines for performing the systematic reviews
and meta-analyses of RCTs (Figure 1). The protocol for this systematic review is registered with
PROSPERO (no. CRD4201811830).
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Figure 1. PRISMA flowchart of study selection. Flow diagram of the identification process for
eligible studies.
2.2. Study Selection
Low-dose aspirin was defined as a daily aspirin regimen (≤100 mg). Patients with either type 1 or
type 2 diabetes without previous major vascular events were included. Furthermore, peer-reviewed
RCTs written in various languages were included. Trials examining aspirin use as the primary
prevention strategy that had subgroups with diabetes were also included. Language with English or
Chinese were included.
Trials identified from the literature search were initially screened for relevance based on titles and
abstracts by two independent reviewers (Cho-Hao Lee and Chin Lin). Studies that did not meet these
criteria during the title and abstract screen were excluded. Full-text reviews were then performed using
the studies included after screening to ensure that they met the eligible criteria. Any disagreement
between the two independent reviewers was resolved via group discussions.
2.3. Data Extraction and Quality Assessment
Two independent reviewers (Cho-Hao Lee and Chin Lin) extracted various data, including author
names, publication year, geographic regions, trial names, study designs, sample sizes, and participant
characteristics (mean age, sex, inclusion criteria, aspirin dosage, follow-up duration, and completion).
The outcomes of interest including MACE (a composite of non-fatal myocardial infarction, non-fatal
stroke, and death from cardiovascular causes), major hemorrhage (major intracranial hemorrhage and
major gastrointestinal bleeding), and all-cause mortality were also extracted. To address the risk of
bias with multiple data extractors, standardized “Google Excel” templates were created. Last, the third
reviewer (Ming-Hsun Lin) double-checked the data for accuracy.
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The quality of trials was appraised using the Cochrane Handbook for Systematic Reviews of
Interventions [16]. Seven domains—selection bias, attrition bias, performance bias, detection bias,
reporting bias, contamination bias, and other risks of bias—are listed in the Figure S1. Any disagreement
between the two reviewers was resolved via group discussions.
2.4. Data Synthesis and Analysis
Data analysis was conducted as recommended in the Cochrane Handbook for Systematic Reviews of
Interventions [17]. We used both random and fixed effects modeling to pool all outcomes and interpreted
random-effects meta-analyses with consideration to the complete distribution of effects. We calculated
dichotomous outcomes by using the Mantel–Haenszel method and evaluated the risk ratio (RR) with
95% CIs.
Heterogeneity and publication biases were evaluated by I2 statistic and funnel plots with
Egger’s test. Statistically significant heterogeneity was defined as an I2 statistic > 50%. The cause
of heterogeneity was investigated for main outcomes by using sensitivity tests and a mixed-effects
meta-regression model with variables including follow-up duration, mean age, sample sizes, country,
completion, and publication year [17]. All statistical analyses were performed using the ‘metafor’ and
‘meta’ [18] packages of R software version 3.3.1 [19]. A two-tailed significance test (p value = 0.05)
denoted statistical significance without multiplicity correction in all exploratory analyses.
Furthermore, to assess the certainty of the evidence for each outcome, we used the GRADE
profiler guideline development tool software [20] and ranked the quality of the evidence according to
the Cochrane Handbook for Systematic Reviews of Interventions [16,21]. This method takes issues related
to internal validity (e.g., risk of bias, inconsistency, imprecision, and publication bias) and external
validity (e.g., directness of results) into account. We downgraded the evidence from “high” certainty
by one level for serious concerns and by two levels for very serious concerns.
A trial sequential analysis (TSA), which is similar to interim analyses in a single trial, was also
conducted [22,23]. Monitoring boundaries were used to decide if a trial could be terminated early
(i.e., when a p value was sufficiently small to show the anticipated effect). We also used monitoring
boundaries to determine if a study produced a sufficiently small p value to demonstrate the anticipated
power. The chance of random errors may have been increased owing to insufficient comparisons
and the repetitive testing of pooled data when the estimated information samples had not been
achieved [22,24,25]. TSA version 0.9 beta [26] was used for the quantification of information samples.
3. Results
The systematic search yielded 443 studies, and 297 studies remained after removing duplicates.
Then 279 studies were excluded after reviewing the abstract and title. There were 20 eligibility
full-text articles; 11 of them were excluded for several reasons after reviewing the full-text articles.
The remaining nine randomized control trials involving 29,814 participants were included (Figure 1).
Among the total sample, 14,897 patients were randomized to low-dose aspirin use, and 14,917 patients
were randomized to a control group. Table 1 shows the characteristics of each study. Four of the nine
trials contained subgroups with diabetes, and the other five trials were studies that primarily focused
on diabetes. These trials were published from 1998 to 2018 and were conducted in more than five
different countries; the mean follow-up period ranged from 3.6 years to 10.3 years. The dosage of
aspirin used ranged from 100 mg/every other day to 100 mg/daily.
Meta-regression analyses were performed for MACE, myocardial infarction (MI), stroke, major
hemorrhage, and all-cause mortality (see Table S3). There was no significant association of aspirin use
with the above outcomes. However, although it was not surprising, all-cause mortality and mean age
were related.
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3.1. Major Adverse Cardiovascular Event and Major Hemorrhage
This study revealed a significant reduction in the risk of MACE (Figure 2A) in the low-dose aspirin
group compared with the placebo and no-treatment groups (eight studies, RR 0.91, 95% CI 0.84–0.98).
No heterogeneity was found between the studies (I2 = 0%, p value = 0.99). Furthermore, TSA was used
to analyze MACE. After including the three large trials (JPAD2, ASCEND, and ASPREE), the analysis
showed a significant reduction in the risk of MACE with low-dose aspirin administration (Figure 2B).
The GRADE system demonstrated a moderate level recommendation for low-dose aspirin
administration in diabetic patients (see Table 2).
Major hemorrhaging, including intracranial bleeding and gastrointestinal (GI) bleeding, was the
most important adverse effect of aspirin use. The results revealed a significant increase in hemorrhage
risk (24%) with aspirin administration (five studies, RR = 1.24, 95% CI =1.03–1.48). The heterogeneity
between studies in this analysis was low (I2 = 23%, p value = 0.27, see Figure 2C).
3.2. Efficacy and Safety End Point
We analyzed several secondary outcomes, including MI, coronary heart disease, and stroke,
and summarized the results in Table 2.
There was no reduction in the risk of MI (six studies, RR = 1.01, 95% CI = 0.84–1.22, see Table 2
and Figure S2) or coronary heart disease (six studies, RR = 0.94, 95% CI = 0.84–1.06, see Table 2
and Figure S2). The heterogeneity of evidence was low for MI (I2 = 21%, p value = 0.27), and no
heterogeneity of evidence was found for coronary heart disease (I2 = 0%, p value = 0.86).
Additionally, there was a reduction in the risk of stroke with aspirin use (seven studies, RR = 0.84,
95% CI = 0.73–0.97, see Table 2 and Figure S2). No heterogeneity of evidence was found in this
analysis (I2 = 0%, p value = 0.65). No significant reduction in the risk of cardiovascular death (five
studies, RR = 0.94, 95% CI = 0.77–1.14, see Table 2 and Figure S2) or all-cause mortality (six studies,
RR = 0.97, 95% CI = 0.90–1.06, see Table 2 and Figure S2) was found. Furthermore, there was no
heterogeneity of evidence in cardiovascular death (I2 = 0%, p value = 0.54) or all-cause mortality
(I2 = 0%, p value = 0.46).
This present study showed increased hemorrhagic risk by 24% in the aspirin group. The subgroup
analyses of major hemorrhage events revealed no statistically significant difference in aspirin use
regarding major gastro-intestinal or intra-cranial hemorrhage (Table 2).
3.3. Sensitivity Tests and Publication Bias
We used sensitivity tests, subgroup analyses, and meta-regression analyses to explore potential
heterogeneity. Meta-regression analyses were performed for MACE, myocardial infarction (MI), stroke,
major hemorrhage, and all-cause mortality (see Figure S2). There was no significant association of
aspirin use with the above outcomes. There was no sex difference in our present study. However,
although it was not surprising, all-cause mortality and mean age were related. Publication bias was
evaluated by visual examination and Egger’s regression test for all interested outcomes. Neither visual
examinations nor Egger‘s regression test showed that significant publication bias existed (see Figure S3).
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Figure 2. Meta-analysis result, (A) Forest plot of major adverse cardiovascular events (MACE) in aspirin
compared with control, (B) Trial sequential analysis (TSA) of MACE, heterogeneity adjustment required
an information size of 37,337 participants calculated on the basis of the proportion of MACE incidence
of 8.7% in the placebo group, as well as α = 5%, β = 20%, power = 0.80, and I2 = 0.00%. Cumulative
Z-curve (solid blue line) crosses the trial sequential monitoring boundary, which shows sufficient
evidence of a statistically significant reduction in MACE risk with low-dose aspirin administration
after involving large trials such as ASCEND [8] and ASPREE [9]. Horizontal dark red lines illustrate
the traditional level of statistical significance (p = 0.05), (C) forest plot of major hemorrhage in aspirin
compared with control. Main outcomes of low-dose aspirin in the primary prevention of cardiovascular
disease (CVD). Risk ratio and 95% CI were used as a measure of effect for dichotomous variables. (Trial
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4. Discussion
This present study demonstrated that use of low dose aspirin in diabetic patients as primary
prevention of cardiovascular disease is warranted. Our sophisticated analysis showed a moderate
level recommendation to use aspirin for reducing the risk of MACE. Although aspirin use increased
the risk of major hemorrhage (i.e., major GI bleeding and major intracranial bleeding), it could be
prescribed among subjects of diabetes without obvious bleeding risk, or otherwise other research has
suggested that the use of proton pump inhibitors (PPIs) can decrease the risk of GI bleeding from
long-term aspirin use [34]. Long-term aspirin therapy achieves the benefit of MACE prevention with
a number needed to treat per year of 122 and carries a risk of GI hemorrhage with a number needed to
harm per year of 115. It is possible to estimate the balance between the benefit and harm for aspirin
use in diabetic patients with different cardiovascular risk levels by comparing the pooled estimate of
the number needed to harm against the number needed to treat from individual trials.
The results confirmed the current guideline of ADA that low dose aspirin may be considered as
a primary prevention strategy in those with diabetes mellitus (DM) who are at increased cardiovascular
risk and are not at increased risk of bleeding [6].
Age is an important factor to determine the usage of low dose aspirin in the primary prevention
of CVD in subjects of DM. A subgroup analysis was performed for those aged 60 years and older.
For this subgroup, aspirin use also showed a protective effect in major adverse cardiovascular events
compared with the control group (RR = 0.91, CI = 0.83–0.98, Table 2). However, GRADE analysis
showed that the recommendation level was low. For those younger than 60 years old, there was no
statistically significant effect in MACE (RR = 1.00, CI = 0.73–1.93, Table 2). This could be attributable to
the high heterogeneity between studies (I2 = 67.2%) and the low power. In conclusion, the benefit only
existed among subjects aged greater than 60 years old instead of below 60 years old in our subgroup
analysis. Elderly diabetic populations may have more cardiovascular risk factors, which may explain
this difference.
4.1. Comparison of Previous Published Meta-Analysis
This study only included low-dosage aspirin (less than 100 mg daily) and used trial sequential
analysis to assess the true results compared with previous published studies. Our finding of a 9%
reduction in the risk of MACE is similar to previously published meta-analyses published between 2009
and 2016 with a non-significant 8 to 10% reduction in MACE [5,14,15,35,36]. The present meta-analysis
enrolled a large sample size and was adequate to detect the benefit of aspirin in the prevention of
CVD among subjects of diabetes. Furthermore, the present study included primary and secondary
end points that revealed little to no heterogeneity of evidence, further supporting the important role
of aspirin.
Compared with previous work, this analysis showed no statistically significance reduction
of MI in the aspirin group, which was similar to previous published meta-analysis that revealed
a non-statistically significance 14% to 17% reduction in MI. Although previous studies revealed the
trend of decreased risk, our study showed a neutral effect after including a large trial of ASCEND,
which enrolled the most diabetic population. In contrast, the individual participant meta-analysis
reported that aspirin may significantly reduce the incidence of MI [2]. Further research is warranted.
Previous published meta-analyses reported a trend for the reduction in stroke risk, and the mean
RR reduction ranged from 14% to 30% [4,5,11–14,35]. Our analysis demonstrated a moderate level
of evidence for a reduction in stroke risk with low-dose aspirin administration. The adequacy of the
present investigation may explain the difference between studies. For major bleeding risk, all previous
results showed increased bleeding risk ranging from 54% to 69%, but no statistical significance.
Our present study also showed similar results that statistically significantly increased bleeding risk by
24%. Furthermore, the bleeding risk in our study was lower than previous results because of three
large trials included (JPAD2, ASCEND, and ASPREE).
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4.2. Strengths and Limitations
The major strength of the present analysis is the focus on the low dose of aspirin in the primary
prevention of CVD among subjects with diabetes. Besides, owing to the well-designed protocol and
detailed inclusion criteria, we conducted the largest meta-analysis of low-dose aspirin in diabetic
patients to date (nearly 30,000 people). This large sample allowed the examination of primary points,
secondary points, efficacy, and safety. To further clarify the effect of aspirin, we also performed
evaluations of internal validity (risk of bias, inconsistency, imprecision, and publication bias) and
external validity (directness of results). Even though the risk of hemorrhage increased, our analysis is
the first analysis to show a significant reduction of MACE with aspirin use for diabetic patients.
One limitation of the current investigation is the exclusion of observational studies, which may
provide more real-world data and longer follow-up times. Compared with RCT, the outcomes of
real-world evidence (RWE) continue to be assigned lower credibility. It must be emphasized that RWE
research is a real-world practice that does not need to be executed as RCT research for it to be reliable.
RCT research, characterized as having the highest reliability, and RWE research, which reflects the
actual clinical aspects, can have a mutually supplementary relationship. We believe that our present
meta-analysis of randomized control trial data proved the efficacy and safety of low dose aspirin;
however, we still need large real-world evidence to inspect the effect on clinical practice [37].
Furthermore, the diversity of the sample is low because five of the trials were conducted in the
United States, two were in Europe (United Kingdom and Italy), three were in Japan, and only one
study utilized a global design. Therefore, the generalizability of these results to other countries, races,
and ethnicities is limited.
An unpublished large trial still in progress, namely the Aspirin and Simvastatin Combination
for Cardiovascular Events Prevention Trial in Diabetes (ISRCTN48110081), enrolled approximately
50,000 participants and followed participants for approximately 5 years [38]. This trial will help clarify
the benefits of aspirin use. Although previous randomized control trials exist, they primarily include
Caucasian and Japanese participants. Additional large-scale trials with a global design are necessary
to better understand the benefits and disadvantages of aspirin use in diabetic individuals around
the world.
5. Conclusions
Previous published data do not recommend aspirin use as the primary prevention strategy for
diabetic individuals. The current investigation has shown a statistically significant protective effect and
a moderate level of confidence for the administration of low-dose aspirin for the primary prevention
in diabetes, particularly in older individuals (age ≥ 60 years). However, clinicians should assess the
effect of aspirin use in each patient on a case-by-case basis and use evidence-based medicine to guide
clinical decision making, especially considered the absolute benefits were largely counterbalanced by
the bleeding hazard.
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Abstract: Previous studies exploring the association between arterial stiffness and prediabetes remain
controversial. This study aimed to investigate the association of the different domains of prediabetes
categorized by glycated hemoglobin A1c (A1c) 5.7–6.4%, impaired fasting glucose (IFG), fasting
plasma glucose of 5.6–6.9 mmol/L, and impaired glucose tolerance (IGT), two-hour post-load glucose
of 7.8–11.0 mmol/L, on arterial stiffness. These were measured by brachial–ankle pulse-wave velocity
(baPWV). We enrolled 4938 eligible subjects and divided them into the following nine groups:
(1) normoglycemic; (2) isolated A1c 5.7–6.4%; (3) isolated IFG; (4) IFG with A1c 5.7–6.4%; (5) isolated
IGT; (6) combined IGT and IFG with A1c <5.7%; (7) IGT with A1c 5.7–6.4%; (8) combined IGT and IFG
with A1c 5.7–6.4%; and (9) newly diagnosed diabetes (NDD). The baPWV values were significantly
high in subjects with NDD (β = 47.69, 95% confidence interval (CI) = 29.02–66.37, p < 0.001), those
with IGT with A1c 5.7–6.4% (β = 36.02, 95% CI = 19.08–52.95, p < 0.001), and those with combined IGT
and IFG with A1c 5.7–6.4% (β = 27.72, 95% CI = 0.68–54.76, p = 0.044), but not in the other subgroups.
These findings suggest that increased arterial stiffness was found in prediabetes individuals having
an A1c 5.7–6.4% with IGT, but not IFG. Isolated A1c 5.7–6.4% and isolated IGT were not associated
with elevated arterial stiffness.
Keywords: prediabetes; arterial stiffness; baPWV
1. Introduction
Type 2 diabetes mellitus is one of the leading causes of premature morbidity and mortality
worldwide, and is an increasing public health concern [1]. Subjects with a condition lying between
normoglycemia and dysglycemia are considered to be prediabetic, and these clinical conditions have
been associated with the development of microvascular and macrovascular complications [2]. Since 2009,
the American Diabetes Association (ADA) has revised the criteria for the detection of prediabetes and
diabetes to include glycated hemoglobin A1c (A1c) levels as diagnostically relevant. This is in addition
to pre-existing diagnostics establishing impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT) [3,4]. Accordingly, these ADA recommendations are based mainly on associations between A1c
levels and microvascular complications [3].
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Diabetes both precedes and contributes to the development of macrovascular disease [1], and the
related diagnosis of prediabetes has become an important public issue [5]. One underlying mechanism
of diabetes and macrovascular disease is the associated elevated serum advanced glycation end products
(AGEs) that may cause the crosslinking of collagen molecules and the loss of collagen elasticity. The
glycosylation of the vessel walls has also been related to the thinning of elastin fibers, subsequently
resulting in arterial stiffness [6–8], which is an independent predictor of future cardiovascular events
and mortality [9,10]. Several non-invasive methods are currently available to evaluate the severity
of arterial stiffness, including one widely used method that measures pulse-wave velocity (PWV).
Although carotid-femoral PWV (cfPWV) is considered the gold standard indicator of arterial stiffness,
brachial–ankle PWV (baPWV) has been validated and is used in most Asian countries due to ease of
execution, reproducibility, and the strong correlations with cfPWV [11,12].
Previous studies exploring the association between arterial stiffness and prediabetes have lacked
consistency [13–17]; one explanation for the discrepancies might be related to the different ways of
defining prediabetes, including determining the fasting plasma glucose (FPG), two-hour post-load
glucose (2hPG), and A1c levels. For example, Ohnishi et al. [13] found significant differences in the
baPWV values of the normal versus the IFG groups based on FPG level alone. In contrast, using both
FPG and 2hPG level measurements, our previous study demonstrated the association of IGT with
greater arterial stiffness and isolated IFG with insignificant differences in baPWV, compared with
normal glucose tolerance [14]. Because 2hPG levels were not determined, the characteristics of the
subjects in the IFG group of the study by Ohnishi et al. may have had similar characteristics to the
subjects in the IGT group. Hence, the effects of IGT may have been misunderstood to be that of IFG.
In addition, in a large study of Caucasian adults [18], the concordance of prediabetes, diagnosed via
IFG, IGT, or A1c 5.7–6.4%, was limited, and, thus, the agreement among the three diagnostic criteria
was only 10.4%. The relationship between arterial stiffness and prediabetes requires consensus among
these three blood glucose indices. The aim of this study was to investigate the different domains of
prediabetes categorized by A1c 5.7–6.4%, IFG, and IGT, as per the ADA criteria parameters of arterial
stiffness shown by the baPWV values of a large Chinese population without known hypertension,
diabetes, or cardiovascular disease.
2. Experimental Section
2.1. Study Population
Subjects who received self-motivated physical check-ups were included in the study, which
covered the period between October 2006 and August 2009. The subjects’ data were extracted
retrospectively for secondary data analysis, without personal identification information, from the
Health Management Center of the National Cheng Kung University Hospital. None of the female
participants were pregnant. To avoid confounding effects, individuals were excluded if they: (1) had a
history of hypertension, diabetes, coronary heart disease, or stroke; (2) were using medications that are
known to influence blood pressure, plasma glucose, and lipid profiles; (3) had either of their lower
limbs amputated; (4) claimed alcohol consumption levels of more than 30 gm per week [19]; (5) had
estimated glomerular filtration rates (eGFR) of <30 mL/min/1.73 m2; (6) were anemic (hemoglobin
levels either <8.38 mmol/L in men or <7.45 mmol/L in women) [20]; or (7) had brachial–ankle indexes
of <0.95 [21]. A total of 4938 subjects (3076 men, 62.3%; 1862 women, 37.7%) met the inclusion criteria
and were enrolled. The study protocol was approved by the Ethics Committee for Human Research at
the National Cheng Kung University Hospital, Taiwan (Approval No. ER-100-164).
2.2. Clinical Parameter Assessment
All participants completed a structured questionnaire containing questions regarding medical
history, medication use, and lifestyle habits including smoking, alcohol consumption, and regular
exercise. Smoking habits were categorized as former, current, or never; alcohol consumption was
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categorized as either current or non-user. Habitual exercise was defined as vigorous exercise at least
three times per week [22]. The subjects’ height and weight were measured to the nearest 0.1 cm
and 0.1 kg, respectively using a certified anthropometry instrument, and body mass indexes (BMI;
kilograms per meter squared) were calculated for all subjects. Systolic and diastolic blood pressure
(SBP and DBP, respectively) were determined using a DINAMAP vital sign monitor (model 1846SX,
Critikon Inc., Tampa, FL, USA). The mean levels, from right and left, of brachial blood pressure
were measured while the subjects were in the supine position and wrapped in appropriately-sized
pneumatic pressure cuffs, after at least 15 min of rest.
All blood samples were collected after overnight fasting of at least 10 h, and creatinine, FPG,
cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), A1c, and hemoglobin levels
were determined. Following a 75 g oral glucose tolerance test, 2hPG levels were measured in
subjects without a history of diabetes. FPG and 2hPG levels were determined using a hexokinase
method (Roche Diagnostic GmbH, Mannheim, Germany). A1c levels were measured using
ion-exchange HPLC (HbA1c, BIO-RAD V-II TURBO Hemoglobin A1c program, Bio-Rad Laboratories,
Inc., Kent, England). Initially, subjects were divided into five groups, according to the ADA
diagnostic criteria [4]: (1) normoglycemic—FPG <5.6 mmol/L, 2hPG <7.8 mmol/L, and A1c <5.7%;
(2) isolated A1c 5.7–6.4%—FPG <5.6 mmol/L, 2hPG <7.8 mmol/L, and A1c 5.7–6.4%; (3) IFG without
IGT—FPG <7.0 mmol/L, 2hPG <7.8 mmol/L, and A1c <6.5%; (4) IGT—2hPG of 7.8–11.0 mmol/L,
FPG <7.0 mmol/L, and A1c <6.5%; and (5) with newly diagnosed diabetes (NDD)—FPG ≥7.0 mmol/L,
2hPG ≥11.1 mmol/L, or A1c ≥6.5% (Figure 1). Groups 3 and 4 were further categorized into two
and four groups, respectively: (3.1) isolated IFG—FPG of 5.6–6.9 mmol/L, 2hPG <7.8 mmol/L, and
A1c <5.7%; (3.2) IFG with A1c 5.7–6.4%—FPG of 5.6–6.9 mmol/L, 2hPG <7.8 mmol/L, and A1c 5.7–6.4%;
(4.1) isolated IGT—FPG <5.6 mmol/L, 2hPG of 7.8–11.0 mmol/L, and A1c <5.7%; (4.2) combined IGT
and IFG with A1c <5.7%—FPG of 5.6–6.9 mmol/L, 2hPG of 7.8–11.0 mmol/L, and A1c <5.7%; (4.3) IGT
with A1c 5.7–6.4%—FPG <5.6 mmol/L, 2hPG of 7.8–11.0 mmol/L, and A1c 5.7–6.4%; and (4.4) combined
IGT and IFG with A1c 5.7–6.4%—FPG of 5.6–6.9 mmol/L, 2hPG of 7.8–11.0 mmol/L, and A1c 5.7–6.4%
(Figure 2).
Figure 1. Venn diagram representing different domains of prediabetes categorized by glycated
hemoglobin A1c (A1c) of 5.7–6.4%, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT).
61
J. Clin. Med. 2019, 8, 603
Figure 2. Venn diagram representing different domains and agreements of prediabetes categorized
by glycated hemoglobin A1c (A1c) 5.7–6.4%, impaired fasting glucose (IFG), and impaired glucose
tolerance (IGT). A) IFG with A1c 5.7–6.4% (n = 137); B) combined IGT and IFG with A1c <5.7% (n = 29);
C) IGT with A1c 5.7–6.4% (n = 305); and D) combined IGT and IFG with A1c 5.7–6.4% (n = 109).
2.3. Vascular Assessment
After 5 min of supine rest, the subjects’ baPWV values were measured using a non-invasive
vascular screening device (BP-203RPE II; Colin Medical Technology, Komaki, Japan). This device allows
pulse-wave measurements from sensors in four wrapped pneumatic pressure cuffs that simultaneously
measure the blood pressure and pulse waves in the brachial arteries of both arms and the tibial arteries
of both legs. Then, we automatically computed baPWV (cm/s) by dividing the brachial–ankle distances
(L = 0.5934 × body height (cm) + 14.4014) by the time interval between rising waveforms of the brachial
region and the ankle (ΔT). Because the left and right baPWV values were significantly positively
correlated (r = 0.968, p < 0.001), the mean baPWV values were used in the final analyses.
2.4. Statistical Methods
Statistical analyses were performed using SPSS software for Windows (version 17.0; SPSS, Inc.,
Chicago, IL, USA). Continuous variables are expressed as mean ± standard deviation, and categorical
variables are expressed as percentages. Differences between the unadjusted group means of continuous
variables were identified using ANOVA with Scheffé’s post hoc test. Categorical variables were
compared using Chi-square tests among groups. Multiple linear regression analyses were performed to
test the relationship between baPWV values (dependent variables) and different glycemic states, with
adjustment for other confounding variables, including age, sex, BMI, SBP, total cholesterol, triglyceride,
HDL, former smoking vs. never, current smoking vs. never, current alcohol consumption, and habitual
exercise. In Models 1 and 2 of the multiple linear regression models, glycemic states were divided into
five and nine subgroups, respectively. Unstandardized regression coefficients and 95% confidence
intervals (CI) were derived from each regression model. Through the statistical tests, the differences
and associations were considered significant when p < 0.05.
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3. Results
Initially, 4938 subjects were classified into groups, normoglycemic (n = 2583), isolated A1c 5.7–6.4%
(n= 1188), IFG without IGT (n= 211), IGT (n= 704), and NDD (n= 252). The Venn diagram representing
different domains of prediabetes, including isolated A1c 5.7–6.4%, IFG without IGT, and IGT, is shown
in Figure 1. The baseline characteristics of the subjects in these five groups are presented in Table 1.
Significant differences were identified in age, sex, BMI, SBP, DBP, FPG, 2hPG, cholesterol, triglyceride,
HDL-C, and prevalence of current alcohol drinking. Within these five groups, the mean baPWV values
were 1253.1 ± 187.6, 1353.7 ± 223.9, 1376.9 ± 227.8, 1406.3 ± 251.7, and 1491.6 ± 276.6 cm/s (ANOVA;
p < 0.001), respectively. The Scheffé’s post hoc test also revealed that baPWV values increased more in
the isolated A1c 5.7–6.4%, IFG without IGT, IGT and NDD groups than in the normoglycemic group
(p < 0.001). Following the discordance in the categorization resulting from the three tests (A1c, FPG,
2hPG), the prediabetic groups were further clarified, as shown in Figure 2, and all subjects were then
classified into nine groups, including normoglycemic (n = 2583), isolated A1c 5.7–6.4% (n = 1188),
isolated IFG (n = 74), IFG with A1c 5.7–6.4% (n = 137), isolated IGT (n = 261), combined IGT and IFG
with A1c <5.7% (n = 29), IGT with A1c 5.7–6.4% (n = 305), combined IGT and IFG with A1c 5.7–6.4%
(n = 109), and NDD (n = 252).
In the multiple linear regression analyses of the clinical variables and the baPWV values of Table 2,
Model 1 shows independently higher baPWV values only in the prediabetic group of IGT (β = 16.59,
95% CI = 4.41–28.76, p = 0.008) and the NDD group (β = 46.35, 95% CI = 27.18–65.04, p < 0.001), but not
in the isolated A1c 5.7–6.4% or IFG without IGT groups, compared with normoglycemic subjects.
In addition, age, current smoking, and SBP were positively associated with the baPWV values, whereas
BMI and habitual exercise were inversely associated with the baPWV values. These above factors
accounted for 63.2% of the total variance (adjusted R2 = 0.632). In Model 2, when the agreement
domains were stratified further using the three tests, the baPWV remained significantly higher in
the NDD group (β = 47.69, 95% CI = 29.02–66.37, p < 0.001) and the prediabetic groups of IGT with
A1c 5.7–6.4% (β = 36.02, 95% CI = 19.08–52.95, p < 0.001) and combined IGT and IFG with A1c 5.7–6.4%
(β = 27.72, 95% CI = 0.68–54.76, p = 0.044). However, compared to the normoglycemic subgroup,
the elevated baPWV values were not significant in the two subgroups—isolated and combined IGT
and IFG with A1c <5.7%—originally included from the IGT group. The above factors accounted for
63.3% of the total variance (adjusted R2 = 0.633).
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4. Discussion
The present study is the first to show the different effects of prediabetes, categorized concomitantly
by A1c, FPG, and 2hPG levels, on arterial stiffness. The results showed that increased arterial stiffness
was found in individuals having either IGT with A1c 5.7–6.4% or combined IGT and IFG with
A1c 5.7–6.4% but not in those having either IGT with A1c <5.7% or combined IGT and IFG with
A1c <5.7%, independent of other cardiovascular risk factors. The elevated arterial stiffness was
insignificant in subjects having either IFG with A1c <5.7% or IFG with A1c 5.7–6.4%. The association
between prediabetes and arterial stiffness is still not consistent [13–17]. The MARK study [17] showed
that A1c, FPG, and postprandial glucose were positively related to arterial stiffness in diabetes subjects,
but not in prediabetes subjects. Ohnishi et al. [13] found that baPWV values were significantly higher
than normal fasting glucose levels in IFG subjects; however, they only had fasting glucose data and
not 2hPG data. Our previous study highlighted the importance of IGT, categorized by FPG and
2hPG values, and the associated risk of increased arterial stiffness based on FPG and 2hPG levels [14].
Di Pino et al.’s study [16] revealed that arterial stiffness, as shown by an augmentation index, was
higher in subjects with normal glucose tolerance with A1c 5.7–6.4% compared to that in subjects with
normal glucose tolerance with A1c <5.7%; however, these values were similar to those of the IGT
and type 2 diabetes patients. Liang et al. [15] found that prediabetic subjects with abnormal A1c,
FPG, and 2hPG had higher cfPWV values, but they did not test the concomitant influence of A1c,
FPG, and 2hPG on cfPWV. The discrepancy between the results of this study and those of Liang et al.
may be related to the different methodologies. Subjects were excluded from our study if they had
history of hypertension, diabetes, coronary heart disease, stroke, or peripheral vascular disease and if
they were taking medications known to influence blood pressure, plasma glucose, and lipid profiles,
whereas such subjects were not excluded from Liang et al.’s study. In Liang et al.’s study, subjects with
cardiovascular disease or those taking medications were included among subjects with A1c 5.7–6.4%,
IFG, or IGT, resulting in elevated arterial stiffness in subjects with abnormal A1c, FPG, and 2hPG.
Discrepancies in the criteria used in the three different tests for diagnosing either prediabetes or
diabetes have been reported and suggest the importance of categorizing the different characteristics
of the subjects. IFG indicates impaired first-phase insulin secretion and reduced hepatic insulin
sensitivity, whereas IGT suggests markedly peripheral insulin resistance and defective second-phase
insulin secretion, contributing to prolonged defects [23]. A1c is a marker representing both basal and
postprandial hyperglycemia, and it provides a “picture” of the average blood glucose level over the past
2–3 months [24]. In this study, increased arterial stiffness was found in prediabetes individuals having an
A1c 5.7–6.4% with IGT, but not IFG. This result highlighted the importance of 2hPG, as possibly having
a stronger associated risk of arterial stiffness than that of FPG. The main mechanism of hyperglycemia
affecting arterial stiffness is the generation and formation of AGEs, whose biochemical process may
involve the glycosylation of vessel walls, subsequent crosslinking of collagen molecules, loss of collagen
elasticity, and thinning of elastin fibers. Otherwise, AGEs can interact with certain receptors, inducing
intracellular signaling with enhanced oxidative stress, triggering the inflammatory process, and, finally,
increasing arterial stiffness [6–8,25,26]. Furthermore, the serum levels of AGEs are positive correlates
of insulin resistance [27], which is related to the reduced production of nitric oxide and its related
vasodilation [28], post-load hyperinsulinemia-induced oxidative stress [29], decreased endothelial
progenitor cells with impaired vascular repair qualities [30], and related metabolic alterations, such as
either dyslipidemia or elevated blood pressure [31]. Importantly, IGT showed a more pronounced
degree of insulin resistance than did IFG [32]. Therefore, the above findings may partially explain
elevated arterial stiffness in prediabetes individuals having an A1c 5.7–6.4% with IGT, but not IFG.
As shown previously, we have identified the independent effects of age, blood pressure, and
smoking status on arterial stiffness [33–35]. Aging is widely associated with compromised arterial
stiffness; the effects of aging on baPWV might be mediated by the intermediate parameters of
cardiovascular risk factors, such as blood pressure [36]. The positive relationship between smoking and
increased arterial stiffness may reflect increased inflammation, thrombosis, oxidation of low-density
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lipoprotein cholesterol, and oxidative stress [34]. Although the association between obesity and arterial
stiffness remained inconclusive, in agreement with Tomiyama et al. [37], BMI was negatively associated
with baPWV in this study. In the work of Ben et al. [38], arterial stiffness was reduced until middle
age, and it was speculated that vascular adaptation to obesity was lost with advanced age, meaning
that the adverse association between obesity and arterial stiffness becomes apparent only later in life.
Moreover, the effects of obesity on arterial stiffness might be mediated by intermediate cardiovascular
risk factors, such as blood pressure, and the highly associated variables included might lead to further
collinearity [39].
Despite the large study cohort, our study was limited to a cross-sectional design, which cannot
be used to establish causal relationships. Our study was also confined to the Chinese population,
and the data complemented the differences between previous studies of different ethnic groups. All
subjects were extracted from a health management center and had received regular health examinations.
Therefore, the present results should be used carefully because they are not indicative of the general
population. In addition, since the arterial stiffness in our study was measured by baPWV, a peripheral
stiffness parameter but not a direct measure of central stiffness, our results are limited and would
be more relevant if the subjects were then used for a longitudinal study, either in terms of future
cardiovascular events or mortality. Additionally, we did not measure either insulin or high sensitivity
C-reactive protein to provide more information about insulin resistance or vascular inflammation status.
5. Conclusions
In conclusion, increased arterial stiffness was found in prediabetes individuals having an
A1c 5.7–6.4% with IGT, but not IFG. Isolated A1c 5.7–6.4%, isolated IGT, and IGT with A1c <5.7% were
not associated with elevated arterial stiffness. Despite the practicality and convenience of FPG and
A1c, it is still important to consider postprandial glucose values to facilitate early recognition of the
significant proportion of the at-risk population.
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Abstract: Diabetes mellitus (DM) is the leading cause of polyneuropathy in the Western world.
Diabetic neuropathy (DNP) is the most common complication of diabetes and is of great clinical
significance mainly due to the pain and the possibility of ulceration in the lower limbs. Early detection
of neuropathy is essential in the medical management of this complication. Early unmyelinated C-fiber
dysfunction is one of the typical findings of diabetic neuropathy and the first clinical manifestation of
dysfunction indicating sudomotor eccrine gland impairment. In order to assess newly developed
technology for the measurement of dermal electrochemical conductance (DEC), we analyzed the
feasibility and effectiveness of DEC (quantitative expression of sudomotor reflex) as a screening
test of DNP in primary health care centers. The study included 197 people (with type 2 diabetes,
prediabetes and normal tolerance) who underwent all the protocol tests and electromyography
(EMG). On comparing DEC with EMG as the gold standard, the area under the receiver operating
characteristic (ROC) curve (AUC, area under the curve) was 0.58 in the whole sample, AUC = 0.65 in
the diabetes population and AUC = 0.72 in prediabetes, being irrelevant in subjects without glucose
disturbances (AUC = 0.47). Conclusions: In usual clinical practice, DEC is feasible, with moderate
sensitivity but high specificity. It is also easy to use and interpret and requires little training, thereby
making it a good screening test in populations with diabetes and prediabetes. It may also be useful in
screening general populations at risk of neuropathy.
Keywords: dermal electrochemical conductance; diabetes mellitus; neuropathy; primary care;
screening; sudomotor reflex
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1. Introduction
The prevalence of diabetes mellitus (DM) is very high in Spain, being approximately 14% according
to oral glucose tolerance test (OGTT) results [1]. The management of DM requires a significant
consumption of health care resources, mainly in relation to the care of vascular complications. Among
the late microvascular events which may develop in patients with DM, polyneuropathy (PN) is the
most common and disabling, and is the leading cause of morbidity and mortality in these patients [2].
Indeed, in Spain, the leading cause of neuropathy is DM, with its prevalence increasing with the
presence of DM and other risk factors such as obesity [3].
PN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in people
with DM, after ruling out other possible causes [4]. The Toronto Panel Consensus on PN defined this
disorder as a symmetrical, length-dependent sensorimotor PN attributed to metabolic and microvessel
alterations due to chronic exposure to hyperglycemia and other risk factors. In patients with PN, thin
fibers (autonomic system—sweating) and thermal and tactile sensitivity are first affected, followed
by the involvement of large fibers, presenting an altered vibrating sensation which eventually alters
electromyography (EMG) patterns. Therefore, dysfunction of the sweat reflex in small distal fibers is
one of the earliest changes detected in these patients [5].
The most common clinical presentation of PN is distal symmetric polyneuropathy (DSPN), being
predominantly sensory in 80% of cases [3]. Pain is the most important symptom and is described as
burning or flashing, lancinanting, deep, and with frequent exacerbations during rest [4]. Pain often affects
the quality of life of these patients, and it is a frequent cause of depression and/or anxiety [6]. Moreover,
some patients may develop hypoesthesia, which may lead to severe foot lesions [7]. The prevalence of
DSPN varies greatly according to the population, definition, and detection method.
In the Rochester study including >64,000 patients, the prevalence of PN was between 66% and
59% for type1 DM and type 2 DM, respectively [8]. The 3rd report of the Technical Study Group of
Diabetes of the World Health Organization (WHO) described a prevalence of 40% [7], and 50% in
patients with >25 years of DM evolution. Pirart et al. [9] reported a prevalence ranging from 25% to
48% [7,10–17], whereas in Spain, Cabezas-Cerrato et al. published a figure of 24.1% [10].
DSPN-related factors are age, DM duration, metabolic control, male gender, acute myocardial
infarction, hyperlipidemia (especially hypertriglyceridemia), smoking, and general cardiovascular risk
factors [2,15,16,18]. Puig et al. [11] also included urinary albumin excretion as a risk factor of presenting
DSPN. The diagnosis of DSPN is commonly made based on signs and symptoms and usually includes
the use of several scores such as the Neuropathy Disability Score (NDS), the Neuropathy Symptoms
Score (NSS), the Michigan Neuropathy Instrument (MNI) and the Douleur Neuropathique 4 Questions
(DN4). These methods are easy to perform and are reproducible, sensitive, and adequate for use in a
screening program [14].
There are many confirmatory tests, including measurements of nerve conduction velocity (EMG)
and biothesiometry or skin biopsy. However, the most commonly used are the measurement of altered
sensations using a vibrating tuning fork with 128 Hz and/or pressure with Semmes-Weinstein 5:07
monofilament [15]. Monofilament testing (MFT) is widely accepted and recommended by all scientific
societies because of its validity, predictive risk, efficiency, and simplicity. Feng et al. [16] reported that
monofilament (MFT) has a sensitivity of 57% to 93%, a specificity of 75% to 100%, a positive predictive
value (PPV) of 36% to 94%, and a negative predictive value (NPV) of 84% to 100% compared with the
measurement of nerve velocity by EMG.
Although electrophysiological measures are more objective and reproducible, they are limited
in that they only detect dysfunction based on the presence of thicker and faster (myelinated) fibers
and show their involvement later. Consequently, EMG is a specific, albeit very insensitive, test.
Recently developed noninvasive techniques are more reproducible and reliable for the detection of
early dysfunction of small fibers. One of these new techniques involves the measurement of dermal
electrochemical conductance (DEC) or the sudomotor dysfunction index and has been evaluated by
well-designed studies which support its use as a screening test [17–21].
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Ramachandran et al. [22] studied the use of DEC to detect diabetes and other disorders of glucose
metabolism. In a study on the use of DEC, Casellini et al. [5] applied a PN test which showed a low
sensitivity of 78% and a specificity of 92% in diabetic patients without neuropathy compared to other
subjects with neuropathy and a control group. In this latter study, correlation with clinical parameters
showed adequate reproducibility of the results, particularly in regard to the measurements of the
feet [5]. Several other studies [23] also obtained significantly lower DEC values on comparing diabetic
patients and controls. In a study of patients following a 12-month program of intense physical activity,
Raisanen et al. [18] observed a greater improvement in DEC compared to weight, waist circumference,
or maximum oxygen volume (VO2 max).
Although we will not discuss the best algorithm to screen diabetic neuropathy, certain tests have
shown promising results in predicting future diabetes-related complications. Some of these tests
include related factors such as obesity, macroangiopathy (i.e., kidney disease) or retinopathy [24–28].
Therefore, taking into account the large number of methods used and the learning curve required
to correctly implement these techniques, as well as the absence of consensus as to which method
is the most adequate to diagnose DSPN, the aim of this study is to validate the usefulness of DEC
measurement in the early diagnosis of DSPN compared with traditional techniques in the primary
care setting.
2. Experimental Section
2.1. Hypothesis and Objectives
The hypothesis of our study was that the measurement of DEC is feasible, sensitive, and specific
and more or equally effective to other techniques commonly used in the initial screening of diabetic
neuropathy in primary care.
2.1.1. Main Objective
To evaluate the feasibility, effectiveness and performance of a new technique which measures
DEC (sudomotor reflex) in the screening of diabetic neuropathy in primary care.
2.1.2. Specific Objectives
Determine the performance of DEC (quantitative assessment of sudomotor reflex) as a tool for
the screening of diabetic neuropathy in primary care compared with the Semmes-Weinstein 5:07 MFT
when an EMG is used to confirm the presence of diabetic PN in patients with prediabetes and type
2 diabetes.
Determine the performance of DEC (quantitative assessment of sudomotor reflex) as a tool for
screening diabetic neuropathy in primary care compared with the Semmes-Weinstein 5:07 MFT when
the NDS is used to confirm the presence of diabetic PN in patients with prediabetes and type 2 diabetes.
2.2. Material and Methods
The study design has been extensively described elsewhere [29]. In brief, this was a prospective
study aimed at evaluating (a) the feasibility of the protocol in primary care and (b) the capacity of
achieving early diagnosis of PN. A prospective and blinded comparison was made between DEC
(sudomotor reflex) (Sudoscan®, Impeto Medical, Paris, France) and EMG; with MFT 5.07 (10 g)
Semmes-Weinstein; with Rydel-Seiffer 128 Hz tuning fork (vibrating sensibility); and the NDS score, in
a consecutive sample of individuals attended in the primary care setting in the Vallès Occidental and
Baix Camp counties (Catalonia, Spain), and their reference hospitals.
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2.2.1. Design
We performed a blind, prospective study comparing DEC (sudomotor reflex) (Sudoscan™, Impeto
Medical, France), EMG, the Semmes-Weinstein 5:07 MFT (10 g), the sensitivity of a vibrating tuning
fork 128 Hz, NDS score and DN4 score in a consecutive series of patients treated in primary care.
2.2.2. Sites
The primary care teams of Terrassa-Sud and other partners belonging to the Mútua Terrassa
reference hospital and those of the primary care teams of Reus (CAP Sant Pere) and the University
Hospital Sant Joan de Reus reference hospital participated in the study.
2.2.3. Study Subjects
We consecutively included patients with type 2 DM over 40 years of age, with or without
symptoms of neuropathy, attended in primary care. We also included the following 2 groups of
patients matched by age and sex: one including patients with prediabetes (intermediate alterations
of glucose metabolism defined as impaired fasting glucose (IFG)) and/or impaired glucose tolerance
(IGT) determined by OGTT after 2-h 75 g oral glucose administration and another including patients
without glucose alterations (normal glucose tolerance) (control group).
Three main diagnostic categories (normal, prediabetes, and diabetes) were defined using the WHO
criteria based on 2-h postload glucose (<7.8 (140 mg/dL), 7.8–11.0 mmol/L (140–200 mg/dL)) and/or
fasting plasma glucose (6.1–6.9 mmol/L; 110–126 mg/dL) and >11.1 mmol/L (>200 mg/dL), respectively.
The exclusion criteria were type 1 DM, upper or lower limb amputation (except phalanges),
diagnosis of neuropathy not related to diabetes, neuropathy by entrapment, use of psychoactive
substances, chronic alcoholism, malnutrition; treatment with beta-blockers, presence of terminal
disease, or life expectancy <3 years. Pregnancy was ruled out in women (negative pregnancy test) and
a history of gestational diabetes was also taken into account.
The study period was from 1 January 2017 to 31 January 2019.
2.2.4. Sample Size
It was estimated that the study should include a total of 160 participants in order to evaluate the
validity and performance of a screening test showing a sensitivity of 82%, a precision of 9%, and a
confidence interval of 95% (95% CI: 128–192), and considering a drop-out rate of 20%. The proportion
of diabetes/prediabetes/normal glucose tolerance was 2:1:1.
The contribution of patients by centers was 66% from the Mutua de Terrassa (minimum 106 cases)
and 34% from Reus (minimum 54 cases), achieving a final sample size of 197 cases.
2.2.5. Variables and Data Collection
This has been described previously elsewhere [29]. In brief, a three-step procedure was carried
out to obtain the study data:
First Visit: In Primary Care
After verifying the inclusion criteria and receiving written informed consent to participate, the
medical history of the patients was obtained and a physical examination was performed using the
MFT, and the NDS score was given to screen for PN. The patients also underwent DEC quantification
using the Sudoscan device. A score of 8 out of 8 with the Semmes-Weinstein 5:07 MFT (10 g) was
considered as sensitive [16]. An NDS score ≥6 points was considered as the presence of moderate or
severe PN [30]. The determination of vibration sensitivity was performed using a 128 Hz Rydel-Seiffer
tuning fork.
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Second Visit: In Hospital
Done at the reference hospital, where a neurologist blinded to previous test results, performed a
neurographic test, including a sensory conduction study of the median, ulnar and sural nerves, and
motor conduction study of the deep peroneal nerve. The variables studied included the amplitude
of compound muscle action potential and distal latency of the motor nerves, and amplitude and
distal latency of sensory nerves. DEC determination and the other neuropathy screening and
electrophysiological tests took no longer than 1 month.
Third Visit: In Primary Care
The results of the previous visit were recorded and the patients were informed of the results and
the diagnosis.
2.2.6. Statistical Analysis
The χ2 test was used to analyze qualitative variables and the Student’s t test was performed for
quantitative variables. Logistic regression was used to identify predictors of diabetic neuropathy.
Dependent variables (response) included the presence of diabetic neuropathy diagnosed by EMG or
the NDS questionnaire. The performance of DEC was compared with the MFT as screening tests of
PN. To determine the validity and reliability of DEC, the sensitivity, specificity, the PPV and NPV,
and the positive and negative likelihood ratios were calculated. A receiver operating characteristic
(ROC) curve was used and the area under the curve was calculated. A p < 0.05 was considered as
statistically significant. The analyses were performed with the statistical packages STATA/SE 12.0
(StataCorp, College Station, TX, USA) and R for Windows (R Foundation, Vienna, Austria).
2.2.7. Ethics Approval and Consent to Participate
The research Ethics Committee board at the Jordi Gol Research Institute (Barcelona) (www.
idiapjordigol.org) approved the protocol (January 2015, reference number P14/147) and each participant
signed written informed consent.
2.2.8. Registry
The study is registered in https://clinicaltrials.gov/ with the reference number NCT03495089.
3. Results
A total of 197 participants were evaluated: 100 with T2D, 50 with prediabetes and 47 controls free
of glucose disturbances.
Table 1 shows the socio-demographical and clinical characteristics of the whole sample. The three
groups showed significant differences in variables usually associated with diabetes, including family
history, body mass index (BMI) and waist circumference, mean systolic blood pressure and comorbidities
(i.e., high blood pressure or dyslipidemia, linked to their pharmacological treatment). Differences were
also observed in triglyceride values and the glomerular filtration rate. Normal Douleur Neuropathique 4
Questions (DN4) questionnaire results were more frequently observed in the control group without DM.
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The prevalence of PN was 14.4% by DEC and 21% by EMG. Considering EMG as the gold standard,
on evaluating the DEC in the whole sample the results were: sensitivity 21%, specificity 95%, PPV 47%
and NPV 81%, with a likelihood ratio of 4.13 and an area under the receiver operating characteristic
(OC) curve (AUC) of 0.58.
The high specificity found indicates that DEC is a reliable test for the detection of individuals
without PN while the low sensitivity suggests that this test is not very useful for the detection of
disease among people with PN.
On comparing DEC with other tests such as the MFT, NDS or DN4 questionnaires, the sensitivity,
specificity, PPV and NPV were similar, in the whole population and in individuals without DM and in
those with prediabetes (Tables 2 and 3).
Table 2. Sensitivity (Sen), specificity (Spe), positive predictive value (PPV), negative predictive value
(NPV) of dermal electrochemical conductance (DEC) compared to different tests as the gold standard.
Gold Standard
EMG MFT NDS DN4
DEC
Sen = 21.2% Sen = 15.3% Sen = 33.3% Sen = 21.4%
Spe = 94.8% Spe = 93.5% Spe = 94% Spe = 93.4%
PPV = 46.6% PPV =26.6% PPV = 26.6% PPV = 20%
NPV = 81.3% NPV = 87.9% NPV = 95.6% NPV = 93.4%
LR+ = 4.13 LR+ = 2.35 LR+ = 5.55 LR+ = 3.24
LR− = 0.83 LR− = 0.90 LR− = 0.71 LR− = 0.77
DEC: dermal electrochemical conductance; EMG: electromyography; MFT: monofilament; NDS: Neuropathy
Disability Score; DN4: Douleur Neuropathique-4 Questions; Sen: sensitivity; Spe: specificity; PPV: positive
predictive value; NPV: negative predictive value. LR+: positive likelihood ratio; LR−: negative likelihood ratio.
Table 3. Comparison between dermal electrochemical conductance (DEC) results and other tests such
as the gold standard based on the glycemic state of the participants.
Gold Standard
MFT EMG NDS DN4
DM No-DM Pre-DM DM No-DM Pre-DM DM No-DM Pre-DM DM No-DM Pre-DM
DEC
Sen 25% 0% 14% 20% 0% 5% 37% 0% 1% 30% 0 0
Spe 93% 95% 93% 96% 95% 93% 93% 95% 93% 93% 95.5% 91%
PPV 33% 0% 25% 67% 0% 25% 33% 0% 25% 33% 0 0
NPV 90% 84% 87% 74% 98% 96% 94.5% 93% 1% 92% 95.5% 93%
LR+ 3.57 0 2 5 0 0.71 5.28 0 0.14 4.28 0 0
LR− 0.80 20 0.92 0.83 20 1.02 0.67 20 1.06 0.75 22.2 11.1
DEC: dermal electrochemical conductance; EMG: electromyography; MFT: monofilament; NDS: Neuropathy
Disability Score; DN4: Douleur Neuropathique-4 Questions; Sen: sensitivity; Spe: specificity; PPV: positive
predictive value; NPV: negative predictive value; DM: type 2 diabetes; No-DM: non-diabetic; pre-DM: prediabetic.
LR+: positive likelihood ratio; LR−: negative likelihood ratio.
Table 4 reports conductance (hands and feet) for the 3 different groups. All the prediabetic
and normotolerant patients underwent oral glucose tolerance test since this was the method used to
rule out ignored diabetes. It was therefore considered mandatory in the 97 cases included without
known diabetes.
Table 4. Comparison between DEC results in the three groups of participants.
Conductance (μS)
Normal Tolerance Pre-DM DM
DEC
H-DEC (hands) 70.3 ± 12.7 63.9 ± 19.2 51.8 ± 17.2
F-DEC (feet) 76.8 ± 15.8 73.3 ± 22.5 71.3 ± 18.0
Painful neuropathy (DN4 >4 points) was observed in a total of 12 patients: 11 in the diabetes
group (11%) and 1 in the prediabetics (0.02%) and none in the group with normal tolerance.
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Figures 1–3 show the ROC curves comparing DEC versus the other tests evaluated.
 
(a) AUC = 0.5804 (b) AUC = 0.5448 
Figure 1. (a) Receiver operating characteristic (ROC) curve of dermal electrochemical conductance
(DEC) versus electromyography (EMG) as the gold standard in the whole study population. (b) ROC
curve of DEC versus monofilament (MFT) as the gold standard in the whole study population. AUC:
Area under the ROC Curve.
(a) AUC = 0.6549 (b) AUC = 0.4767 
Figure 2. (a) Receiver operating characteristic (ROC) curve of dermal electrochemical conductance
(DEC) versus electromyography (EMG) as the gold standard in the population with diabetes mellitus.
(b) ROC curve of DEC versus EMG as the gold standard in the population without glucose disturbances.
AUC: Area under the ROC curve.
In the whole sample, the ROC curve comparing DEC with MTF (AUC = 0.65) showed greater
effectiveness than that comparing DEC vs. EMG (AUC = 0.54). On the other hand, in the population
with type 2 diabetes, the comparison of DEC with EMG showed the greatest significance (AUC = 0.66).
Although the results are not very high, DEC may be a good screening test for populations with PN
compared to the gold standard (EMG).
It was of note that in the screening of prediabetic subjects the AUC was 0.72, which is reasonable
for a screening test.
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AUC = 0.7181 
Figure 3. Receiver operating characteristic (ROC) curve of DEC versus electromyography (EMG) as the
gold standard in the population with prediabetes.
4. Discussion
As mentioned in the Introduction, state-of-the-art methods demonstrate a high variability in PN
diagnostic methods, being directly related to the variability in prevalence rates. For example, with the
use of EMG, Puig and Portillo obtained prevalences of 75 and 86%, respectively [11,25]. However, most
authors use clinical methods based on exploratory symptoms and signs, obtaining diverse prevalences
ranging from 13% up to 81% [10,12,14,26–28]. It is clear that the tests used to determine the diagnosis
of PN and the type of patients included have an impact on the prevalence, as does the cut-off to
consider pathology. Gordon Smith [17] found poor DEC results in feet with PN, reporting a sensitivity
higher than in our study (77%) but with a lower specificity (67%) and with a higher cut-off (70 μS vs.
60 μS, respectively). Casellini [5] compared three groups (diabetic individuals with and without PN,
and healthy volunteers) and also concluded that DEC is less effective in diabetic subjects with PN,
showing similar results to our study (sensitivity 78%, specificity 92%). In a study of 75 individuals,
but including 45 patients with type 1 diabetes, Selvarajah [23] also described similar results with DEC
(sensitivity 87%, specificity 76% and AUC 0.85). Nonetheless, unlike our study, these three studies
included subjects with known confirmed (or discarded) PN. The aim of the present study was to
validate DEC as a method to diagnose PN, and the presence of PN or causes other than diabetes were
an exclusion criterion. Eranki [20] used DEC for the detection of cardiovascular complications in
308 patients with diabetes, reporting complications in 120 cases, 79% due to neuropathy. They reported
a sensitivity of 83%, a specificity of 55% and an AUC = 0.73 for PN. The results of the study by Erank
et al. differed greatly from ours, which showed a very low sensitivity but a very high specificity due to
the low number of cases.
One important difference of our study is that we also evaluated a group with prediabetes. With
the addition of this group, the definitive results differ from the preliminary results, with the NDS
questionnaire showing the best AUC compared to MFT before the addition of prediabetes. There are
few studies in this regard. However, some have suggested the utility of DEC for detecting diabetes
in subjects with glucose intolerance, being even better than basal glycemia. With the use of DEC in
212 subjects, Ramachandran [22] diagnosed 24 type 2 diabetes, 30 cases with glucose intolerance and
57 subjects with normal glucose tolerance but with metabolic syndrome.
In a study evaluating 47 patients with type 2 diabetes and 16 controls, Kneger et al. [31] reported
very similar results to those of the present study. DEC was effective in detecting subjects with PN and
correlated well with clinical signs and symptoms of neuropathy.
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Bins-Hall et al. [32] studied a one-step approach for the diagnosis of PN in 236 patients with
diabetes undergoing funduscopy. These authors evaluated a battery of tests including: the Toronto
scale, MFT, and two devices: DPN-Check™ and Sudoscan™. The results showed high performance
(with the Toronto scale as the gold standard (30.9%)) with DPN-check (sensitivity 84.3%, specificity
68.3%) and Sudoscan (sensitivity 77.4%, specificity 68.3%) compared to MFT (underestimation, only
14.4% detection).
In a Chinese cohort, Sudoscan™ was a useful method to detect PN in a screening of
394 asymptomatic persons with diabetes [33].
In a systematic review and meta-analysis on MFT, Wang et al. [34] reported that the sensitivity of
this test was very low.
It is of note that in present study we prioritized the NDS and DN4 scores; the first provides clinical
data (questionnaire) and exploration data (vibration, temperature, reflexes) while the second is an
abbreviation of the first, and provides a greater amount of clinical data.
Limitations and Strengths of the Study
The main limitation of the present study is accurate diagnosis of diabetic neuropathy since some
studies have shown that some cases of diabetic neuropathy present no alterations in the EMG.
Indeed, both EMG and MFT examine large nerve fibers. However, since they are the usual tests
available, they represent a limitation of the study. Therefore, several considerations should be taken
into account. First, the EMG test is more specific, albeit not very sensitive, showing positive results
in advanced stages of PN. The fingerboard and the NDS questionnaire are commonly used for the
diagnosis of diabetic neuropathy, probably because the NDS is carried out before EMG and is actually
often used to avoid the need for EMG.
Another inherent limitation of this study may be the low number of participants, although this
number fulfilled that obtained in the calculation of the sample size.
Therefore, both the EMG and the NDS score, which mainly assess the dysfunction of myelinated
fibers, provide a good profile for diagnostic confirmation. On the contrary, both the DEC and the MFT
are able to diagnose and stage diabetic neuropathy earlier than the previous 2 tests by the detection of
unmyelinated fiber dysfunction. Nonetheless, another limitation is that MFT is a good test for the
prediction of foot ulcers but is certainly insensitive for the detection of early neuropathy. Therefore,
for purposes of simplification and taking into account the possible limitations, we compared the
effectiveness of the measurement of DEC and the use of MFT as diagnostic tools in primary care
according to whether the true diagnosis is achieved by the EMG or the score of the NDS questionnaire.
Although other tests are available to detect early neuropathy, such as the Utah Early Neuropathy
Scale (UENS) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN) scale,
these questionnaires are not practical in the clinical scenario. However, the latter test is a good tool to
detect neuropathy unawareness in patients with diabetes [35]. Indeed, in the study by Veresiu et al.,
the Norfolk QOL-DN scale was used in 25,000 patients with diabetes and it was found that neither
6600 patients nor their physicians were aware of the presence of neuropathy.
In regard to technical aspects, the use of DEC in clinical examinations has a few limitations as
described in previous studies (the use of drugs such as tricyclic antidepressants, non-cardioselective
beta-blockers, or extensive dermatitis on the palms of the hands or soles of the feet). However, we do
not believe that these aspects apply to the present study since they were exclusion criteria and were not
affected by age, sex or previous physical exercise or changes in temperature or acute alterations in blood
pressure. According to these studies, the results of DEC do not depend on the rate of perspiration [36],
having a high correlation (correlation coefficient 0.814; coefficient of variation 1.15%) [5].
One of the strengths of this study was that DEC and physical examinations were performed
by only a few investigators in order to avoid biases in sample selection or erroneous categorization
of the diagnosis of PN. This is one of the first studies to compare DEC measurement with the gold
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standard (EMG). Other studies, even those by the manufacturer, are based on other devices or clinical
questionnaires, thereby making our study innovative.
Considering the limitation of resources in primary care and the health care system as a whole, we
are currently performing a cost-effectiveness analysis of the use of DEC in the primary care setting.
5. Conclusions
In conclusion, in the usual clinical practice, DEC is feasible, with a moderate sensitivity but a high
specificity. It is also easy to use and interpret and requires little training, thereby making it a good
screening test in populations with diabetes and prediabetes. It may also be useful in screening general
populations at risk of neuropathy.
Nonetheless, the results of cost-effectiveness analyses must first be analyzed before recommending
the implementation of DEC in primary care in Catalonia.
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Abstract: Background: Diabetic foot syndrome (DFS) is a prevalent complication in the diabetic
population and a major cause of hospitalizations. Diverse clinical studies have related alterations in
the system formed by fibroblast growth factor (FGF)-23 and Klotho (KL) with vascular damage. In
this proof-of-concept study, we hypothesize that the levels of FGF23 and Klotho are altered in DFS
patients. Methods: Twenty patients with limb amputation due to DFS, 37 diabetic patients without
DFS, and 12 non-diabetic cadaveric organ donors were included in the study. Serum FGF23/Klotho
and inflammatory markers were measured by enzyme-linked immunosorbent assay (ELISA). Protein
and gene expression levels in the vascular samples were determined by immunohistochemistry
and quantitative real-time PCR, respectively. Results: Serum Klotho is significantly reduced and
FGF23 is significantly increased in patients with DFS (p < 0.01). Vascular immunoreactivity and
gene expression levels for Klotho were decreased in patients with DFS (p < 0.01). Soluble Klotho
was inversely related to serum C-reactive protein (r = −0.30, p < 0.05). Vascular immunoreactivities
for Klotho and IL6 showed an inverse association (r = −0.29, p < 0.04). Similarly, vascular gene
expression of KL and IL6 were inversely associated (r = −0.31, p < 0.05). Logistic regression analysis
showed that higher Klotho serum concentrations and vascular gene expression levels were related to
a lower risk of DFS, while higher serum FGF23 was associated with a higher risk for this complication.
J. Clin. Med. 2019, 8, 448; doi:10.3390/jcm8040448 www.mdpi.com/journal/jcm85
J. Clin. Med. 2019, 8, 448
Conclusion: FGF23/Klotho system is associated with DFS, pointing to a new pathophysiological
pathway involved in the development and progression of this complication.
Keywords: diabetic foot syndrome; vascular disease; fibroblast growth factor 23;
Klotho; inflammation
1. Introduction
Type 2 diabetes mellitus (T2DM) has become a critical health problem, with more than 450 million
people living with this disease worldwide [1]. Diabetic foot syndrome (DFS) is a prevalent complication
in this population and a major cause of hospitalizations. This syndrome carries the risk of limb
amputation, which represents the most prevalent non-traumatic amputation surgery in the hospital
setting [2]. Mortality associated with DFS is similar to that of breast, prostate, or colon cancer [3]. Hence,
there is an overwhelming need for a better understanding of the molecular mechanisms underlying
the development of DFS and foremost to detect early those at the highest risk of this complication and
develop more specific and effective therapies.
DFS has a complex and multifactorial pathogenesis where an underlying vascular atherogenic
process affecting both the endothelium and the smooth muscle cell layer is a critical factor.
Atherosclerosis is a chronic inflammatory phenomenon involving several pathways and molecules,
including inflammatory cytokines [4,5]. Closely related with the atherogenic phenomena, the
alterations of the mineral metabolism have gained special prominence as pathogenic factors in the
development and progression of vascular damage [6,7].
The newly described system formed by the fibroblast growth factor (FGF)-23 and Klotho (KL)
proteins is recognized as one of the main regulators of mineral metabolism. FGF23 is a phosphaturic
hormone that is synthesized in the bone in response to dietary phosphate intake in order to keep a
normal phosphate homeostasis [8]. To this end, it binds to cognate fibroblast growth factor receptors
(FGFRs; primarily FGFR1 and 3) in the renal tubular cells in the presence of the obligated co-receptor
Klotho, a type 1 trans-membrane protein predominantly expressed in the kidneys [8]. In addition,
a soluble form of Klotho is generated by the shedding of the ectodomain by the A Disintegrin
and A Metalloproteinase 17 (ADAM17), or by an alternative RNA splicing [9–11]. Beyond this
physiological role, the FGF23/Klotho system has been related to various processes associated with
cardiovascular damage.
Diverse clinical studies have directly related the increase in serum concentrations of FGF23 with
cardiovascular damage and with an increased mortality [12,13]. Moreover, recent works suggest that
high levels of FGF23 can exert deleterious effects on the cardiovascular system by establishing low
affinity bonds with FGFRs, independently of Klotho [14,15]. On the other hand, reduced concentrations
of soluble Klotho have been involved in processes related to premature aging, including the appearance
of vascular damage [16]. This soluble form of Klotho is detectable in urine, serum, and cerebrospinal
fluid, acting as a humoral factor with multiple functions such as anti-oxidation, modulation of ion
channels, anti-Wnt signaling or anti-apoptosis, and anti-senescence effects [17]. Importantly, the
expression of KL has been recently demonstrated in human vascular tissue [16,18] and both the levels
of systemic and vascular Klotho have been related with cardiovascular complications [16,19–21].
In this proof-of-concept study, we hypothesize that the levels of FGF23 and Klotho are altered in
DFS patients. We determined the serum concentrations and the vascular expression levels of FGF23
and Klotho in a group of diabetic patients, with and without DFS. We also measured the levels of
inflammatory mediators, including the cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6 and
IL10, and analyzed the relationship among these variables and the presence of DFS.
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2. Materials and Methods
2.1. Patients
Eighty-five diabetic patients undergoing an elective open vascular surgery procedure due
to established clinical atherosclerotic artery disease were considered for enrollment in this study.
Exclusion criteria included hemodynamic instability; history of chronic inflammatory, immunologic,
or tumoral disease; positive serology to hepatitis B, hepatitis C, or HIV; acute inflammatory
or intercurrent infectious episodes in the previous month; institutionalization; treatment with
immunotherapy or immunosuppressive drugs; previous organ transplantation and advanced renal
disease (estimated glomerular filtration rate (eGFR) lower than 30 mL/min/1.73m2).
For comparative purposes in the immunohistochemical and gene expression analyses, femoral
samples from 12 cadaveric non-diabetic organ donors matched by age, sex, and eGFR, and without
any medical history of cardiovascular disease were recovered during organ retrieval surgery.
The study protocol was approved by the Institutional Ethics Committee of the University Hospital
Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) and complied with ethical standards of
the Declaration of Helsinki. Written informed consent was obtained from all participants before they
participated in the study.
2.2. Samples and Biochemical Markers
During the surgical procedure, a sample of the carotid or femoral arteries, according to the
affected vessel, was obtained from the participants. At the same time, serum samples were drawn,
aliquoted, and immediately stored at −80 ◦C for further analysis. Routine biochemical parameters
were determined using standard methods. Serum levels of intact FGF23 were measured by specific
enzyme-linked immunosorbent assay (ELISA) (EMD Millipore Corporation, Milford, MA, USA),
which detects only the intact form of FGF23 with a sensitivity of 3.5 pg/mL and intra- and inter-assay
coefficients of 9.5% and 6.85%, respectively. Serum Klotho was measured using the human Klotho
ELISA kit (Immuno-Biological Laboratories, Takasaki, Japan), with a sensitivity of 6.15 pg/mL and
intra- and inter-assay coefficients of variation of 3.1 % and 6.9 %, respectively. High-sensitivity serum
C-reactive protein (hsCRP) was measured by a high-sensitivity particle enhanced immunoturbidimetric
fully automated assay (Roche Diagnostics GmbH, Mannheim, Germany) in a Cobas 6000 analyzer
from the same manufacturer with a sensitivity of 0.3 mg/L and intra- and inter-assay coefficients
of variation of 1.6 and 8.4, respectively. Levels of the inflammatory cytokines TNFα, IL6 and IL10
were also measured by high-sensitivity ELISA methods (Quantikine®, R&D Systems, Abingdon, UK).
Minimum detectable concentrations were 0.10 pg/mL, 0.70 pg/mL, and 0.50 pg/mL, respectively.
Intra- and inter-assay coefficients of variability were <10.8%.
2.3. Immunohistochemistry
Sections of blood vessels were fixed in 4% buffered formalin for 24 h and subsequently dehydrated
in ascending concentrations of ethanol, cleared in xylene, and embedded in paraffin. Blocks were
trimmed and 3 μm sections were processed for immunohistochemistry. Primary antibodies used were:
mouse monoclonal anti-FGFR1, 1:400 dilution (Abcam, Cambridge, UK); rabbit polyclonal anti-FGFR3,
1:300 dilution (Abcam); rabbit polyclonal anti-Klotho, 1:100 dilution (Abcam); mouse monoclonal
anti-IL6, 1:300 dilution (Santa Cruz Biotechnology Inc., Dallas, TX, USA); and rabbit monoclonal
anti-TNFα, 1:100 dilution (Santa Cruz Biotechnology Inc.). For the quantification analysis, a total of
five images of each slide that include intima and media layers were captured and processed with a
high-resolution video camera (Sony, DF-W-X710, Kōnan, Japan) connected to a light microscope (Nikon
Eclipse 50i). The areas of tissue stained by the antibodies were quantified by using ImageJ software
(Rasband, W.S., ImageJ, National Institutes of Health, Bethesda, MD, USA). Results are expressed in
square microns.
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2.4. Quantitative Real-Time PCR
After surgery, vascular tissue fragments were immediately placed in RNAlater® solution (Ambion
(Europe) Limited, Cambridge, UK) and stored at 4 ◦C for subsequent RNA extraction. Total RNA
was isolated by homogenization in TRI Reagent® (Sigma-Aldrich, Saint Louis, MO, USA) employing
TissueRuptor (QIAGEN, Hilden, Germany). Further purification was performed using RNeasyMini
kit (QIAGEN), according to manufacturer’s specifications, and stored at −80 ◦C. RNA was quantified
using a Thermo Scientific NanoDrop Lite Spectrophotometer (Thermo Scientific, Waltham, MA,
USA) and its quality was assessed by the A260/A280 ratio measured in this equipment. cDNA was
obtained using a High Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA) for
further use in quantitative RT-PCR (qRTPCR). Transcripts encoding for KL, ADAM17, TNF, IL6, IL10,
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were measured by TaqMan quantitative PCR
with TaqMan Fast Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA). TaqMan
gene expression assays for each transcript (Hs00183100_m1 (KLOTHO), Hs01041915_m1 (ADAM17),
Hs00174128_m1 (TNFα), Hs00985639_ml (IL6), Hs0961622_m1 (IL10), and Hs99999905_m1 (GAPDH))
were analyzed in a 7500 Fast Real-Time PCR System (Applied Biosystems). The level of target mRNA
was estimated by relative quantification using the comparative method (2−ΔΔCt) by normalizing to
GAPDH expression. mRNA levels were expressed as arbitrary units (a.u.). Quantification of each
cDNA sample was tested in triplicate.
2.5. Statistical Analysis
All analyses were performed using SPSS software version 25 (IBM Corp. Armonk, NY, USA).
Continuous variables are reported as mean ± SD or median with interquartile range (IQR), and
categorical data as number and percent frequency. Continuous variables were checked for the normal
distribution assumption using the Kolmogorov–Smirnov statistics, and those that did not satisfy the
criteria were log-transformed. Comparisons between groups were performed by Chi-square test,
Mann–Whitney U test, or Kruskal-Wallis test as appropriate. The Spearman correlation coefficient was
calculated to assess the relationship between variables. Partial correlation analysis was performed
to measure the association of serum and vascular Klotho expression with inflammatory parameters
whilst controlling for the effect of covariates that were selected based on clinical relevance and the
results of comparison and correlation analysis. A multiple logistic regression was performed to assess
independent predictors of the presence of DFS. For this purpose, we adopted three models: In model 1,
we introduced age, sex, uric acid, eGFR, and hsCRP. In model 2, we additionally included serum
Klotho, FGF23, IL6, and IL10. Finally, in model 3 we adjusted the analysis for the immunoreactivity
and gene expression levels of KL. Regarding gene expression analysis, quantification of each sample
was tested in triplicate and data are expressed as arbitrary units. A two tailed p-value < 0.05 was
considered statistically significant.
3. Results
3.1. Characteristics of the Patients and Biochemical Parameters
Eighty-five diabetic patients with established vascular disease that underwent elective
revascularization surgical or lower limb amputation were initially evaluated, with 28 subjects being
excluded due to exclusion criteria. Finally, 57 patients (46 males and 11 females) with a mean age of
69.8 ± 9.7 were included in the study: 20 patients were subjected to elective limb amputation by DFS,
and the remaining 37 underwent elective shunt vascular surgery in the lower extremities. The specific
indications for amputation included unsuccessful previous revascularization, extensive non-healing
ulcers or non-healing wounds, non-reconstructable disease with persistent tissue loss, unrelenting rest
pain due to muscle ischemia and gangrene. At the time of amputation, no patient had foot infection.
In all cases a standard below knee transtibial amputation was performed. The clinical, biochemical,
and demographic characteristics of the 57 patients included in the study are presented in Table 1.
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There were no differences in any demographic characteristic between the group of patients with
DFS and the remaining patients included in the study. Percentages of subjects with smoking habits,
alcoholism, and hypertension were also similar in both groups. Similarly, no differences were observed
in general laboratory measurements including total cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL), triglycerides, HbA1c, glucose, eGFR, albumin, calcium, phosphorous,
and alkaline phosphatase. However, the levels of pro-inflammatory markers were higher in patients
with DFS, although only reached statistical significance for hsCRP (6 (2.3–10.5) vs. 5.3 (2.4–13.6) pg/mL,
p < 0.05) and IL6 (22 (51–28.6) vs. 6.42 (0.7–26.7) pg/mL, p < 0.05). Conversely, the level of
anti-inflammatory cytokine IL10 was diminished in the DFS group (1.1 (0.6–6.7) vs. 3.9 (0.5–6.8) pg/mL,
p < 0.01). Interestingly, the serum levels of Klotho were significantly diminished in patients with DFS
(397.4 (318–515) vs. 617 (484–779) pg/mL, p < 0.01), whereas the FGF23 concentration was significantly
higher (23.8 (17–32.2) vs. 15.5 (10.1–24.5) pg/mL, p < 0.01). On comparison with the respective levels
in patients without DFS, these differences represent a median percent decrease of 37.4% for Klotho and
30.3% increase for iFGF23 concentrations in patients with DFS (Table 1 and Figure 1).
Table 1. Clinical characteristics and biochemical assessments of the diabetic patients included in the study.
Variable Overall DFS No. DFS p–Value
n 57 20 37
Age (years) 69.8 ± 9.7 71.8 ± 10.2 68.7 ± 9.4 NS
Male gender, n (%) 46 (80) 15 (75) 31 (84) NS
BMI (kg/m2) 30.1 ± 3.8 30.8 ± 4.7 29.7 ± 3.3 NS
Hypertension, n (%) 51 (89.4) 17 (85) 34 (91.9) NS
Alcoholism, n (%) 22 (38.6) 7 (35) 15 (40.5) NS
Smoking habits, n (%) 36 (63.2) 12 (60) 24 (64.8) NS
Total Cholesterol (mg/dL) 159.2 ± 38.9 159 ± 45.8 159.3 ± 35.3 NS
HDL (mg/dL) 42.4 ± 10.2 40 ± 9.8 43.7 ± 10.4 NS
LDL (mg/dL) 84.8 ± 29.4 87.5 ± 33.4 83.3 ± 27.3 NS
Triglycerides, mg/dL 155 ± 80.2 156.6 ± 100 154.2 ± 68.4 NS
HbA1c, % 7.3 ± 1.4 7.3 ± 1.9 7.2 ± 1.3 NS
Glucose 132.9 ± 42.8 126.3 ± 40.1 136.6 ± 44.4 NS
eGFR, mL/min/1.73 m2 77.5 ± 24.7 76.6 ± 24 77.8 ± 25.4 NS
Albumin (g/L) 3.8 ± 0.7 3.7 ± 0.8 3.8 ± 0.6 NS
Calcium (mg/dl) 9.1 ± 0.6 9 ± 0.6 9.1 ± 0.6 NS
Phosphorous (mg/dl) 3.6 ± 0.5 3.6 ± 0.5 3.6 ± 0.5 NS
AP (mU/mL) 78.8 ± 58.1 77.9 ± 43.3 79.2 ± 65.3 NS
hsCRP (mg/dL) 5.8 (2.4–11.9) 6 (2.3–10.5) 5.3 (2.4–13.6) <0.05
IL6, pg/mL 11.2 (1.1–28.1) 22 (5.1–28.6) 6.42 (0.7–26.7) <0.05
IL10, pg/mL 1.3 (0.5–6.7) 1.1 (0.6–6.7) 3.9 (0.5–6.8) <0.01
TNFα, pg/mL 1.3 (0.8–1.3) 1.4 (0.9–2.1) 1.1 (0.7–1.7) NS
KLOTHO, pg/mL 532.8 (375–677) 397.4 (318–515) 617.3 (484–779) <0.01
iFGF23, pg/mL 17.5 (12–27) 23.8 (17–32) 15.5 (10.1–24.5) <0.01
DFS, diabetic foot syndrome; BP, blood pressure; BMI, body mass index; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; AP, alkaline
phosphatase; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; TNF, tumor necrosis factor; FGF23, fibroblast
growth factor 23; NS, not significant. p-value reflects differences between with DFS and without DFS.
p p
Figure 1. Differences in the log-transformed blood levels of (a) Klotho and (b) FGF23 between patients
with and without diabetic foot syndrome (DFS).
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3.2. Immunohistochemical Analysis
For immunohistochemical determinations, serial sections of femoral or carotid were obtained
from the participants. All the vascular samples obtained from the 20 patients with DFS were excised
from the femoral artery. Fragments obtained from the group of 37 patients without DFS included
carotid and femoral samples (21 and 16, respectively). All the fragments from the donor group were
obtained from the femoral artery.
The results obtained show the presence of Klotho protein, as well as the receptors for FGF23
(FGFR1 and FGFR3), in all the samples studied (Figure 2A). Mean immunoreactivity levels for Klotho
were significantly decreased in vascular sections obtained from patients with DFS as compared to
sections from diabetic patients without DFS (p < 0.05) and from the control group (p < 0.01) (Figure 2B).
No differences were observed in Klotho levels between patients without DFS and the control group.
The difference in Klotho values between the patients with and without DFS remained when only the
fragments of femoral arteries were considered in the analysis (p < 0.05). No differences were observed
in the immunoreactivity levels for FGFR1 and FGFR3 between the two groups of diabetic patients.
However, the levels of both proteins were higher in diabetic patients than in controls (p < 0.01). Finally,
mean immunoreactivity levels of the pro-inflammatory cytokines IL6 and TNFα were higher in the
group of diabetic patients than in controls (p < 0.05), with no differences regarding the presence or
absence of DFS (Figure 2B).
Figure 2. (a) Immunohistochemical staining for Klotho, FGFR1 (fibroblast growth factor receptor
(1), FGFR3, TNFα (tumor necrosis factor α), and IL6 (interleukin 6) in arterial sections of patients
with and without diabetic foot syndrome (DFS), and control donors (magnification 4×). (b) Mean
immunoreactivity levels. * p < 0.01 vs. control group; # p < 0.05 vs. patients without DFS.
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3.3. Vascular Gene Expression
Gene expression levels of KL, ADAM17, and the cytokines IL6, IL10, and TNF were analyzed in all
the vascular samples. Results showed that expression levels of Klotho were significantly reduced in DFS
patients (2.04 (0.79–3.36)) when comparing to either diabetic patients without DFS (4.21 (1.98–6.61))
or to the control group (6.81 (8.51–5.12)); p < 0.01, for both comparisons (Figure 3). These differences
represent a mean 51.4% and 70% lower expression of KL in the vascular wall of DFS patients compared
to patients without DFS and to control individuals, respectively. ADAM17 expression levels were
similar among all the groups. Concerning inflammatory cytokines, the vascular gene expression levels
of TNF and IL6 were higher in the group of patients with DFS when compared to control subjects
(p < 0.05 and p < 0.01, respectively), although only the IL6 levels differed between patients with and
without DFS (2.04 (0.79–3.36) vs. 1.41 (0.34–7.83), p < 0.01). This difference represented a mean 30.9%
higher expression of IL6 in the vascular wall of patients with DFS. Finally, the expression levels of the
anti-inflammatory cytokine IL10 in both groups of diabetic patients were reduced with respect to the
control subjects (p < 0.05).
        KL                  ADAM17             TNF                      IL6                       IL10
Figure 3. Gene expression levels of KL, ADAM17 (A Disintegrin and A Metalloproteinase 17), TNF
(tumor necrosis factor α), IL6 (interleukin 6), and IL10 determined by quantitative RT-PCR in vascular
walls of patients with diabetic foot syndrome (DFS), without DFS, and controls. * p < 0.01 vs. control
group; # p < 0.05 vs. patients without DFS.
3.4. Correlations and Multivariate Analysis
A correlation analysis was performed between Klotho levels and the other parameters determined
in the study (Table 2). A statistically significant positive correlation was found between eGFR and
serum and vascular expression levels of Klotho (r = 0.329 and r = 0.354, respectively, p < 0.01). Vascular
Klotho levels were also directly related to serum Klotho concentrations (r = 0.288, p < 0.05) and
inversely related to serum uric acid (r = 0.342, p < 0.01), serum creatinine (r = −0.389, p < 0.01), and
vascular protein levels of IL6 (r = −0.337, p < 0.01). Finally, vascular expression levels of KL and
ADAM17 showed a positive correlation (r = 0.369, p < 0.01).
Partial correlation analysis was performed to measure the associations of serum and vascular
Klotho expression with inflammatory parameters after controlling for covariates (age, eGFR, HbA1c,
hemoglobin, hematocrit, HDL, LDL, triglycerides, and uric acid) (Table 3). In the first analysis, soluble
Klotho was significantly related to serum CRP (r = −0.30, p < 0.05), with a marginal association with
serum IL6. In the second analysis, vascular mRNA expression of KL was directly associated with the
expression of ADAM17 (r = 0.41, p = 0.01), whilst a significant inverse association was observed with
IL6 expression (r = −0.31, p < 0.05). Regarding vascular immunoreactivity for Klotho, this parameter
showed an inverse association with vascular immunoreactivity for IL6 (r = −0.29, p < 0.04).
Finally, the multivariate logistic regression analysis using the presence/absence of DFS as the
dependent variable showed that higher serum Klotho concentrations and gene expression levels in the
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vascular wall were associated with a lower risk for DFS, with immunoreactivity values for vascular
Klotho showing a marginal association. On the contrary, higher serum FGF23 was related to a higher
risk for this complication (Table 4).
Table 2. Correlations of serum and vascular gene expression levels of Klotho in diabetic patients.
Log Serum KL Log Vascular KL
Variable r p-Value r p-Value
BMI (kg/m2) 0.129 NS −0.062 NS
Total Cholesterol (mg/dL) 0.055 NS −0.139 NS
HDL (mg/dL) 0.255 <0.05 −0.131 NS
LDL (mg/dL) 0.021 NS −0.152 NS
Triglycerides, mg/dL −0.058 NS 0.134 NS
HbA1c, % −0.034 NS 0.131 NS
Hemoglobin 0.344 <0.05 0.104 NS
Albumin (g/L) −0.038 NS 0.065 NS
Hematocrit 0.341 <0.05 0.109 NS
Calcium (mg/dl) 0.206 NS −0.51 NS
Phosphorous (mg/dl) 0.071 NS 0.17 NS
AP (mU/mL) −0.62 NS 0.03 NS
Uric acid (mg/dL) 0.096 NS −0.342 <0.01
eGFR, mL/min/1.73 m2 0.329 <0.01 0.354 <0.01
hsCRP (mg/dL) −0.196 <0.05 0.076 NS
Serum IL6 (pg/mL) −0.204 NS −0.094 NS
Serum IL10 (pg/mL) 0.172 NS −0.099 NS
Serum TNFα (pg/mL) −0.159 NS −0.114 NS
Serum Klotho (pg/mL) 0.125 NS
Serum iFGF23 (pg/mL) 0.042 NS −0.064 NS
VIR Klotho (μm2) 0.288 <0.05 0.097 NS
VIR FGFR1 (μm2) −0.15 NS 0.158 NS
VIR FGFR3 (μm2) 0.153 NS −0.106 NS
VIR IL6 (μm2) −0.124 NS −0.337 <0.01
VIR TNFα (μm2) 0.076 NS −0.177 NS
Log KL mRNA (a.u.) 0.125 NS
Log ADAM17 mRNA (a.u.) 0.183 NS 0.369 <0.01
Log IL6 mRNA (a.u.) −0.81 NS 0.133 NS
Log IL10 mRNA (a.u.) −0.069 NS 0.223 NS
Log TNF mRNA (a.u.) 0.069 NS 0.183 NS
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; AP,
alkaline phosphatase; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; IL,
interleukin; TNF, tumor necrosis factor; KL, Klotho; a.u., arbitrary units; FGF23, fibroblast growth factor 23; VIR,
vascular immunoreactivity; NS, not significant.
Table 3. Association between serum and vascular expression levels of Klotho with inflammatory
parameters assessed by partial correlation analysis.
Serum Klotho Concentrations
Serum hsCRP r = −0.30 p < 0.05
Serum IL6 r = −0.23 p = 0.10
Serum IL10 r = 0.20 p = 0.17
Serum TNFα r = −0.12 p = 0.39
Vascular mRNA KL Expression Levels
Expression ADAM17 r = 0.41 p = 0.001
Expression IL6 r = −0.31 p < 0.05
Expression IL10 r = 0.19 p = 0.20
Expression TNF r = 0.03 p = 0.81
Vascular Klotho Immunoreactivity Levels
Immunoreactivity IL6 r = −0.29 p < 0.05
Immunoreactivity TNFα r = −0.06 p = 0.64
hsCRP, high-sensitivity C-reactive protein; IL6, interleukin 6; IL10, interleukin 10; TNFα, tumor necrosis factor α;
ADAM17, A Disintegrin and A Metalloproteinase 17. Covariates: age, estimated glomerular filtration rate, glycated
hemoglobin, hemoglobin, hematocrit, HDL, LDL, triglycerides, and uric acid.
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Table 4. Multivariate logistic regression analysis for the presence of DFS.
Model 1
Independent Variable Odds Ratio (95% CI) p-Value
Age 1.03 (0.97 to 1.10) 0.28
Gender 0.59 (0.13 to 2.78) 0.51
Uric acid 0.96 (0.64 to 1.45) 0.87
eGFR 1.05 (0.97 to 1.03) 0.72
hsCRP 0.99 (0.93 to 1.06) 0.95
Model 2 (Model 1 + Serum Klotho, FGF23, IL6 and IL10)
Independent Variable Odds Ratio (95% CI) p-Value
Age 1.00 (0.91 to 1.10) 0.82
Gender 0.75 (0.08 to 7.04) 0.80
Uric acid 1.09 (0.57 to 2.08) 0.78
eGFR 1.01 (0.97 to 1.05) 0.49
hsCRP 0.97 (0.89 to 1.07) 0.64
Serum Klotho 0.99 (0.98 to 0.99) <0.01
Serum FGF23 1.10 (1.05 to 1.21) <0.05
Serum IL6 1.00 (0.98 to 1.01) 0.88
Serum IL10 1.06 (0.85 to 1.32) 0.60
Model 3 (Model 2 + Soluble Klotho)
Independent Variable Odds Ratio (95% CI) p-Value
Age 0.91 (0.78 to 1.06) 0.23
Gender 4.98 (0.17 to 14.63) 0.35
Uric acid 0.64 (0.27 to 1.50) 0.31
eGFR 1.04 (0.98 to 1.12) 0.15
hsCRP 1.16 (0.93 to 1.33) 0.23
Serum Klotho 0.99 (0.98 to 0.99) <0.05
Serum FGF23 1.22 (1.02 to 1.47) <0.05
Serum IL6 0.99 (0.97 to 1.01) 0.53
Serum IL10 0.97 (0.77 to 1.23) 0.83
VIR Klotho 1.00 (0.99 to 1.00) 0.06
KL gene expression 0.66 (0.43 to 0.99) <0.05
eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; FGF23, fibroblast growth
factor 23; IL, interleukin; VIR, vascular immunoreactivity.
4. Discussion
The main results of the present study show that patients with DFS have lower serum
concentrations of soluble Klotho and elevated concentrations of FGF23, while at the vascular level, both
immunoreactivity and gene expression levels of KL were also diminished. Moreover, these alterations
in the components of the FGF23/Klotho system are independently associated with the presence of
DFS. These findings have been not reported previously and suggest an intriguing possibility about the
potential role of FGF23/Klotho in the development and/or progression of DFS.
Vascular disease is a critical factor underlying the pathogenesis of DFS [22]. The FGF23/Klotho
system has been decisively related to various processes associated with vascular damage. Recent
works suggest that FGF23 can exert direct effects on the cardiovascular system. It has been proven that
at high concentrations, FGF23 is able to establish low affinity bonds with its receptors, independently
of the presence of Klotho, which could cause deleterious effects on multiple organs and tissues [14].
From a clinical point of view, elevated levels of FGF23 have been associated with the presence of
vascular dysfunction [15], as well as with a greater severity of atherosclerotic vascular damage [23].
A direct effect of FGF23 on the integrity of vascular tissue has been proposed, a hypothesis that has
been reinforced by the recent demonstration of the expression of its receptors, as well as Klotho,
in the human vascular wall [16,18]. Our results show that patients with DFS present not only higher
serum levels of FGF23, but also increased vascular expression of FGFRs. These findings point out
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the possibility that high FGF23 could exert direct pathogenic actions on the vasculature even though
vascular levels of Klotho are diminished.
On the other hand, Klotho deficiency has been also associated with vascular damage. In murine
models, absence of Klotho causes a syndrome of accelerated aging, which included arteriosclerosis and
vascular calcifications [24], alterations that could be reversed by administration of the Kl gene or by
parabiosis with the wild mice [25]. More recent studies have confirmed the protective effects of Klotho
on the vascular system, including its participation in the maintenance of endothelial homeostasis
and vascular functionality [26]. In the clinical setting, low serum Klotho concentrations in adult
subjects without known risk factors for cardiovascular disease have been related to a reduced capacity
of flow-mediated dilation of the brachial artery and higher values of epicardial fat thickness and
carotid artery intima-media thickness, suggesting that Klotho deficiency may be an early predictor
of subclinical atherosclerosis [27]. Moreover, recent works have related the presence of established
clinical atherosclerotic disease with low serum Klotho levels [19,21,28]. To the best of our knowledge,
only one previous study has evaluated the serum Klotho concentrations in T2DM in relation to diabetic
complications. In that study, Zhang et al. [29] studied 102 T2DM patients with DFS and observed
that these individuals presented a 44.79% reduction in serum Klotho as compared with non-diabetic
controls, with no differences with respect to patients with other complications but no diabetic foot. In
the present work, patients with DFS presented a median percent decrease of 37.4% in serum Klotho
concentrations as compared with diabetic subjects without DFS. These differences could be explained
by the distinct subjects’ characteristics between the studies, since in the work by Zhang et al. the
patients were younger (mean age, 56.1 vs. 71.8 years), with a greater female proportion (43.1% vs. 25%),
lower mean BMI (27.4 vs. 30.8 kg/m2), and more importantly, all of our patients had severe DFS with
lower limb amputation, whereas in the study by Zhang et al. the criteria for the DFS group included
foot ulcers, deformity, infection, or gangrene. Therefore, it is possible to speculate that reduction in
serum Klotho may reflect a progressive process that is associated with the severity of DFS.
Importantly, the endogenous expression of KL in human arteries has been recently demonstrated,
an issue of special relevance since the vascular wall may constitute a source of soluble Klotho, with
putative autocrine and/or paracrine protective beneficial effects on vascular homeostasis [16,18].
Clinical data regarding the relationship between vascular KL expression and atherosclerotic disease
are scarce. In previous works, our group reported that low vascular KL gene expression was associated
with the presence and severity of coronary artery disease [21] and clinical atherosclerotic disease [19]
independently of established cardiovascular risk factors. The present study reports for the first-time
data about vascular expression of Klotho, both at gene and protein levels, in patients with DFS.
In particular, we have detected a 51.4% lower gene expression and a 52.1% lower protein expression
of Klotho in vascular samples of patients with DFS as compared with diabetic subjects without this
complication. Overall, these findings may be relevant from a mechanistic perspective since Klotho has
been involved in maintaining the health of the vasculature, and thus, disruption of Klotho homeostasis
may be an important factor in the development and progression of atherosclerotic disease in general,
and DFS in particular.
Finally, it is important to note the interplay between inflammation and Klotho, since inflammation
induces the reduction of KL expression, both in the kidney as well as in the vessels [16,20,30]. Our
results show that subjects with DFS presented higher serum concentrations of hsCRP and IL6, and
reduced levels of the anti-inflammatory cytokine IL10. In addition, the immunoreactivity levels of
TNFα and IL6 were increased in the two groups of diabetic patients as compared with non-diabetic
subjects. Regarding gene expression, diabetic subjects presented a higher expression of TNF and lower
levels of IL10 compared to control subjects, whereas IL6 expression was significantly higher in patients
with DFS as compared with non-diabetic individuals and diabetic subjects without DFS. Importantly,
after adjusting for the effect of other variables, arterial KL mRNA levels showed an independent
negative relationship with IL6 expression, while vascular Klotho immunoreactivity was also negatively
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associated with immunoreactivity levels for IL6, supporting the role of inflammation as an inducer of
vascular Klotho downregulation in DFS.
Although this study provides novel information about the relationship between DFS and
FGF23/Klotho, several limitations need to be acknowledged. First, the small sample size since
this work was designed as a proof-of-concept study, which might imply that some of our results
did not reach statistical significance and limit the ability to adequately describe the closeness of the
relationship between the variables; however, the results indicate that the initial assumptions can be
valid for generating new hypotheses. Second, given the cross-sectional nature of the study, we can only
demonstrate associations without definitive inferences on their direction or causality. Third, serum
levels of other factors related to Klotho and FGF23, such as vitamin D, which may potentially impact
DFS, were not measured, and therefore, their potential influence on the results may not be completely
ruled out.
5. Conclusions
In conclusion, this paper describes that patients with DFS present lower serum concentrations
of Klotho and elevated FGF23, and reports the reduced expression of Klotho, both at the protein and
gene level, in their vascular beds. Importantly, these parameters were independently associated with
DFS. Overall, these findings point to a new pathophysiological pathway potentially involved in DFS.
Further studies are imperative to elucidate the role of the FGF23/Klotho system in the development
and progression of this complication.
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Abstract: The aim of the study was to investigate ultrasound tissue characterization of carotid plaques
in subjects with and without diabetes type 1 (T1D). B-mode carotid ultrasound was performed to
assess the presence and type of plaque in a group of 340 subjects with and 304 without T1D, all of
them without cardiovascular disease. One hundred and seven patients with T1D (49.5% women;
age 54 ± 9.8 years) and 67 control subjects without diabetes who had at least one carotid plaque
were included in the study. The proportion of subjects who had only echolucent plaques was
reduced in the group of patients with T1D (48.6% vs. 73.1%). In contrast, the proportion with only
echogenic (25.2% vs. 7.5%) and calcified plaques (9.4% vs. 1.5%) was increased compared with
subjects without diabetes. Moreover, having at least one echogenic plaque was more frequent in T1D
patients compared with subjects without diabetes (49.5% vs. 26.9% p = 0.005). In addition to diabetes
(OR 2.28; p = 0.026), age (OR 1.06, p = 0.002) was the other variable associated with echogenic plaque
existence in multiple regression analysis. Patients with T1D exhibit a differential pattern of carotid
plaque type compared with subjects without diabetes, with an increased frequency of echogenic and
extensively calcified plaques.
Keywords: type 1 diabetes; plaque characteristics; carotid plaque; echogenic plaque
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1. Introduction
Atherosclerotic cardiovascular disease (CV) is a major cause of mortality in patients with type 1
diabetes [1,2]. Its main clinical manifestations include myocardial infarction, stroke and peripheral
vascular disease. The common nexus of this group of cardiovascular events is atherosclerosis, which
is characterized as a chronic lipid deposition process in the sub-endothelial space that develops
insidiously throughout life and is typically in an advanced stage when its symptoms manifest clinically
in the form of a cardiovascular event.
Ultrasonography is a non-invasive, safe, reproducible and well-validated method for visualizing
and quantifying atherosclerotic lesions [3]. The presence and burden of subclinical carotid
atherosclerotic plaque is strongly associated with future arterial CV events [4,5]. A high prevalence
of carotid plaques has been described in patients with type 2 diabetes without evidence of clinical
CV disease [6]. Data regarding atherosclerotic plaques in patients with type 1 diabetes are very
scarce. In this sense, our group has recently described an increased proportion and burden of carotid
plaques in a group of 340 patients with T1D without CV events compared with a group of subjects
without diabetes [7]. On the other hand, plaque echogenicity as assessed by carotid ultrasound reliably
predicts the content of soft tissue and the amount of calcification in carotid plaques [8]. In this regard,
echolucent plaques exhibit more lipid, inflammatory cells and haemorrhage compared with echogenic
plaques, which contain more calcification and fibrous tissue; characteristics that have been validated by
histopathology [8–10]. Otherwise, calcified plaques in the coronary arteries determined by computed
tomography scanning coronary artery calcium (CAC) are accepted as a measure of CV disease burden
both in patients with [11] and without diabetes [4]. Vascular calcification beyond coronary arteries (i.e.,
carotid and aortic plaques) has also been described to be associated with all-cause and CV mortality
both in patients with [12] and without type 2 diabetes [13].
Studies that have evaluated plaques characteristics by carotid ultrasonography demonstrated
that lipid rich plaques (echolucent) are associated with an increased risk of CV events in patients
with symptomatic stenotic (≥50%) plaques [14,15]. Most studies that have analyzed the presence
and ultrasound characteristics of carotid plaques in patients with diabetes have been performed in
asymptomatic subjects with T2D. In these patients both echolucent [16,17] and echogenic [18] plaques
were shown to be associated with an increased risk of future CV events. Data regarding subclinical
atherosclerotic plaques characteristics assessed by carotid ultrasound in patients with type 1 diabetes
are lacking. To our knowledge, no studies to date have analyzed plaque characteristics by carotid
ultrasound in patients with type 1 diabetes.
The present study aimed to analyze ultrasound non-stenotic carotid plaque echogenicity in a
group of patients with type 1 diabetes and to compare the results obtained with a group of subjects




This study is a sub-analysis of a previous study from our research group [7]. From that study,
174 subjects with at least one atherosclerotic plaque, including 107 patients with type 1 diabetes
and 67 without diabetes, were selected. Our previous study was a cross-sectional study conducted
in 340 patients with type 1 diabetes and 304 subjects without diabetes matched by sex and age.
All participants were free from previous CV disease. Subjects with type 1 diabetes were recruited from
the diabetic outpatient clinics at University Hospital Germans Trias i Pujol and University Hospital
Arnau de Vilanova in the north-western region of Spain (Catalonia). All potential participants were
identified from the electronic clinical records from the two participating institutions that belong to the
same health care organization.
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For type 1 diabetic subjects, the inclusion criteria were as follows: age >18 years; diabetes for
at least 1 year; normal renal function (estimated glomerular filtration rate (eGFR >60 mL/min));
no previous CV disease defined as any form of clinical coronary heart disease, stroke or peripheral
vascular disease (including any form of diabetic foot disease). Moreover, we excluded patients with a
urine albumin excretion ratio >300 mg/g. The selection of subjects without diabetes was based on the
same criteria, except for the criteria that concerned the diabetic specific microvascular complications.
Additionally, subjects in the control group had fasting glucose and HbA1c values less than 100 mg/dL
and 5.7% (39 mmol/mol), respectively.
For each subject, age, sex, body mass index and waist circumference were obtained by
standardized methods. Subjects were considered to have hypertension or dyslipidaemia if they
were under anti-hypertensive or lipid-lowering agent treatment, respectively. Serum and spot urine
samples were collected in the fasting state, and all serum and urine tests were performed using
standard laboratory methods as previously described [19].
2.2. Carotid Ultrasound Imaging
The detailed protocol used to evaluate the presence of carotid plaques by ultrasound has been
previously described [19]. Briefly, carotid ultrasonography imaging was performed using a LOGIQ® E9
(General Electric, Wauwatosa, WI, USA) equipped with a 15-MHz linear array probe or a Sequoia 512
(Siemens, North Rhine, Westphalia, Germany) equipped with a 15-MHz linear array probe. Plaques
were identified using B-mode and colour Doppler examinations in both the longitudinal and transverse
planes to consider circumferential asymmetry and were defined as a “focal structure that encroaches
into the arterial lumen of at least 0.5 mm or 50% of the surrounding carotid intima media thickness
value or demonstrates a thickness of 1.5 mm, as measured from the media-adventitia interference
to the intima-lumen surface” according to the Mannheim consensus [20]. Further, the LOGIQ E9
ultrasound system had a 3D image acquisition system with a low depth sweep box with a 45◦ angle
and a slow acquisition time to scan the volume. Volume acquisition used 3 orthogonal sectional plans
(A, B, C) and started with the sectional image (A), which gave a 2D image showing the longitudinal
view of the carotid arteries and bulb. Images B and C showed the transverse and horizontal axes,
respectively. The volume sweep was recorded as raw data and used for volume calculations. Volume
calculation was made by delineating the plaque contours and with the transverse plane (B) as described
previously [21]. Plaque volume was evaluated in 96 subjects (67 with type 1 diabetes and 29 without
diabetes. Volume plaque was measured as total and mean plaque volume. Total plaque volume was
defined as the sum of all plaque volume, and mean plaque volume is the sum of the mean plaque
volume of each subject.
Atherosclerotic plaques were classified using the well-known five-type classification system
based on visual assessment of echogenicity with vessel lumen and adventitia as reference structures:
Uniformly echolucent, predominantly echolucent, uniformly echogenic, predominantly echogenic and
extensively calcified plaques [19]. We additionally reclassified individuals into 4 clinical categories that
have been shown to be useful in terms of future outcomes [16]: Echolucent (lipid- and haemorrhage-rich
plaques), mixed (when patients had both echolucent and echo-rich plaques), echogenic (fibrotic
or fibro-fatty plaque); and extensively calcified plaques (echo-shadowing from calcifications) as
previously described [9]. This classification has been validated against histopathology [9,22] and grey
scale medium measured on ultrasound images [23]. The arterial territories explored included the
common and internal carotid territories and the bifurcation from the left and right carotid arteries.
All participants in the study underwent the same carotid ultrasound examination, and all measures
and ultrasound studies were assessed at each participating hospital by the same researcher.
The Local Ethics Committee of both participating centers approved the protocol (PI11/11 and
PI-13-095) in accordance with the Declaration of Helsinki, and all participants signed informed
consent forms.
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2.3. Statistical Analysis
The descriptive statistics of the mean (standard deviation) or median [interquartile range] were
estimated for quantitative variables with a normal or non-normal distribution, respectively. For the
qualitative variables, absolute and relative frequencies were used. Normally distributed data were
analyzed using the Shapiro–Wilk test. The differences between groups were assessed by Student’s test,
analysis of variance or Mann–Whitney test, and Kruskal–Wallis test depending on the distributions
of the quantitative variables. The significance of the differences in qualitative variables was assessed
by Chi-squared test or Fisher’s exact test. A conditional logistic regression model was performed to
study the echogenic plaque and its association with other variables. All variables of the bivariate
analysis with a p-value < 0.2 were used. Only the main effects with a significant contribution to the
final model according to the likelihood ratio test were included in the final model. Goodness of fit
logistic model assumptions were evaluated using the Hosmer–Lemeshow test. Statistical significance
was established at a p-value < 0.05. Data management and analyses were performed with the free
software environment R version 3.3.1 and SPSS software (version 22, SPSS, Chicago, IL, USA).
3. Results
Clinical characteristics of the 174 subjects with carotid plaque included in this study are presented
in Table 1. Patients with type 1 diabetes exhibited an increased prevalence of hypertension and
dyslipidaemia. Among them, up to 60 (56.1%) had diabetic retinopathy. The duration of diabetes
was 24.7 (±12) years. In addition, 76 (71%) patients were under statin treatment, and 53 (49.5%) were
under antiplatelet treatment. Patients with type 1 diabetes also exhibited reduced waist circumference,
diastolic blood pressure, and plasma triglyceride, total cholesterol and low-density lipoprotein (LDL)
cholesterol concentrations compared with the non-diabetic group. Moreover, patients with type 1
diabetes exhibited increased systolic blood pressure, heart rate, and high-density lipoprotein (HDL)
cholesterol concentrations compared with the group of subjects without diabetes (Table 1).




(n = 107) p-Value
Age, years 52.6 (9.13) 54 (9.8) 0.351
Sex, women, n (%) 28 (41.8%) 53 (49.5%) 0.401
Race, non-Caucasian, n (%) 2 (3%) 0 (0%) 0.147
Tobacco exposure, n (%) 35 (53%) 70 (65.4%) 0.144
Antiplatelet treatment, n (%) 3 (10.3%) 53 (49.5%) <0.001
Dyslipidaemia, n (%) 20 (29.9%) 78 (72.9%) <0.001
Hypertension, n (%) 13 (19.4%) 60 (56.1%) <0.001
Systolic blood pressure, mmHg 131 (14.2) 137 (18) 0.010
Diastolic blood pressure, mmHg 79.6 (8) 74.7 (11.6) 0.001
Statin treatment, n (%) 8 (11.9%) 76 (71%) <0.001
Heart rate, beats/min 71 (11.1) 76.8 (11.9) 0.002
Body mass index, kg/m2 27.8 [25; 30.3] 26.4 [24.3; 29.6] 0.124
Waist, cm 99.6 (12.8) 92.9 (12.7) 0.001
HbA1c, % 5.5 [5.3; 5.7] 7.6 [7.15; 8.15] <0.001
HbA1c, mmol/mol 36.6 [34; 39] 60 [54; 65.5] <0.001
Total cholesterol, mg/dL 203 [185; 228] 173 [155; 198] <0.001
HDL cholesterol, mg/dL 54 [46; 63] 59 [52; 70] 0.005
LDL cholesterol, mg/dL 124 [112; 148] 97.4 [80.6; 113] <0.001
Triglycerides, mg/dL 99 [65; 142] 71 [57; 90] 0.001
Creatinine, mg/dL 0.81 [0.7; 0.9] 0.79 [0.7; 0.9] 0.166
GFR, mL/min/1.73 m2 97.9 [85.6; 105] 96.1 [88.3; 105] 0.899
Diabetes duration, years - 24.7 (12) -
Plaque 0.581
One plaque 35 (52.2%) 50 (46.7%)
Multiple plaques (≥2) 32 (47.8%) 57 (53.3%)
Data are mean (SD) or median [interquartile range] or n (%). GFR, Glomerular filtration rate estimate based on the
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation; HDL, high-density lipoprotein; HDL,
low-density lipoprotein.
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3.1. Ultrasound Examination
No differences were observed in the proportion of subjects with either one or more carotid
plaque between patients with type 1 diabetes and subjects without diabetes (Table 1). Regarding
plaque echogenicity, differences were observed between study groups (p = 0.001) (Figure 1A).
The proportion of patients with type 1 diabetes who had only echolucent, i.e., lipid-rich plaques, was
reduced in patients with type 1 diabetes compared with subjects without diabetes (48.6% vs. 73.1%,
respectively). In contrast, the proportion of patients with only echogenic plaques, i.e., those who
contain more calcification and fibrous tissue, was increased in the group of patients with type 1 diabetes
(25.2% vs. 7.5%). In addition, the proportion of patients with at least one echogenic plaque was
increased in patients with type 1 diabetes compared with subjects without diabetes (49.5% vs. 26.9%,
p = 0.005) (Figure 1B). When stratifying the groups by sex, differences in the proportion of patients
with echogenic plaques were observed. In subjects without diabetes, the proportion of those with
echogenic plaques was increased in men (12.8% vs. 0%). In the group of patients with type 1 diabetes













Figure 1. Atherosclerotic plaque type. (A) Proportion of patients with different types of atherosclerotic
plaques (only echolucent, only echogenic, mixed of echolucent and echogenic plaques, and calcified
with or without another plaque type). (B) Proportion of patients with different types of atherosclerotic
plaques (at least one echolucent plaque, at least one echogenic plaque, and at least one calcified plaque).
Finally, no differences were noted in the proportion of patients with mixed plaque types
(echolucent and echogenic) between the study groups (16.8% vs. 17.9%). Additionally, the proportion
of patients with at least one extensively calcified plaque was increased in patients with type 1 diabetes
compared with subjects without diabetes (9.4% vs. 1.5%) (Figure 1B). None of the study subjects had
high-grade (>50%) carotid artery stenosis.
3.2. Measurements of the Plaque Volume
Plaque volume was assessed in 96 subjects; 67 type 1 diabetes patients and 29 control subjects.
There were no differences of total plaque volume between subjects with and without diabetes, median
[IQR], (60 [30; 130] mm3 vs. 50 [20; 80] mm3; p = 0.260). However, the mean plaque volume was higher
in type 1 diabetes patients compared to control subjects (40 [30; 70] mm3 vs. 30 [20; 40] mm3; p = 0.028).
On the other hand, plaque volume (total and mean) were higher in individuals with echogenic plaque
compared with individuals with non-echogenic plaque 100 [60; 160] mm3 vs. 40 [20; 69] mm3; p < 0.001
and 55 [34.2; 80] mm3 vs. 30 [20; 50] mm3; p = 0.003, respectively).
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3.3. Characteristics of Patients with Echogenic Plaques
Seventy-one study subjects exhibited echogenic plaques (including those with or without type 1
diabetes). Among them, up to 53 (74.6%) had type 1 diabetes and up to 41 (57.7%) were under
statin treatment. Subjects with echogenic plaques were older, exhibited an increased frequency of
hypertension and dyslipidaemia, had higher systolic blood pressure and were more frequently under
antiplatelet treatment. On the other hand, total and LDL cholesterol concentrations were reduced in
those patients with echogenic plaques compared with the group without echogenic plaques. Finally,
the proportion of patients with more than one plaque was increased in the group of subjects with
echogenic plaques (Table A1 in Appendix A).
3.4. Logistic Regression Model of Echogenic Plaques
The multiple regression model was constructed using the candidate parameters identified in
the bivariate analysis and the clinically relevant variables to explain the risk of having echogenic
plaques. The model for having echogenic plaques vs. not having echogenic plaques revealed that the
variables associated with the presence of echogenic plaques were older age (OR = 1.06; p = 0.002) and
type 1 diabetes (OR = 2.28; p = 0.026); this model had a good discriminatory ability (AUCROC = 0.73;
p < 0.001) (Table 2).
Table 2. Logistic regression model for the presence of any echogenic plaques.
Presence of any Echogenic Plaque vs. No Echogenic Plaque a
Odds Ratio 95% CI p
Age 1.062 1.023–1.103 0.002
Sex, women 0.539 0.272–1.068 0.076
BMI 0.949 0.872–1.032 0.221
Diabetes 2.276 1.104–4.690 0.026
sBP 1.019 0.998–1.040 0.075
BMI, body mass index; sBP, systolic blood pressure. a The logistic model showed a good discrimination with an
AUC of 0.73 (95% CI: [0.65–0.80] and no significant lack of calibration (Hosmer–Lemeshow test p-value = 0.21).
4. Discussion
In the present study that included a large sample of patients with type 1 diabetes and subjects
without diabetes, all of whom had at least one carotid atherosclerotic plaque, we report for the first
time that the ultrasound tissue characterization of carotid plaques differs between patients with type 1
diabetes and subjects without diabetes. The results obtained show that the proportion of subjects with
echogenic or extensively calcified plaques is increased in patients with type 1 diabetes compared with
subjects without diabetes, whereas the proportion of echolucent plaques is lower in the former.
In the general population, non-invasive measures of subclinical atherosclerosis, such as CAC
burden and atherosclerotic plaque presence and burden in the carotid arteries, are features associated
with an increased risk of CV events [4,8,12,13]. In addition, plaque characteristics are associated with
the future risk of CV events. Regarding carotid plaques, ultrasonographic plaque characterization
studies performed in the general population have demonstrated that echolucent plaques are
independently associated with an increased risk of cerebrovascular and other CV events [24] in
symptomatic patients with stenotic plaques (≥50%) [15] and those with non-stenotic plaques [25].
On the other hand, plaque volume, as well as the number of atherosclerotic plaques (i.e., plaque
burden), have both been associated with an increased risk of future CV events [26]. First, in our
study, the mean plaque volume in type 1 diabetic subjects was higher, although this preliminary
finding should be interpreted with caution as the number of subjects is quite low. This prevented
us from further statistical work-up using these data. Interestingly, the proportion of patients with
more than one plaque was increased in the group of subjects with echogenic plaques. In concordance
with this finding, these patients had a higher total plaque volume than the non-echogenic group.
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Thus, the presence of echogenic plaques in a given patient is associated with an increased burden
of atherosclerosis (total number and volume of plaques). Therefore, future studies should address
the issue of whether subjects with echogenic plaques, especially if they have type 1 diabetes, are
at a higher risk of cardiovascular events than those with echolucent plaques. Additionally, in the
general population, carotid plaque calcification, which is defined as that with an acoustic shadowing,
is a strong and an independent predictor of vascular events in asymptomatic subjects [11,27]. In
type 2 diabetes, the presence of both echolucent [16,17,28] and echogenic plaques [12,18] is also
independently associated with an increased risk of CV events. In contrast to echolucent plaques, which
are lipid rich, echogenic plaques contain more calcification and fibrous tissue. In the general population
and patients with type 2 diabetes carotid plaque calcification, as assessed by computed tomography, is
independently associated with a future risk of cardiovascular events [12]. Not only the presence of
calcium in the atherosclerotic plaque but also the pattern of the calcium depots has been suggested to
be involved in the vulnerability of the atherosclerotic lesion. In this sense, microcalcification patterns,
i.e., spotty calcium depots, are associated with vulnerability of coronary atherosclerotic plaques in
contrast to extensive calcifications, which are associated with stable plaques [29–31]. These findings
suggest that microcalcification may increase wall stress in the fibrous cap, resulting in plaque instability
as a characteristic of vulnerable plaques [31,32]. In the present study, presence and characteristics
of carotid plaques were evaluated with carotid B-mode ultrasound. Actually, as contrast-enhanced
modalities that are the best method to analyze the characteristics of vulnerable atherosclerotic plaques
such as inflammation, intraplaque haemorrhage and ulceration, the use of this ultrasound method
might have clearly improved the adequate characterization of carotid atherosclerotic plaques of type
1 diabetic patients; unfortunately, this is a rather time-consuming and expensive procedure that we
could not use in the current study.
Few studies have analyzed the presence and tissue characteristics of atherosclerotic plaques
in type 1 diabetes. Atherosclerotic CV disease is the leading cause of death in people with type 1
diabetes whose risk of CV disease is two- to seven-fold increased and not completely accounted for
by traditional CV risk factors [33]. For example, women exhibit a two-fold increased risk of fatal
and nonfatal vascular events compared with men with type 1 diabetes [1]. Our group has recently
described an increased proportion and burden of carotid plaques in type 1 diabetic patients without
CV events compared with subjects without diabetes [7]. In this group of patients, the presence of
advanced stages of diabetic retinopathy is independently associated with the presence and the burden
of subclinical carotid atherosclerosis. Plaque tissue characteristics in patients with type 1 diabetes
have been mainly studied in coronary arteries by computed tomography. Studies demonstrate that
diabetes is associated with an increased prevalence of any degree of calcification compared with
control subjects [32]. Moreover, coronary artery calcification is greatly increased in women, and the
gender difference in calcification observed in the general population is lost in subjects with type 1
diabetes [34,35]. In addition, Djaberi et al., used multislice computed tomography to assess coronary
atherosclerosis and found no differences in average CAC scores and the prevalence of coronary
atherosclerosis between asymptomatic patients with type 1 and type 2 diabetes, with the exception of
an increased percentage of noncalcified plaques in patients with type 2 diabetes [36].
To the best of our knowledge, no studies to date have analyzed the ultrasound characteristics of
carotid plaques in patients with type 1 diabetes. The results obtained in the present study demonstrated
that the proportion of subjects with echogenic plaques is increased in patients with type 1 diabetes
compared with subjects without diabetes without differences between gender in the proportion
of subjects who have echogenic plaques. These results point to a greater effect of calcification in
women compared with men given that echogenic plaques contain more calcified tissue compared
with echolucent plaques. These results are similar to those that have described a reduction in the
gender difference in coronary artery calcification given that the prevalence of CAC is similar in men
and women [35]. The analysis performed in the present study to analyze those variables associated
with the risk of having echogenic plaques noted that older age and type 1 diabetes were the only ones
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that were independently associated with the risk of having this type of plaque. However, we must
acknowledge that although we found an association between each of these two variables with the
presence of echogenic plaques, the low number of subjects studied may reduce the chance of finding
an association with other cardiovascular disease-related or unexplored factors. Finally, regarding
extensive plaque calcification, our results demonstrate that the proportion of patients with at least one
extensively calcified plaque was increased in patients with type 1 diabetes compared with subjects
without diabetes, which is similar to the increased coronary artery calcification described in patients
with type 1 diabetes compared with nondiabetic subjects.
In the general population, treatment with statins promotes coronary artery calcification [37].
Few studies have analyzed the effect of statin treatment on calcium content in coronary arteries in
patients with diabetes mellitus. These studies have been performed in patients with type 2 diabetes.
The results indicate that patients who receive statins exhibit an increased degree of calcification as
assessed by CAC compared with those who are not receiving statins; however, the progression of
CAC scores is faster in those who are not receiving statins [38,39]. In this sense, some authors have
suggested that statins render microcalcifications more confluent, which could be associated with a
reduction in vessel wall stress [40]. In fact, patients with diabetes and patients with a previous CV
event are frequently treated with statins given that this treatment decreases the incidence of CV events
in these populations. Our study reported no differences in the plaque type distribution between the
complete series and patients without statin treatment (Figure A1 in Appendix A), or between subjects
under statin treatment with and without echogenic plaques.
Our study has several limitations. First, although we adjusted for risk factors known to be
associated with atherosclerosis, it is possible that some confounding factors exist and were incompletely
accounted for. Second, the cross-sectional design precludes conclusions about causality; therefore,
a larger prospective study is needed to establish the usefulness of plaque type characterization as a
predictive factor for CV events in patients with type 1 diabetes. Finally, an additional limitation is that
only a limited number of patients with echogenic plaques were studied; therefore, larger studies are
warranted as no final conclusions can be drawn from our findings.
5. Conclusions
In summary, our study demonstrates that in the absence of previous CV disease, non-stenotic
carotid plaque ultrasound characteristics differ between patients with type 1 diabetes and subjects
without diabetes. The proportion of echogenic plaques, which comprise calcified tissue, is increased
in patients with type 1 diabetes, and no differences exist in the proportion of subjects with echogenic
plaques between genders. This finding is consistent with the notion that diabetes is associated with
vascular calcification and the loss of gender differences in calcification. Whether the increase in the
proportion of plaques with this ultrasonographic pattern observed in patients with type 1 diabetes will
translate into an increased risk of future cardiovascular events will be determined in the prospective
follow-up of this cohort of patients.
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Appendix A




n = 103 n = 71
Age, years 51.2 (9.22) 56.7 (9.11) <0.001
Sex, women, n (%) 52 (50.5%) 29 (40.8%) 0.272
Race, non Caucasian, n (%) 2 (1.94%) 0 (0.00%) 0.514
Diabetes mellitus type 1, n (%) 54 (52.4%) 53 (74.6%) 0.005
Diabetes duration, years 22.2 (11.8) 27.2 (11.8) 0.030
Tobacco exposure, n (%) 58 (56.9%) 47 (66.2%) 0.281
Hypertension, n (%) 33 (32.0%) 40 (56.3%) 0.002
Dyslipidaemia, n (%) 47 (45.6%) 43 (60.6%) 0.075
BMI, kg/m2 27 [25;29.9] 26.7 [24.2;29.8] 0.424
Waist, cm 96.0 (12.0) 94.5 (14.6) 0.469
Systolic blood pressure, mmHg 132 (17.4) 139 (15.5) 0.004
Diastolic blood pressure, mmHg 76.3 (10.2) 76.9 (11.3) 0.730
Heart rate, beat/min 74.1 (12.8) 75.6 (10.6) 0.391
Antiplatelet treatment, n (%) 23 (29.1%) 33 (57.9%) 0.001
Statin treatment, n (%) 43 (41.7%) 41 (57.7%) 0.055
Glucose, mg/dL 99 [87.5; 140] 127 [88; 211] 0.034
HbA1c, % 6.7 [5.5; 7.6] 7.40 [6.3; 7.9] 0.006
HbA1c, mmol/mol 49.7 [36.6; 60] 57 [45; 63] 0.006
Triglycerides, mg/dL 74 [59; 106] 81 [60.5; 126] 0.313
Total cholesterol, mg/dL 192 [170; 218] 178 [160; 202] 0.016
HDL, mg/dL 58 [49.5; 70] 56 [47.5; 68.5] 0.296
LDL, mg/dL 112 [92.5; 141] 107 [82.5; 120] 0.036
Creatinine, mg/dL 0.8 [0.67; 0.9] 0.79 [0.66; 0.92] 0.756
GFR, mL/min/1.73 m2 97.6 [87.4; 106] 96 [86.8; 104] 0.485
Plaque, n (%)
<0.001One plaque 67 (65%) 18 (25.4%)
Multiple plaques 36 (35%) 53 (74.6%)
Data are mean (SD) or median [interquartile range] or n (%). GFR, Glomerular filtration rate estimate by the






Figure A1. Proportion of patients without statin treatment with different types of atherosclerotic plaque
(only echolucent, only echogenic, mixed of echolucent and echogenic plaques, and calcified with or
without another plaque type), n = 90.
107
J. Clin. Med. 2019, 8, 424
References
1. Huxley, R.R.; Peters, S.A.; Mishra, G.D.; Woodward, M. Risk of all-cause mortality and vascular events in
women versus men with type 1 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol.
2015, 3, 198–206. [CrossRef]
2. Peters, S.A.; Huxley, R.R.; Woodward, M. Articles Diabetes as a risk factor for stroke in women compared
with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539
strokes. Lancet 2014, 383, 1973–1980. [CrossRef]
3. Stein, J.H.; Korcarz, C.E.; Hurst, R.T.; Lonn, E.; Kendall, C.B.; Mohler, E.R.; Najjar, S.S.; Rembold, C.M.;
Post, W.S. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid
ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus
statement from the American Society of Echocardiography carotid intima-media thickness task force
endorsed by the Society for Vascular Medicine. J. Am. Soc. Echocardiogr. 2008, 21, 93–111. [PubMed]
4. Baber, U.; Mehran, R.; Sartori, A.; Schoos, M.M.; Sillesen, H.; Muntendam, P.; Garcia, M.J.; Gregson, J.;
Pocock, S.; Falk, E.; et al. Prevalence, impact, and predictive value of detecting subclinical coronary and
carotid atherosclerosis in asymptomatic adults. J. Am. Coll. Cardiol. 2015, 65, 1065–1074. [CrossRef]
5. Inaba, Y.; Chen, J.A.; Bergmann, S.R. Carotid plaque, compared with carotid intima-media thickness, more
accurately predicts coronary artery disease events: A meta-analysis. Atherosclerosis 2012, 220, 128–133.
[CrossRef]
6. Catalan, M.; Herreras, Z.; Pinyol, M.; Sala-Vila, A.; Amor, A.J.; de Groot, E.; Gilabert, R.; Ros, E.; Ortega, E.
Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutr. Metab.
Cardiovasc. Dis. 2015, 25, 742–748. [CrossRef] [PubMed]
7. Carbonell, M.; Castelblanco, E.; Valldeperas, X.; Betriu, À.; Traveset, A.; Granado-Casas, M.; Hernández, M.;
Vázquez, F.; Martín, M.; Rubinat, E.; et al. Diabetic retinopathy is associated with the presence and burden of
subclinical carotid atherosclerosis in type 1 diabetes. Cardiovas. Diabetol. 2018, 17, 66. [CrossRef] [PubMed]
8. Grønholdt, M.-L.M. Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the
carotid artery. Arter. Thromb. Vasc. Biol. 1999, 19, 2–13. [CrossRef]
9. Gray-Weale, A.C.; Graham, J.C.; Burnett, J.R.; Byrne, K.; Lusby, R.J. Carotid artery atheroma: Comparison
of preoperative B-mode ultrasound appearance with carotid endarterectomy specimen pathology.
J. Cardiovasc. Surg. 1988, 29, 676–681.
10. Mitchell, C.C.; Stein, J.H.; Cook, T.D.; Salamat, S.; Wang, X.; Varghese, T.; Jackson, D.C.; Sandoval Garcia, C.;
Wilbrand, S.M.; Dempsey, R.J. Histopathological Validation of Grayscale Carotid Plaque Characteristics
Related to Plaque Vulnerability. Ultrasound Med. Biol. 2017, 43, 129–137. [CrossRef]
11. Mathiesen, E.B.; Bønaa, K.H.; Joakimsen, O. Echolucent plaques are associated with high risk of ischemic
cerebrovascular events in carotid stenosis: The tromsø study. Circulation 2001, 103, 2171–2175. [CrossRef]
[PubMed]
12. Grønholdt, M.-L.M.; Nordestgaard, B.G.; Schroeder, T.; Vorstrup, S.; Sillesen, H. Ultrasonic echolucent carotid
plaques predict future strokes. Circulation 2001, 104, 68–73. [CrossRef] [PubMed]
13. Agarwal, S.; Morgan, T.; Herrington, D.M.; Xu, J.; Cox, A.J.; Freedman, B.I.; Carr, J.J.; Bowden, D.W. Coronary
calcium score and prediction of all-cause mortality in diabetes: The diabetes heart study. Diabetes Care 2011,
34, 1219–1224. [CrossRef] [PubMed]
14. Cox, A.J.; Hsu, F.-C.; Agarwal, S.; Freedman, B.I.; Herrington, D.M.; Carr, J.J.; Bowden, D.W. Prediction of
mortality using a multi-bed vascular calcification score in the Diabetes Heart Study. Cardiovasc. Diabetol.
2014, 13, 160. [CrossRef]
15. Allison, M.A.; Hsi, S.; Wassel, C.L.; Morgan, C.; Ix, J.H.; Wright, C.M.; Criqui, M.H. Calcified atherosclerosis
in different vascular beds and the risk of mortality. Arter. Thromb. Vasc. Biol. 2011, 32, 140–146. [CrossRef]
16. Katakami, N.; Takahara, M.; Kaneto, H.; Sakamoto, K.; Yoshiuchi, K.; Irie, Y.; Kubo, F.; Katsura, T.;
Yamasaki, Y.; Kosugi, K.; et al. Ultrasonic tissue characterization of carotid plaque improves the prediction
of cardiovascular events in diabetic patients: A pilot study. Diabetes Care 2012, 35, 2640–2646. [CrossRef]
[PubMed]
17. Irie, Y.; Katakami, N.; Kaneto, H.; Takahara, M.; Nishio, M.; Kasami, R.; Sakamoto, K.; Umayahara, Y.;
Sumitsuji, S.; Ueda, Y.; et al. The utility of ultrasonic tissue characterization of carotid plaque in the
prediction of cardiovascular events in diabetic patients. Atherosclerosis 2013, 230, 399–405. [CrossRef]
108
J. Clin. Med. 2019, 8, 424
18. Vigili de Kreutzenberg, S.; Fadini, G.P.; Guzzinati, S.; Mazzucato, M.; Volpi, A.; Coracina, A.; Avogaro, A.
Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. Diabetes Care 2015, 38,
1937–1944. [CrossRef]
19. Alonso, N.; Traveset, A.; Rubinat, E.; Ortega, E.; Alcubierre, N.; Sanahuja, J.; Hernández, M.; Betriu, A.;
Jurjo, C.; Fernández, E.; et al. Type 2 diabetes-associated carotid plaque burden is increased in patients with
retinopathy compared to those without retinopathy. Cardiovasc. Diabetol. 2015, 14, 33–39. [CrossRef]
20. Touboul, P.-J.; Hennerici, M.G.; Meairs, S.; Adams, H.; Amarenco, P.; Bornstein, N.; Csiba, L.; Desvarieux, M.;
Ebrahim, S.; Hernandez, R.; et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus
(2004–2006–2011). Cerebrovasc. Dis. 2012, 34, 290–296. [CrossRef]
21. Ludwig, M.; Zielinski, T.; Schremmer, D.; Stumpe, K.O. Reproducibility of 3-dimensional ultrasound readings
of volume of carotid atherosclerotic plaque. Cardiovas. Ultrasound 2008, 26, 42. [CrossRef]
22. European Carotid Plaque Study Group. Carotid Artery Plaque Composition—Relationship to Clinical
Presentation and Ultrasound B-mode Imaging. Eur. J. Vasc. Endovasc. Surg. 1995, 10, 23–30. [CrossRef]
23. Mayor, I.; Momjian, S.; Lalive, P.; Sztajzel, R. Carotid plaque: Comparison between visual and grey-scale
median analysis. Ultrasound Med. Biol. 2003, 29, 961–966. [CrossRef]
24. Larsen, J.R.; Tsunoda, T.; Tuzcu, E.M.; Schoenhagen, P.; Brekke, M.; Arnesen, H.; Hanssen, K.F.; Nissen, S.E.;
Dahl-Jorgensen, K. Intracoronary ultrasound examinations reveal significantly more advanced coronary
atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls. Diab. Vasc.
Dis. Res. 2007, 4, 62–65. [CrossRef] [PubMed]
25. Costacou, T.; Edmundowicz, D.; Prince, C.; Conway, B.; Orchard, T.J. Progression of coronary artery calcium
in type 1 diabetes mellitus. Am. J. Cardiol. 2007, 100, 1543–1547. [CrossRef] [PubMed]
26. Polak, J.F.; Szklo, M.; Kronmal, R.A.; Burke, G.L.; Shea, S.; Zavodni, A.E.; O’Leary, D.H. The value of carotid
artery plaque and intima-media thickness for incident cardiovascular disease: The multi-ethnic study of
atherosclerosis. J. Am. Heart Assoc. 2013, 2, e000087. [CrossRef] [PubMed]
27. Djaberi, R.; Schuijf, J.D.; Boersma, E.; Kroft, L.J.; Pereira, A.M.; Romijn, J.A.; Scholte, A.J.; Jukema, J.W.;
Bax, J.J. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as
assessed by multislice computed tomography. Diabetes Care 2009, 32, 1507–1512. [CrossRef] [PubMed]
28. Zavodni, A.E.H.; Wasserman, B.A.; McClelland, R.L.; Gomes, A.S.; Folsom, A.R.; Polak, J.F.; Lima, J.A.;
Bluemke, D.A. Carotid artery plaque morphology and composition in relation to incident cardiovascular
events: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology 2014, 271, 381–389. [CrossRef]
29. Prabhakaran, S.; Singh, R.; Zhou, X.; Ramas, R.; Sacco, R.L.; Rundek, T. Presence of calcified carotid plaque
predicts vascular events: The Northern Manhattan Study. Atherosclerosis 2007, 195, e197–e201. [CrossRef]
30. Hunt, K.J.; Evans, G.W.; Folsom, A.R.; Sharrett, A.R.; Chambless, L.E.; Tegeler, C.H.; Heiss, G. Acoustic
shadowing on B-mode ultrasound of the carotid artery predicts ischemic stroke: The Atherosclerosis Risk in
Communities (ARIC) study. Stroke 2001, 32, 1120–1126. [CrossRef]
31. Wilson, P.W.; Kauppila, L.I.; O’Donnell, C.J.; Kiel, D.P.; Hannan, M.; Polak, J.M.; Cupples, L.A. Abdominal
aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001, 103,
1529–1534. [CrossRef] [PubMed]
32. Nonin, S.; Iwata, S.; Sugioka, K.; Fujita, S.; Norioka, N.; Ito, A.; Nakagawa, M.; Yoshiyama, M. Plaque surface
irregularity and calcification length within carotid plaque predict secondary events in patients with coronary
artery disease. Atherosclerosis 2017, 256, 29–34. [CrossRef] [PubMed]
33. McClelland, R.L.; Jorgensen, N.W.; Budoff, M.; Budoff, M.; Blaha, M.J.; Post, W.S.; Kronmal, R.A.; Bild, D.E.;
Shea, S.; Liu, K.; et al. 10-year coronary heart disease risk prediction using coronary artery calcium and
traditional risk factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in
the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J. Am. Coll. Cardiol. 2015, 66,
1643–1653. [PubMed]
34. Lin, R.; Chen, S.; Liu, G.; Xue, Y.; Zhao, X. Association between carotid atherosclerotic plaque calcification
and intraplaque hemorrhage A Magnetic Resonance Imaging Study. Arterioscler. Thromb. Vasc. Biol. 2017, 37,
1228–1233. [CrossRef]
35. Beckman, J.A.; Ganz, J.; Creager, M.A.; Ganz, P.; Kinlay, S. Relationship of clinical presentation and
calcification of culprit coronary artery stenoses. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1618–1622.
[CrossRef] [PubMed]
109
J. Clin. Med. 2019, 8, 424
36. Shemesh, J.; Stroh, C.I.; Tenenbaum, A.; Hod, H.; Boyko, V.; Fisman, E.Z.; Motro, M. Comparison of
coronary calcium in stable angina pectoris and in first acute myocardial infarction utilizing double helical
computerized tomography. Am. J. Cardiol. 1998, 81, 271–275. [CrossRef]
37. Ehara, S. Spotty Calcification typifies the culprit plaque in patients with acute myocardial infarction:
An Intravascular Ultrasound Study. Circulation 2004, 110, 3424–3429. [CrossRef] [PubMed]
38. Maldonado, N.; Kelly-Arnold, A.; Vengrenyuk, Y.; Laudier, D.; Fallon, J.T.; Virmani, R.; Cardoso, L.;
Weinbaum, S. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability:
Potential implications for plaque rupture. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H619–H628.
[CrossRef]
39. Lee, S.E.; Chang, H.J.; Sung, J.M.; Park, H.B.; Heo, R.; Rizvi, A.; Lin, F.Y.; Kumar, A.; Hadamitzky, M.; Kim, Y.J.;
et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM (Progression of AtheRosclerotic
PlAque DetermIned by Computed TomoGraphic Angiography Imaging) Study. JACC Cardiovasc. Imaging
2018, 11, 1475–1484. [CrossRef]
40. Puri, R.; Libby, P.; Nissen, S.E.; Wolski, K.; Ballantyne, C.M.; Barter, P.J.; Chapman, M.J.; Erbel, R.; Raichlen, J.S.;
Uno, K.; et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma
composition: Insights from SATURN. Eur. Heart J. Cardiovasc. Imaging 2014, 15, 380–388. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Poorer Quality of Life and Treatment Satisfaction is
Associated with Diabetic Retinopathy in Patients
with Type 1 Diabetes without Other Advanced
Late Complications
Minerva Granado-Casas 1,2, Esmeralda Castelblanco 1,3, Anna Ramírez-Morros 1,
Mariona Martín 4, Nuria Alcubierre 2, Montserrat Martínez-Alonso 5, Xavier Valldeperas 6,
Alicia Traveset 7, Esther Rubinat 8, Ana Lucas-Martin 4, Marta Hernández 2,9, Núria Alonso 1,3
and Didac Mauricio 2,3,10,*
1 Department of Endocrinology and Nutrition, Health Sciences Research Institute & University Hospital
Germans Trias i Pujol, 08916 Badalona, Spain; mgranado@igtp.cat (M.G.-C.);
esmeraldacas@gmail.com (E.C.); aramirez@igtp.cat (A.R.-M.); nalonso32416@yahoo.es (N.A.)
2 Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida,
25198 Lleida, Spain; cubito@lleida.org (N.A.); martahernandezg@gmail.com (M.H.)
3 Centre for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de
Salud Carlos III, 08907 Barcelona, Spain
4 Department of Endocrinology & Nutrition, University Hospital Germans Trias i Pujol, 08916 Badalona,
Spain; marionamarting@gmail.com (M.M.); alucas.germanstrias@gencat.cat (A.L.-M.)
5 Systems Biology and Statistical Methods for Biomedical Research, IRBLleida, University of Lleida,
25198 Lleida, Spain; mmartinez@irblleida.cat
6 Department of Ophthalmology, University Hospital Germans Trias i Pujol, 08916 Badalona, Spain;
xvalldeperas@gmail.com
7 Department of Ophthalmology, University Hospital Arnau de Vilanova, 25198 Lleida, Spain;
atravesetm@gmail.com
8 Department of Nursing and Physiotherapy, University of Lleida, 25198 Lleida, Spain;
rubinatesther@gmail.com
9 Department of Endocrinology & Nutrition, University Hospital Arnau de Vilanova, 25198 Lleida, Spain
10 Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
* Correspondence: didacmauricio@gmail.com; Tel.: +34-935-565-661
Received: 16 January 2019; Accepted: 14 March 2019; Published: 18 March 2019
Abstract: Diabetic retinopathy (DR) may potentially cause vision loss and affect the patient’s quality
of life (QoL) and treatment satisfaction (TS). Using specific tools, we aimed to assess the impact of DR
and clinical factors on the QoL and TS in patients with type 1 diabetes. This was a cross-sectional,
two-centre study. A sample of 102 patients with DR and 140 non-DR patients were compared. The Audit
of Diabetes-Dependent Quality of Life (ADDQoL-19) and Diabetes Treatment Satisfaction Questionnaire
(DTSQ-s) were administered. Data analysis included bivariate and multivariable analysis. Patients with
DR showed a poorer perception of present QoL (p = 0.039), work life (p = 0.037), dependence (p = 0.010),
and had a lower average weighted impact (AWI) score (p = 0.045). The multivariable analysis showed
that DR was associated with a lower present QoL (p = 0.040), work life (p = 0.036) and dependence
(p = 0.016). With regards to TS, DR was associated with a higher perceived frequency of hypoglycaemia
(p = 0.019). In patients with type 1 diabetes, the presence of DR is associated with a poorer perception of
their QoL. With regard to TS, these subjects also show a higher perceived frequency of hypoglycaemia.
Keywords: diabetic retinopathy; type 1 diabetes; quality of life; treatment satisfaction; patient-reported
outcomes
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1. Introduction
Diabetic retinopathy (DR) is a significant diabetic complication in patients with type 1 diabetes [1].
This complication is a potential cause of vision loss in the diabetic population that can negatively affect
their quality of life (QoL) [2]. Moreover, DR is also associated with an increased risk for all-cause
mortality and cardiovascular disease in patients with type 1 diabetes [3].
QoL is a multidimensional, subjective and dynamic construct comprising the individual’s
subjective perception of the physical, psychological and social well-being aspects of his or her
life [4]. Treatment satisfaction (TS) is an individual’s subjective appraisal of his or her experience
of the treatment, including both the process and results [4]. From the patient’s point of view,
QoL and TS as patient-reported outcomes (PROs) are two important measures because these are
often stronger determinants of medical outcomes such as hospitalization, mortality and the presence
of complications [5,6]. Furthermore, an assessment of PROs has been accepted to complement visual
acuity information in clinical trials, interventions or research [7]. Regarding QoL and TS, recent studies
have found that having DR negatively impacts the QoL and TS in patients with type 2 diabetes [8–14].
To our knowledge, only one study with a cross-sectional design has assessed the relationship
between QoL and the presence of DR in patients with type 1 diabetes using a diabetes-specific QoL
questionnaire [15]. So far, all of the published scientific evidence regarding this issue used generic
instruments or visual function scales to appraise the impact of DR in the QoL of patients with type
1 diabetes [16–30]. The FinnDiane study, which included a large sample of patients with type 1
diabetes, did not find any association between the presence of DR and health-related quality of
life (HRQoL) using a generic instrument [16]; it should be pointed out that, in this study, DR was
determined to be present if the subject had ever received treatment for DR and that 53% of the
patients had also diabetic nephropathy, which could influence the results. Other cross-sectional studies
with large samples of patients with type 1 diabetes did not report any association between DR and
HRQoL [17,23,24]. However, other prospective cohort and cross-sectional studies observed a negative
impact of DR on HRQoL in patients with type 1 diabetes using generic instruments [25,28]. Two
recently published studies found a lower HRQoL in patients with type 1 diabetes and more severe DR
in the presence of other diabetic complications such as neuropathy, nephropathy and cardiovascular
disease [29,30]. The Wisconsin Epidemiologic Study of Diabetic Retinopathy did not find changes
in the QoL with the presence of DR over time using a visual function scale [18,19]; nevertheless,
researchers included a study sample of patients with other important diabetic complications that
could influence the results. Furthermore, the Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications (DCCT/EDIC) Study designed to assess the effects of
intensive insulin treatment and risk factors on the patient-reported visual function in patients with
type 1 diabetes did not find changes with DR [20]. Although researchers used a diabetes-specific QoL
questionnaire and a visual function scale, these patients also showed other diabetic complications.
Other studies performed in patients with type 1 and type 2 diabetes using a visual function scale related
lower scores with DR [21,22]; however, the study subjects had also other diabetic complications and
comorbidities such as cardiovascular diseases, cancer, arthritis or rheumatism and hearing problems.
Regarding DR and PROs, it has been pointed out that generic instruments have a lack of sensitivity
to assess specific domains of QoL that are related to diabetic complications [7]. This is an important
point because the scientific evidence has shown that patients can report a good patient-reported
health status, often measured with generic questionnaires, even though their diabetes-specific QoL
is negative [8,9,31]. Besides, visual function scales cannot be regarded as sufficient to assess the
diabetes-related QoL due to the lack of specific quality of life domains related to diabetes. For this
reason, the disease-specific questionnaires, but not the generic tools, are the more adequate instruments
to measure specific disease-related QoL [31].
To the best of our knowledge, there have not been any studies primarily designed to assess the
impact of DR on QoL and TS in patients with type 1 diabetes. In addition, there are not any studies that
have assessed the impact of DR on QoL and TS that included a well-defined sample of patients with
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type 1 diabetes and that used diabetes-specific questionnaires. Therefore, we hypothesized that patients
with type 1 diabetes who have been diagnosed with DR have a lower perception of their QoL and TS in
comparison to their non-DR counterparts. The aim of the study was to assess the association of DR with
QoL and TS in adult type 1 diabetic patients with DR as compared to a group of patients without this
condition. Additionally, we also determined which clinical factors that could be related to QoL and TS.
2. Materials and Methods
This was a cross-sectional, two-centre study. Participants were patients with type 1 diabetes regularly
cared for at their reference hospital from two health care regions (Lleida and Badalona). The recruitment
took place between January 2013 and May 2015. From a total number of 330 patients with type 1 diabetes
that were invited to participate, 276 accepted to be included in the study, while 17 could not be included
because of exclusion criteria. Finally, a total sample of 259 patients with type 1 diabetes was included in the
previously published study [32]. From this sample, 16 patients were excluded because they had not had
their eyes assessed; furthermore, one patient was excluded because he did not answer the questionnaires.
A final sample of 102 patients with DR and 140 without DR were included. A detailed description of the
characteristics of the study are provided elsewhere [32]. The inclusion criteria were: having the diagnosis
of type 1 diabetes, a current age greater than 18 years, and a disease duration of more than 1 year. We
intended to avoid the inclusion of other advanced late diabetic complications to exclude their negative
impact on top of DR. Thus, the exclusion criteria were as follows: psychological or cognitive deterioration
(e.g., mental diseases or dementia); being a healthcare professional; the presence of previous clinical
cardiovascular diseases (ischemic heart disease, cerebrovascular disease, peripheral arterial disease
and heart failure) or diabetic foot disease; the presence of any eye disease that could influence the
results (macular oedema, media opacity that hindered assessment of the retina, other concomitant retinal
pathology, ophthalmological surgery in the previous year and laser treatments during the six months
before the study visit); pregnancy; and the presence of other advanced diabetic late complications such
as macroalbuminuria (urine albumin/creatinine ratio > 299 mg/g) and renal insufficiency (estimated
glomerular filtration rate < 60 mL/min). In the DR group, three patients had glaucoma and one patient
had myopia superior to 5 dioptres. In the non-DR group, three patients had myopia superior to 5
dioptres. The assessment of DR was performed and classified by an expert ophthalmologist according
to the international clinical classification system [33]. Optic coherence tomography measurements were
performed using spectral-domain OCT (SD-OCT) (Cirrus HD-OCT, model 4000, Carl Zeiss Meditec,
Dublin, CA, USA) and deep Enhanced Imaging (EDI-OCT), with HD 5 Line Raster scan pattern.
An ophthalmologist assessed and classified DR as follows: no apparent retinopathy, mild non-proliferative
retinopathy, moderate non-proliferative retinopathy, severe non-proliferative retinopathy and proliferative
retinopathy. The ethics committee of each of the two participating centres (Ethics Committee of the
University Hospital Arnau de Vilanova, and Ethics Committee of the University Hospital Germans Trias i
Pujol) approved the study. Written informed consent form was obtained from all participants.
2.1. Clinical Variables
Anthropometric measures, including waist circumference, weight, height and body mass index
(BMI), blood pressure and laboratory variables were determined according to standard procedures.
Cardiovascular disease was excluded based on detailed anamnesis and careful review of all clinical records.
Besides, predefined questionnaires specially designed for the study were used for conduction of personal
interviews and data extraction for collection of all other variables: medication use, physical activity,
educational level, ethanol consumption and smoking habit. Hypertension and dyslipidaemia were
defined by the use of specific medication for treatment of these two conditions. Microalbuminuria was
defined as an albumin creatinine ratio above 30 mg/g. Physical activity was assessed according to two
previously validated methods [34,35]. This was classified as regular physical activity (if the patients spent
more than 25 min/day in any activity that requires 4 METS (the metabolic equivalent), or as sedentary if
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the participants spent up to 25 min/day. Ethanol consumption (g per day) was estimated from frequency,
beverage type, and average amount according to previously validated methods [32].
2.2. Quality of Life
The Audit of Diabetes-Dependent Quality of Life (ADDQoL-19) questionnaire in Spanish was
used to assess the QoL of the patients. This is an instrument specifically designed for its use in subjects
with diabetes, and validated in the diabetic Spanish population [36–38]. The questionnaire consists
of 21 items, 19 of which are related to specific life domains and are scored multiplying the impact
rating (from −3 to +1) by the importance rating (from +3 to 0); these produce scores ranging from +3 to
−9 points. The overall score is the mean of 19 specific domains and is assigned as the average weighted
impact score (AWI); this ranges from +3 (highest QoL) to −9 (poorest QoL). Additionally, there are
two overview items that are scored separately; they measure present QoL ranging from +3 (excellent)
to −3 (very bad) and diabetes-specific QoL, which is scored from −3 (maximum negative impact)
to +1 (maximum positive impact). Two trained researchers (MG-C and MM) conducted individual
interviews with all of the patients. All questionnaires have been recommended by the World Health
Organization and the International Diabetes Federation to assess the PROs [6].
2.3. Treatment Satisfaction
The Diabetes Treatment Satisfaction Questionnaire-status version (DTSQ-s) in Spanish,
a diabetes-specific questionnaire validated for Spanish diabetic subjects was administered [39,40].
This questionnaire consists of 8 items scored on a 6-point scale from 0 (very unsatisfied) to
6 (very satisfied). The final score is calculated by summing up the individual scores from six items
(current treatment, convenience, flexibility, understanding, recommend to others and continue with);
this final score ranges from 36 (very satisfied) to 0 (very unsatisfied). Additionally, two items are
calculated separately and measure the perceived frequency of hyperglycaemia and hypoglycaemia,
respectively; they are scored from 0 (never) to 6 (always).
2.4. Sample Size
The sample size was determined by using the standard deviation for the ADDQoL items from a
previously published study on DR and QoL that was performed in patients with type 2 diabetes by
our group in the same region [8]. Then, we assumed that the differences would be similar in patients
with type 1 diabetes for present QoL, diabetes-specific QoL and AWI items. A sample of 54 patients
with DR and 54 without DR was deemed necessary to detect significant differences between both
groups. We used the Mann-Whitney test and a statistical power of 80% with a significance level of 5%.
From our previous study, a sufficiently large number of patients with type 1 diabetes was available to
fulfil the sample size [32].
2.5. Statistical Methods
The descriptive analysis of quantitative variables included mean and standard deviation for the
normally distributed variables, as well as median and interquartile intervals. Qualitative variables were
summarized by absolute and relative frequencies. Bivariate analysis comparing the groups of patients
with and without diabetic retinopathy included the t-test (or the Mann–Whitney test for non-normally
distributed variables) and the chi-squared test for quantitative and qualitative patient characteristics
as well as QoL and TS outcomes (including overall and subscale scores), respectively. Simple linear
regression analysis was performed to assess the univariate association of patients’ characteristics with
overall QoL and TS, as well as each of their domains. Those domains showing a significant univariate
association with DR were evaluated in a linear multivariable regression analysis to assess the statistical
significance of their association after having adjusted by other patients’ characteristics. For this purpose,
in a first step and separately for each domain associated with DR, we estimated a multivariable linear
(or ordinary least squares) regression model including all variables with a p-value <0.25 according to
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the likelihood ratio test (LRT). In the next step, we used the same method (LRT) to simplify the model
by dropping non-significant variables, starting with the one with the highest and non-significant
p-value, until obtaining a model with variables showing a significant contribution according to the
LRT. Afterwards, we checked the possible additional significant contribution of any other patient
characteristics. The final proposed regression models included any possible interactions involving
the patient characteristics that were included in the corresponding regression model. We used a
significance level of 0.05 and the open-source program R for all statistical analysis [41].
3. Results
The clinical and demographic characteristics of the participants are shown in Table 1. Patients with
DR were older (p = 0.004), had higher systolic blood pressures (p = 0.003), higher glycated haemoglobin
(HbA1c) (p < 0.001), longer diabetes duration (p < 0.001) and lower high density lipoprotein (HDL)
concentrations (p = 0.015) in comparison with non-DR patients. Furthermore, the former had a higher
frequency of hypertension (p < 0.001) and microalbuminuria (p = 0.014).
Table 1. Clinical and demographic characteristics of the study groups.
Characteristics No DR (n = 140) DR (n = 102) p
Age (years) 42.1 ± 10.3 46.2 ± 10.8 0.004
Sex (men) 62 (44.3) 47 (46.1) 0.884
Race (Caucasian) 137 (97.9) 101 (99.0) 0.640
Study site 0.168
Badalona 85 (60.7) 52 (51.0)
Lleida 55 (39.3) 50 (49.0)
Educational level 0.069
Less than primary school 8 (5.9) 4 (4.1)
Completed primary school 34 (25.2) 35 (36.5)
Secondary/high school 49 (36.3) 39 (40.6)
Graduate school or higher 44 (32.6) 18 (18.8)
Smoking 0.282
Non or former smoker 106 (75.7) 70 (68.6)
Yes 34 (24.3) 32 (31.4)
Regular physical activity 98 (70.0) 77 (75.5) 0.425
Insulin dose (UI/kg/day) 0.57 [0.41; 0.75] 0.65 [0.45; 0.86] 0.027
Waist circumference (cm) 86.0 [79.0; 95.0] 90.0 [81.0; 100.0] 0.050
Systolic blood pressure (mmHg) 120.0 [110.0; 134.0] 130.0 [118.0; 140.0] 0.003
Diastolic blood pressure (mmHg) 74.2 ± 9.6 73.6 ± 9.3 0.666
Body mass index (kg/m2) 24.7 [22.4; 27.3] 25.9 [23.1; 28.3] 0.091
Hypertension 20 (14.3) 40 (39.2) <0.001
Dyslipidaemia 49 (35.0) 48 (48.0) 0.056
Microalbuminuria 5 (3.6) 13 (12.9) 0.014
Diabetes duration (years) 17.0 [11.0; 22.0] 26.5 [19.2; 33.0] <0.001
Glaucoma – 3 (2.9) –
Myopia over 5 dioptres 3 (2.1) 1 (0.9) –
HbA1c (%) 7.3 [6.8; 7.8] 7.7 [7.2; 8.5] <0.001
HbA1c (mmol/mol) 56.3 [50.8; 61.7] 60.7 [55.2; 69.4] <0.001
Total cholesterol (mg/dL) 177.0 [164.0; 201.0] 176 [158.0; 200.0] 0.560
HDL cholesterol (mg/dL) 65.5 [55.0; 75.0] 59.5 [51.0; 71.0] 0.015
LDL cholesterol (mg/dL) 102.0 [87.0; 115.0] 100.0 [83.2; 119.0] 0.777
Triglycerides (mg/dL) 64.0 [49.8; 80.0] 68.0 [53.0; 89.8] 0.084
Ethanol consumption (g/day) 5.6 ± 9.2 6.5 ± 11.6 0.686
Data are shown as median [interquartile], means ± SD or n (%). DR, diabetic retinopathy; HbA1c, glycated
haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein.
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3.1. Diabetes-Related Quality of Life
Patients with DR showed lower present QoL (p = 0.039) in comparison with their counterparts
without DR (Table 2). Work life and dependence scores were also lower in patients with DR (p = 0.037
and p = 0.010, respectively). Although no differences between the groups in the diabetes-specific QoL
item (p = 0.069) were observed, the AWI score showed a poorer QoL in patients with DR (p = 0.045).
In the multivariable analysis, DR was associated with a low score in present QoL (β = −0.25; p = 0.040)
and with a poorer perception of QoL items such as work life (β = −0.78; p = 0.036) and dependence
(β = −0.83; p = 0.016) (Table 3). Together with smoking habit, these variables only explained a 2.0%,
2.3% and 3.8% of the variability of those scores, respectively. On the other hand, no association was
found between DR and the AWI score (p = 0.111) after adjusting for smoking status, age, insulin dose
and physical activity (Supplemental Table S1). However, there was a negative correlation between
older age and the AWI score (p = 0.015). Conversely, physical activity and the daily insulin dose
showed a positive association with a higher AWI score (p = 0.005 and p = 0.028, respectively).
Table 2. Bivariate analysis for the Audit of Diabetes Dependent Quality of Life (ADDQoL-19) and the
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) by diabetic retinopathy status.
Items No DR (n = 140) DR (n = 102) p
ADDQoL-19
Present QoL 1.00 [1.00; 2.00] 1.00 [0.00; 1.00] 0.039
Diabetes-specific QoL −1.00 [−2.00; −1.00] −2.00 [−2.00; −1.00] 0.069
Leisure −1.00 [−3.00; 0.00] −2.00 [−3.75; 0.00] 0.198
Work life 0.00 [−3.00; 0.00] −2.00 [−4.00; 0.00] 0.037
Travel −2.00 [−4.00; 0.00] −1.00 [−3.75; 0.00] 0.242
Holidays −2.00 [−3.00; 0.00] −2.00 [−3.00; 0.00] 0.987
Physical ability −2.00 [−4.00; 0.00] −2.00 [−4.00; 0.00] 0.306
Family life 0.00 [−3.00; 0.00] 0.00 [−3.00; 0.00] 0.333
Friends/social life 0.00 [0.00; 0.00] 0.00 [0.00; 0.00] 0.556
Personal relationships 0.00 [−2.00; 0.00] 0.00 [−2.00; 0.00] 0.122
Sex life 0.00 [−2.00; 0.00] 0.00 [−3.00; 0.00] 0.054
Physical appearance 0.00 [−1.00; 0.00] 0.00 [−2.00; 0.00] 0.144
Self-confidence 0.00 [−2.25; 0.00] 0.00 [−3.75; 0.00] 0.315
Motivation 0.00 [−2.00; 0.00] 0.00 [−2.00; 0.00] 0.950
Society/people’s reactions 0.00 [0.00; 0.00] 0.00 [0.00; 0.00] 0.301
Future −2.00 [−4.00; 0.00] −2.00 [−6.00; 0.00] 0.144
Finances 0.00 [0.00; 0.00] 0.00 [0.00; 0.00] 0.070
Living conditions 0.00 [0.00; 0.00] 0.00 [0.00; 0.00] 0.853
Dependence 0.00 [−3.00; 0.00] −2.00 [−4.00; 0.00] 0.010
Freedom to eat −4.00 [−6.00; −2.00] −4.00 [−9.00; −2.00] 0.447
Freedom to drink −2.00 [−4.50; 0.00] −2.50 [−6.00; 0.00] 0.270
AWI −1.32 [−2.05; −0.68] −1.61 [−2.66; −0.94] 0.045
DTSQ-s
Hyperglycaemia frequency perception 3.00 [2.00; 4.00] 3.00 [2.00; 4.00] 0.385
Hypoglycaemia frequency perception 2.00 [2.00; 3.00] 3.00 [2.00; 4.00] 0.022
Final score 28.00 [23.00; 31.00] 28.00 [24.00; 31.80] 0.987
Data are shown as median [interquartile]. AWI, average weighted impact score; DR, diabetic retinopathy; QoL,
quality of life.
To further explore the effect of advanced DR stages on QoL and TS, we analyzed differences
between study groups: without DR, with mild DR (grade 1), and more than mild DR (grades 2–4)
(Supplemental Table S2). The comparison among the 3 groups revealed no statistical differences.
However, head to head comparison between groups yielded some differences. For instance,
patients with mild DR showed a poorer perception of the present QoL (p = 0.040), dependence
(p = 0.005), and an AWI score (p = 0.038) in comparison with non-DR patients (Supplemental Table S2).
Furthermore, patients with advanced (more than mild) DR had a lower AWI score (p = 0.032) in
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comparison with the non-DR group. No statistical differences were observed between groups with the
other items (Supplemental Table S2).
Table 3. Multivariable linear regression models for present quality of life, work life and dependence as
reported on the Audit of Diabetes Dependent Quality of Life (ADDQoL-19) questionnaire.
Present QoL 1 Work Life 2 Dependence 3
Estimate β (95% CI) p Estimate β (95% CI) p Estimate β (95% CI) p
(Intercept) 1.00 (0.83; 1.17) <0.001 −1.81 (−2.31; −1.32) <0.001 −2.45 (−1.51; −1.73) <0.001
Retinopathy −0.25 (−0.49; −0.01) 0.040 −0.78 (−1.50; −0.05) 0.036 −0.83 (−1.51; −0.16) 0.016
Smoker, current 0.12 (−0.14; 0.39) 0.361 0.07 (−0.74; 0.87) 0.867 0.49 (−0.26; 1.24) 0.197
No significant contribution of the variables according to the likelihood ratio test: age, sex, race, educational
level, insulin dose, physical activity, hypertension, dyslipidaemia, diabetes duration, body mass index, waist
circumference, microalbuminuria, glycated haemoglobin, systolic and diastolic blood pressure, HDL and LDL
cholesterol and triglycerides. Model estimates (β) refers to the overall mean (intercept) and the estimated change in
the score mean between patient with and without the corresponding characteristic. 1 Coefficient of determination,
r-squared: 2.0%. 2 Coefficient of determination, r-squared: 2.3%. 3 Coefficient of determination, r-squared: 3.8%.
QoL, quality of life.
3.2. Treatment Satisfaction
The perception of the frequency of hypoglycaemia was higher in the DR group (p = 0.022) (Table 2).
However, no significant differences were observed between the groups in terms of hyperglycaemia
frequency perception and the DTSQ-s final score. We did not find any difference among groups defined
by the status of DR in any of the DTSQ-s items (Supplemental Table S2). In the multivariable analysis
for the hypoglycaemia frequency perception item of the DTSQ-s, we observed a higher hypoglycaemia
frequency perception in subjects with DR (β = 0.019; p = 0.019) (Table 4). In addition, male sex was
associated with a lower hypoglycaemia frequency perception (β = −0.60; p = 0.001). DR together with
male sex only explained 6.3% of the variability. In Supplemental Table S3, the multivariable analysis
of the DTSQ-s final score did not show any relationship with DR (p = 0.244). Only sex and diabetes
duration were associated with the DTSQ-s final score.
Table 4. Multivariable linear regression model for hypoglycaemia frequency perception of the Diabetes
Treatment Satisfaction Questionnaire-status (DTSQ-s).
Estimate β (95% CI) p
(Intercept) 2.91 (2.62; 3.20) <0.001
Retinopathy 0.44 (0.07; 0.80) 0.019
Sex, male −0.60 (−0.96; −0.24) 0.001
No significant contribution of the variables according to the likelihood ratio test: age, race, educational level, insulin
dose, physical activity, hypertension, dyslipidaemia, diabetes duration, body mass index, waist circumference,
smoking, systolic and diastolic blood pressure, triglycerides, glycated haemoglobin, microalbuminuria, HDL and
LDL cholesterol. Model estimates (β) refers to the overall mean (intercept) and the estimated change in the score
mean between patient with and without the corresponding characteristic. Coefficient of determination, r-squared:
6.3%.
4. Discussion
Our results indicate that patients with type 1 diabetes and DR had a poorer QoL than those
without DR. In addition, DR is associated with poorer individual items related to QoL, i.e., present
QoL, work life and dependence. Additionally, older age was also associated with a poorer QoL;
however, physical activity and insulin dose were associated with a higher QoL. In terms of overall
TS, although no difference between the two groups was observed, DR was associated with a higher
hypoglycaemia frequency perception. In addition, a longer diabetes duration in men was associated
with higher TS.
The current study showed a poorer perception of the QoL in the presence of DR; this could be
due to the fact that DR is a condition that more frequently develops in those patients with poorer
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management of the disease and less healthy lifestyle behaviour. This could explain, at least in part, the
poorer perceived QoL of patients with DR in comparison with those without DR. However, there is
only one previous cross-sectional study that has assessed the QoL in patients with type 1 diabetes
using a diabetes-specific QoL instrument [15]. That study did not find any association between DR
and QoL, which is in contrast with our results. Nevertheless, this could be because patients in that
study had a high frequency of advanced late complications, such as diabetic foot disease, which could
be potential confounders. In addition, the previous study was not specifically designed to assess the
relationship between DR and QoL; the authors studied a sample of patients with type 1 and type 2
diabetes together, with a small sample of patients with DR (n = 74) [15]. Other cross-sectional studies
that focused on patients with type 1 diabetes and used generic instruments to measure QoL also did
not find an association between DR and QoL [16,17,24]. Fenwick et al. [23] performed a cross-sectional
study to assess the impact of DR on the QoL with a sample of patients that included both type 1
and type 2 diabetes. They did not find any association between DR and QoL because they used a
generic instrument; besides, these cross-sectional studies were not specifically designed to assess the
relationship between the QoL and DR in this population. Nevertheless, a prospective study performed
on patients with type 1 diabetes using generic instruments found a negative relationship between
the presence of late diabetic complications and HRQoL [25]. However, these patients had a higher
frequency of comorbidities and other complications apart from DR. Peasgood et al. [28] conducted
a post hoc analysis from an interventional study and observed a decreased HRQoL in patients with
type 1 diabetes who also had DR. These results are consistent with the results of the current study.
Although they also used generic instruments to measure a specific condition associated with diabetes,
the sample showed other diabetic complications, which were self-reported; all of these characteristics
could influence the results. Furthermore, another cross-sectional study involving patients with type 1
diabetes observed a lower HRQoL in patients with severe DR; this is similar to our findings, although
their results were not adjusted for other complications [29]. There are two cross-sectional studies
performed with a sample of patients with type 1 and type 2 diabetes that found a lower HRQoL in the
presence of DR [26,27]. These are similar findings to the current study, even though the authors used
generic instruments and data from both types of diabetes were pooled. A previous study performed
on patients with type 2 diabetes by our group showed the negative impact of the presence and severity
of DR on the QoL [8]. Additionally, the PANORAMA study, which was conducted with a large sample
of patients with type 2 diabetes, also showed that a negative perception of QoL was associated with the
presence of DR [9]; this is similar to the current results in patients with type 1 diabetes, even though
the two types of diabetes have remarkably different characteristics. There are other studies that yielded
results that are discordant with our findings. First, the Wisconsin Epidemiologic Study for Diabetic
Retinopathy did not find changes in the QoL with the presence and severity of DR [18,19]. We should
point out that in that study the authors used a visual function scale to assess the diabetes-specific
QoL. Furthermore, a relevant proportion of the study subjects had other diabetic complications that
could significantly impact on QoL, such as nephropathy, neuropathy, cardiovascular diseases and
limb amputations. Finally, the DCCT/EDIC study did not observe a relationship of QoL with DR [20];
although they used a diabetes-specific instrument and a visual function scale, again the study subjects
showed other complications that could influence QoL.
The factor associated with a poorer QoL was advanced age; this is in line with our previous
results in subjects with type 2 diabetes [42]. Nyanzi et al. [15] found a negative relationship between
age and some aspects of QoL, which is similar to our results; moreover, in line with our study, they did
not find any association between smoking status and perceived QoL. Other studies performed in
patients with type 1 and type 2 diabetes also found that a reduced QoL was associated with older
age [9,24,43,44]. However, a cross-sectional study of patients with type 2 diabetes did not find any
association between QoL and these factors, despite using a diabetes-specific QoL instrument [14].
On the other hand, physical activity was associated with a higher QoL in patients with type 1 diabetes,
which is in line with our previously published results about patients with type 2 diabetes [8,42].
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However, we could not identify any study that has specifically assessed this issue in the diabetic
population. The association of the daily insulin dose with a higher QoL has not been described in type
1 diabetes. We have no clear explanation for this finding. Lastly, emotional factors, such as the lack of
optimism and a depressive style, contribute to impairing the QoL in women with type 1 diabetes [44].
However, in the current study we did not find any statistical difference between men and women in
the emotional items of the QoL questionnaire.
In the current study, the DTSQ-s final score was neither different between the two study groups
nor correlated with the presence of DR; this is similar to the results of the recent PANORAMA study
and other studies performed on patients with type 2 diabetes [8,9,45]. However, no studies have
assessed the relationship between DR and TS in patients with type 1 diabetes specifically. Furthermore,
we found that DR was associated with a higher hypoglycaemia frequency perception. This increased
perception of hypoglycaemia is probably associated with poorer glycaemic control, which is associated
with a high risk for the development of diabetic complications such as DR [3]. Another factor that may
influence this perception in patients with type 1 diabetes is ethanol consumption. However, there were
no differences between both study groups in ethanol intake. A longer diabetes duration in men was
associated with higher TS and a lower hypoglycaemia frequency perception; this is also in line with
our previous results [8,42] and with other cross-sectional studies performed in patients with type 2
diabetes [9,45].
This study has several limitations. A causality association between QoL, TS and DR in patients
with type 1 diabetes cannot be established due to the cross-sectional study design; additionally, changes
over time in terms of QoL and TS cannot be determined by this study. In addition, hypoglycaemia
unawareness and the frequency of self-blood glucose monitoring are factors that may influence
the hypoglycaemia frequency perception in patients with type 1 diabetes. The absence of data on
these aspects in our study is another limitation. Furthermore, it is well-known that insulin pump
therapy is a treatment option for those patients with recurrent episodes of severe hypoglycaemia.
Therefore, this treatment option may also have an impact on the perception of hypoglycaemia
frequency; unfortunately, although the proportion of patients treated with pump therapy is low
in our region, we did not collect data on this mode of therapy. Unfortunately, in the current study
we did not assess the visual function of the study participants. In this regard, we should point out
that the impact of DR on QoL is mainly produced by impairment of the visual function. Furthermore,
although we could analyse the effect of advanced DR stages, the number of patients with advanced DR
(moderate, severe and proliferative DR) was very low; for this reason, we cannot draw any conclusion
as to whether patients with more severe DR are those than have poorer QoL and treatment satisfaction
outcomes. This also applies to conditions known to produce visual impairment (e.g., myopia) that were
present in a low number of participants. Although DR was significantly associated with specific QoL
domains and overall diabetic treatment satisfaction, according to our results, there is a high percentage
of variability in these patient-reported outcomes that remains unexplained. Actually, some other
factors or comorbidities associated with DR, that were not assessed in the current study, could have a
relevant contribution to explain our findings on QoL and TS. For instance, although we used diabetic
foot disease as an exclusion criterion, we did not assess diabetic neuropathy in this sample of patients,
a complication that could affect the QoL and TS of the patients. All the limitations mentioned above
call for caution when interpreting the current results. Further studies are clearly needed to address all
the aforementioned issues, especially those in relation to eye-related burden, i.e., the contribution of
the impairment of visual function and the impact of advanced stages of DR.
On the other hand, this study has several strengths. This is the first study that has assessed the
potential relationship between QoL and TS in adult patients with type 1 diabetes and DR by using
diabetes-specific QoL and TS questionnaires. Many studies have used generic instruments to assess
QoL. In point of fact, generic instruments cannot assess the impact of a specific condition on the aspects
of patient’s life due to a demonstrated lack of sensitivity of these instruments; this has been described
in scientific literature [5–7]. Additionally, we recruited a relevant number of patients with type 1
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diabetes without other diabetic complications and comorbid conditions in this two-centre study and
included a representative sample of subjects.
5. Conclusions
In conclusion, DR was associated with poorer QoL and TS in patients with type 1 diabetes.
Moreover, DR was associated with a higher hypoglycaemia frequency perception. Finally, the current
results have implications for potential future research because there has been no other study that
specifically assesses the impact of DR on the QoL and TS of adult patients with type 1 diabetes.
Future research should lead to the identification of the individual contribution of each of the relevant
factors on these patient-reported outcomes.
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Abstract: Type 2 diabetes mellitus accelerates loss of muscle mass and strength. Patients with
Alzheimer’s disease (AD) also show these conditions, even in the early stages of AD. The mechanism
linking glucose management with these muscle changes has not been elucidated but has implications
for clarifying these associations and developing preventive strategies to maintain functional capacity.
This study included 69 type 2 diabetes patients with a diagnosis of cognitive impairment (n = 32) and
patients with normal cognition (n = 37). We investigated the prevalence of sarcopenia in diabetes
patients with and without cognitive impairment and examined the association of glucose alterations
with sarcopenia. Daily glucose levels were evaluated using self-monitoring of blood glucose, and
we focused on the effects of glucose fluctuations, postprandial hyperglycemia, and the frequency
of hypoglycemia on sarcopenia. Diabetes patients with cognitive impairment displayed a high
prevalence of sarcopenia, and glucose fluctuations were independently associated with sarcopenia,
even after adjusting for glycated hemoglobin A1c (HbA1c) levels and associated factors. In particular,
glucose fluctuations were significantly associated with a low muscle mass, low grip strength, and
slow walking speed. Our observation suggests the importance of glucose management by considering
glucose fluctuations to prevent the development of disability.
Keywords: Alzheimer’s disease; type 2 diabetes mellitus; glucose fluctuations; sarcopenia
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1. Introduction
The definition and diagnosis of sarcopenia were updated by the European Working Group on
Sarcopenia in Older People [1]. The revised consensus focuses on the importance of promoting early
detection and treatment of sarcopenia [1]. Because sarcopenia predicts adverse outcomes such as
chronic disease progression, mortality, and functional disability [2], developing strategies to prevent
sarcopenia in older adults is necessary.
Older adults with type 2 diabetes have a higher prevalence of sarcopenia than non-diabetic
individuals [3,4]. Some studies have reported that increased glycated hemoglobin A1c (HbA1c) levels
are associated with impaired muscle quality, muscle strength and physical performance [5–7]. However,
HbA1c levels do not adequately reflect the mean glucose concentration and are not associated with
hypoglycemic risk in diabetes patients [8,9]. Severe hypoglycemic events lead to deterioration in general
health, resulting in an increased risk of mobility disabilities [10]. Therefore, continuous assessments of
daily glucose excursions are needed to determine the association of glucose management with sarcopenia.
Muscle changes and physical dysfunctions are observed in the early stages of Alzheimer’s disease
(AD) [11,12]. Lean mass is reduced in early AD and is associated with brain atrophy [11]. Furthermore,
the nutritional status is correlated with regional cerebral glucose metabolism in prodromal AD, and
the prevalence of sarcopenia increases with the degree of cognitive decline [13,14]. These studies
suggest that AD-related degenerative pathologies have a negative impact on muscle structure and
physical function. Additionally, AD patients with diabetes have a variety of difficulties in glucose
management and therefore might have a higher prevalence of sarcopenia than diabetes patients
without AD. However, to date, the prevalence of sarcopenia in diabetes patients with and without
cognitive impairment remains unclear. Furthermore, the association of glucose management with
sarcopenia in these patients is also unknown.
The aims of this study were as follows: (1) to clarify the prevalence of sarcopenia in older type
2 diabetes patients with cognitive impairment or normal cognition, and (2) to clarify the association
of glucose management with sarcopenia in these patients. We hypothesized that diabetes patients
with cognitive impairment would display a high prevalence of sarcopenia and that abnormal glucose
profiles would be associated with muscle changes and physical dysfunction.
2. Methods
2.1. Participants
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of the National Center for Geriatrics and Gerontology (NCGG)
(approval no. 682). All participants provided written informed consent before participating in the
study. We included 69 outpatients (cognitive impairment: n = 32; normal cognition: n = 37) who
visited the NCGG hospital from 2014 to 2016. The presence of cognitive impairment was defined as
probable or possible AD and amnestic mild cognitive impairment (aMCI) according to the criteria of
the National Institute on Aging–Alzheimer’s Association workgroups and the definition provided by
Petersen et al. [15,16]. Persons with NC attended NCGG hospital for suspected memory impairment
but were assessed as having normal cognition. Patients meeting all the following criteria were included
in this study: (1) outpatients with type 2 diabetes treated with antidiabetic agents; (2) aged 65 years or
older; (3) living in their houses; (4) with families or caregivers who support self-monitoring of blood
glucose (SMBG); and (5) a Mini-Mental State Examination (MMSE) score ≥10 for cognitive impairment.
The exclusion criteria were as follows: (1) severe hearing loss and visual impairment; (2) severe health
conditions, such as cardiac failure, renal disorder or liver dysfunction; and (3) neurological disorders
other than AD or aMCI.
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2.2. Assessment of Clinical Parameters and Comorbidities Associated with Diabetes
Clinical data and blood samples were distributed from the Biobank, which collects and stores
biological material and associated clinical data for biomedical research. Data on the diagnosis,
antidiabetic medication use, and polypharmacy (defined as taking five or more types of oral
medicine) [17] were obtained from clinical charts. Global cognitive function was assessed by the
MMSE [18]. Diabetes-associated complications were evaluated for the coexistence of neuropathy,
retinopathy and nephropathy [19]. Diabetic neuropathy was defined as either the loss of Achilles
tendon reflex or the presence of neuropathic symptoms. Diabetic retinopathy was fundoscopically
assessed through dilated pupils by experienced ophthalmologists. Diabetic nephropathy was defined
as an albumin-to-creatinine ratio >300 μg/mg or a urinary protein concentration >0.5 mg/dL.
We obtained information on the following biochemical parameters: HbA1c, triglyceride, total
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, estimated
glomerular filtration rate, serum albumin, and urinary albumin. HbA1c levels were expressed in the
National Glycohemoglobin Standardization Program units.
2.3. Measurement of Daily Glucose Levels
Daily glucose levels were recorded by SMBG (MS-FR201B; Terumo Corp., Tokyo, Japan) and
were measured at five time points per day (05:00 h, before breakfast, 2 h after breakfast, before lunch,
and before dinner) on eight separate days during a two-month period. Glucose levels usually nadir
early in the morning and before each meal, and postprandial glucose levels usually peak at 2 h after
breakfast [20]. Therefore, we evaluated the glucose levels at these time points. When diabetic patients
with cognitive impairment used SMBG, their families helped with the measurement. Hypoglycemia
was defined as a glucose level ≤70 mg/dL [21], and the presence or absence of hypoglycemic symptoms
was recorded at every SMBG measurement point. Glucose fluctuations were determined based on the
diurnal range from minimum glucose levels to maximum glucose levels.
2.4. Evaluation of Sarcopenia
Sarcopenia was defined as low muscle mass plus low muscle strength and/or low physical
performance according to the Asian Working Group for Sarcopenia (AWGS) [22]. Low muscle mass
was defined as a calf circumference <31 cm [23], which was measured with the patient in the supine
position with the left knee raised at a right angle from the thigh. Calf circumference was correlated
with appendicular skeletal muscle mass measured by dual-energy X-ray absorptiometry and has been
proposed as a surrogate marker of muscle mass for diagnosing sarcopenia [24]. Low muscle strength
was determined by low hand grip strength (<26 kg in men and <18 kg in women). Hand grip strength
was measured with a Smedley dynamometer (Matsumiya Medical Instruments, Tokyo, Japan). Low
physical performance was assessed by slow walking speed. The presence of slow walking speed was
defined as individuals who answered “No” to the following question: "Can you cross the road within
the green signal interval?" [25].
2.5. Statistical Analysis
All analyses were performed using SPSS for Windows version 22.0 (IBM Corp., Armonk, NY,
USA). The distributions of data were assessed for normality using the Shapiro–Wilk test. Differences
in demographics between diabetic patients with cognitive impairment and patients with normal
cognition were examined by unpaired t-tests (for parametric variables) or the Mann-Whitney U
test (for non-parametric variables). Categorical variables were analyzed by the chi-squared test or
Fisher’s exact test. Differences in glucose levels with and without sarcopenia were analyzed using
unpaired t-tests or the Mann–Whitney U test. To identify the factors associated with sarcopenia,
we performed logistic regression analysis. First, we conducted stepwise analysis to select the most
influential glucose index for sarcopenia. Next, we conducted logistic regression with forward variable
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selection to construct a model based on the variables associated with sarcopenia, defined as those
with p < 0.05, adjusted for factors related to the development of sarcopenia (i.e., age, HbA1c level and
the presence of diabetic neuropathy) [4,5,7]. In this analysis, we calculated the adjusted odds ratio
(OR) and 95% confidence interval (CI) for factors associated with sarcopenia. The dependent variable
was sarcopenia, and the independent variable was the glucose index, which was selected as the most
influential variable associated with sarcopenia in a first regression analysis. Statistical significance was
set at p < 0.05.
3. Results
3.1. Clinical Characteristics of the Study Participants
The demographics of the participants are shown in Table 1. No differences in age, sex, body
mass index, diabetic comorbidities or medication use were found between the diabetic patients with
cognitive impairment and the normal cognition group. The cognitive impairment group had a lower
MMSE score than the normal cognition group. Serum triglyceride levels were higher and albumin
concentrations were lower in the cognitive impairment group, but the other metabolic markers did not
differ between the groups. Regarding the average glucose levels during the 2 months of study, the
glucose level before lunch was high in the cognitive impairment group. The prevalence of sarcopenia,
represented by a low muscle mass, low grip strength and slow walking speed, was higher in the
cognitive impairment group than that in the normal cognition group.
Table 1. Clinical characteristics of the study participants.
Total (n = 69) Cognitive Impairment








Age, years 75.0 (5.3) 65–87 76.0 (5.8) 65–87 74.2 (4.7) 65–83 0.146
Male, n (%) 36 (52.2) 15 (46.9) 21 (56.8) 0.413
Body mass index, kg/m2 23.8 (2.7) 17.8–31.0 23.6 (2.6) 17.8–29.4 24.0 (2.7) 19.9–31.0 0.597
Mini-Mental State Examination 24.4 (5.0) 13–30 21.0 (5.2) 13–29 27.4 (2.0) 22–30 <0.001
Diabetes and comorbidities
Duration of diabetes, years 15.3 (10.8) 2–48 15.3 (10.6) 2–40 15.4 (11.0) 2–48 0.899
Diabetic neuropathy, n (%) 45 (65.2) 22 (68.8) 23 (62.2) 0.567
Diabetic retinopathy, n (%) 16 (23.2) 5 (15.6) 11 (29.7) 0.166
Diabetic nephropathy, n (%) 21 (30.4) 12 (37.5) 9 (24.3) 0.236
Coronary artery disease, n (%) 15 (21.7) 6 (18.8) 9 (24.3) 0.576
Hypertension, n (%) 53 (76.8) 24 (75.0) 29 (78.4) 0.740
Medications and antidiabetic agents, n (%)
Polypharmacy 56 (81.2) 29 (90.6) 27 (73.0) 0.061
Biguanide 20 (29.0) 10 (31.3) 10 (27.0) 0.700
Thiazolidine 8 (11.6) 6 (18.8) 2 (5.4) 0.132
DPP4 inhibitor 49 (71.0) 23 (71.9) 26 (70.3) 0.884
Sulfonylurea 40 (58.0) 19 (59.4) 21 (56.8) 0.826
Insulin secretion promoter 2 (2.9) 2 (6.3) 0 (0.0) 0.211
α-Glucosidase inhibitor 16 (23.2) 7 (21.9) 9 (24.3) 0.810
Insulin 13 (18.8) 7 (21.9) 6 (16.2) 0.549
GLP-1 receptor agonists 2 (2.9) 1 (3.1) 1 (2.7) 1.000
Biochemical parameters
HbA1c, % 7.1 (0.6) 6.2–9.3 7.3 (0.7) 6.2–9.3 7.0 (0.5) 6.3–8.6 0.107
Triglyceride, mg/dL 139.8 (69.4) 44–330 165.5 (72.1) 65–330 117.6 (57.2) 44–279 0.004
Total cholesterol, mg/dL 190.3 (41.1) 108–316 192.0 (41.1) 108–316 188.9 (41.6) 137–309 0.524
HDL cholesterol, mg/dL 53.6 (13.7) 27–92 50.8 (13.6) 27–83 56.0 (13.5) 37–92 0.112
LDL cholesterol, mg/dL 109.2 (36.0) 46–238 109.5 (37.2) 46–211 108.9 (35.4) 67–238 0.928
eGFR, mL/min/1.73 m2 63.7 (17.6) 28.3–115.9 64.8 (16.9) 28.3–110.3 62.7 (18.3) 30.6–115.9 0.621
Albumin, g/dL 4.3 (0.4) 3.5–5.2 4.2 (0.3) 3.5–5.2 4.4 (0.3) 3.8–5.2 0.014
UACR, mg/gCr 156.7 (339.4) 1.5–1808.3 167.1 (349.2) 1.5–1705.4 147.8 (335.3) 2.7–1808.3 0.516
Daily blood glucose level
05:00 h, mg/dL 116.6 (22.2) 57–254 113.5 (19.6) 57–205 119.4 (24.2) 58–254 0.485
Before breakfast, mg/dL 123.0 (21.7) 51–215 119.5 (20.4) 63–201 126.0 (22.6) 51–215 0.216
2 h after breakfast, mg/dL 180.7 (34.3) 68–383 184.7 (38.8) 68–349 177.3 (29.9) 72–383 0.880
Before lunch, mg/dL 126.7 (33.6) 43–313 137.3 (38.5) 43–313 117.6 (25.9) 45–243 0.011
Before dinner, mg/dL 134.9 (27.5) 55–331 139.2 (33.0) 60–331 131.2 (21.3) 55–267 0.339
Fluctuation, mg/dL 91.4 (28.5) 32–155 97.0 (29.7) 49–155 86.5 (26.8) 32–137 0.127
Frequency of hypoglycemia * 0.71 (1.3) 0–7 0.72 (1.5) 0–7 0.70 (1.2) 0–4 0.719
128
J. Clin. Med. 2019, 8, 319
Table 1. Cont.
Total (n = 69) Cognitive Impairment









Sarcopenia, n (%) 8 (11.6) 7 (21.9) 1 (2.7) 0.021
Low muscle mass, n (%) 10 (14.5) 9 (28.1) 1 (2.7) 0.004
Low grip strength, n (%) 24 (34.8) 17 (53.1) 7 (18.9) 0.003
Slow walking speed, n (%) 4 (5.8) 4 (12.5) 0 (0.0) 0.042
Data are presented as the mean (standard deviation) or as numbers and percentages. * Indicates the per-patient
averages at the measuring points during the study period. † The quantitative variables age, body mass index, eGFR,
daily blood glucose levels before breakfast and fluctuation were examined by unpaired t-tests, and other quantitative
variables were analyzed by the Mann–Whitney U test. The categorical variables thiazolidine, insulin secretion
promoter, and GLP-1 receptor agonists were examined by Fisher’s exact test, and other categorical variables were
analyzed by the chi-squared test. Abbreviations: DPP4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration
rate; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin A1c; HDL cholesterol, high-density lipoprotein
cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; UACR, urine albumin-to-creatinine ratio.
3.2. Differences in Glucose Profiles According to Sarcopenia
First, we examined the differences in glucose profiles with and without sarcopenia in all subjects
(Figure 1). Patients with sarcopenia displayed larger fluctuations in daily glucose levels compared to
non-sarcopenia patients (117.3 mg/dL vs. 88.0 mg/dL, p = 0.005). In addition, patients with sarcopenia
showed high glucose levels 2 h after breakfast and before lunch (209.5 mg/dL vs. 177.0 mg/dL,
p = 0.011, and 152.2 mg/dL vs. 123.4 mg/dL, p = 0.037, respectively).
Figure 1. Daily glucose profiles based on sarcopenia. The figure shows the average ± standard error
(SE) glucose level based on sarcopenia in all participants. Average of the highest glucose level: the
average of the maximum glucose level of the day during the measurement period. Average of the
lowest glucose level: the average of the minimum glucose level of the day during the measurement
period. The solid line represents the sarcopenia group, and the dotted line indicates the no sarcopenia
group. Fluctuation: the average of the diurnal range from the minimum glucose level to the maximum
glucose level. ** p < 0.01, * p < 0.05.
Next, we examined the glucose profile differences with and without sarcopenia in the cognitive
impairment group (Figure A1). Cognitive impairment patients with sarcopenia displayed large glucose
fluctuations (119.5 mg/dL vs. 90.7 mg/dL, p = 0.021) and elevated glucose levels 2 h after breakfast
(210.6 mg/dL vs. 177.4 mg/dL, p = 0.044). In the normal cognition group, because only one patient
was diagnosed with sarcopenia, we could not examine the association between glucose profiles
and sarcopenia.
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3.3. Differences in Glucose Profiles Based on Sarcopenia Components
The differences in glucose profiles with and without sarcopenia components in all subjects are
shown in Figure 2. Patients with a low muscle mass, low grip strength and slow walking speed
displayed larger glucose fluctuations compared to patients without these conditions (low muscle mass:
110.8 mg/dL vs. 88.1 mg/dL, p = 0.018; low grip strength: 104.4 mg/dL vs. 84.4 mg/dL, p = 0.005; and
slow walking speed: 136.6 mg/dL vs. 88.6 mg/dL, p = 0.003, respectively). Furthermore, patients with
these conditions displayed high glucose levels 2 h after breakfast (low muscle mass: 203.8 mg/dL vs.
176.8 mg/dL, p = 0.020; low grip strength: 198.1 mg/dL vs. 171.5 mg/dL, p = 0.002; and slow walking
speed: 241.8 mg/dL vs. 177.0 mg/dL, p < 0.001, respectively). In addition, patients with low grip
strength showed high glucose levels before lunch (146.2 mg/dL vs. 116.4 mg/dL, p = 0.001) and before
dinner (145.3 mg/dL vs. 129.4 mg/dL, p = 0.034), and patients with a slow walking speed showed
high glucose levels before dinner (155.2 mg/dL vs. 133.7 mg/dL, p = 0.041).
In the cognitive impairment group, patients with a low muscle mass tended to have large glucose
fluctuations and high glucose levels 2 h after breakfast, but this difference did not reach statistical
significance (111.9 mg/dL vs. 91.2 mg/dL, p = 0.076, and 204.1 mg/dL vs. 177.1 mg/dL, p = 0.077,
respectively) (Figure A2). Patients with low grip strength displayed large glucose fluctuations and
high glucose levels 2 h after breakfast and before lunch (107.4 mg/dL vs. 85.2 mg/dL, p = 0.033,
197.6 mg/dL vs. 170.0 mg/dL, p = 0.038, and 151.4 mg/dL vs. 121.3 mg/dL, p = 0.025, respectively).
In addition, patients with a slow walking speed displayed large glucose fluctuations and high glucose
levels 2 h after breakfast (136.6 mg/dL vs. 91.4 mg/dL, p = 0.009, and 241.8 mg/dL vs. 176.5 mg/dL,
p = 0.001, respectively).
3.4. Prevalence of Hypoglycemia and its Association with Sarcopenia
Hypoglycemia (glucose range: 43–70 mg/dL) was observed at 49 measurement points (1.78%
of all measurement points) in all subjects. Severe hypoglycemic symptoms or events were not
observed in this study. Typical hypoglycemic symptoms, such as hand tremor and palpitations, were
observed in one normal cognition subject whose glucose level was 45 mg/dL. Hypoglycemia-related
symptoms, such as nausea, dizziness, light-headedness, blurred vision and fatigue, were reported
at four measurement points in the cognitive impairment group and four measurement points in the
normal cognition group.
There was no difference in the frequency of hypoglycemia between patients with and without
sarcopenia in all subjects (1.3 ± 2.5 vs. 0.6 ± 1.1, p = 0.884, Mann–Whitney U test). The effect of
mild hypoglycemia (glucose level ≤80 mg/dL or ≤90 mg/dL) on sarcopenia was also examined.
However, there was no difference in the frequency of mild hypoglycemia among the patients (glucose
level ≤80 mg/dL; 2.4 ± 3.9 vs. 1.8 ± 2.5, p = 0.922, glucose level ≤90 mg/dL; 4.9 ± 6.8 vs. 4.6 ± 4.7,
p = 0.741, Mann–Whitney U test).
We conducted the same analysis in the cognitive impairment group. However, no difference was
found in the frequency of hypoglycemia between patients with and without sarcopenia.
3.5. Association of Glucose Indices with Sarcopenia
Because the patients with sarcopenia displayed large glucose fluctuations, high glucose levels at
2 h after breakfast and before lunch, we conducted a regression analysis using the stepwise method
to extract the most influential glucose index on sarcopenia. The results revealed glucose fluctuations
as the most influential variable on sarcopenia (OR = 1.041, p = 0.012). Therefore, we used glucose
fluctuations as an independent variable for the subsequent logistic regression analysis.
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Figure 2. Daily glucose profiles based on the sarcopenia components. The figures show the average ±
SE glucose level based on the components of sarcopenia in all participants. ** p < 0.01, * p < 0.05.
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After adjusting for age, HbA1c level and the presence of diabetic neuropathy, glucose fluctuations
were independently associated with sarcopenia (Table 2). Additionally, among the components of
sarcopenia, glucose fluctuations were significantly associated with low muscle mass, low grip strength,
and slow walking speed.
Table 2. Association of glucose fluctuations with sarcopenia.
Glucose Fluctuations
Differences * OR 95% CI p-Value
No sarcopenia Reference
Sarcopenia 29.3 mg/dL 1.045 (1.007; 1.083) 0.018
Normal muscle mass Reference
Low muscle mass 22.7 mg/dL 1.031 (1.000; 1.064) 0.0499
Normal grip strength Reference
Low grip strength 20.0 mg/dL 1.029 (1.006; 1.053) 0.014
Normal walking speed Reference
Slow walking speed 48.0 mg/dL 1.092 (1.018; 1.172) 0.014
Logistic regression with a step-wise method. The dependent variables were sarcopenia and its components.
The independent variable was glucose fluctuations. All analyses were adjusted for age, HbA1c level and the
presence of diabetic neuropathy. * Indicates the differences relative to glucose levels in individuals in the no
sarcopenia, normal muscle mass, normal grip strength, and normal walking speed groups. Abbreviations: CI,
confidence interval; OR, odds ratio.
In the cognitive impairment group, glucose fluctuations were independently associated with
sarcopenia (OR = 1.038, p = 0.035). Furthermore, glucose fluctuations were significantly associated
with low grip strength (OR = 1.034, p = 0.049) and slow walking speed (OR = 1.077, p = 0.023).
The association between glucose fluctuation and low muscle mass did not reach statistical significance,
which may have been caused by the low statistical power due to the small sample size.
4. Discussion
The present study revealed that diabetes patients with cognitive impairment had a high prevalence
of sarcopenia. Glucose fluctuations were independently associated with sarcopenia after adjusting for
HbA1c levels and associated factors. Our observation suggests the importance of glucose management
by considering glucose fluctuations in older adults with diabetes.
In the current study, the prevalence of sarcopenia was higher in the cognitive impairment
group than the normal cognition group. However, diabetes comorbidities and medication were
comparable between the groups. Regarding the underlying mechanisms of sarcopenia in diabetes,
insulin resistance in peripheral tissues has been suggested [3,26]. Insulin resistance is associated
with impaired mitochondrial function in muscles, leading to the production of oxidative damage [3].
In addition, increased levels of inflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor
necrosis factor alpha (TNF-α), are observed in diabetes but are also found in AD patients [27]. These
factors are closely related to decreased muscle function [28]. Furthermore, anabolic hormones play a
major role in muscle integrity; testosterone decline is found in diabetes patients and also involved in
the development of AD [3,29]. More recently, AD-related brain pathology has also been associated with
low physical performance [30,31]. Thus, diabetes patients with cognitive impairment have multiple
factors that may contribute to the development of sarcopenia.
In this investigation, we found an independent association between glucose fluctuations and
sarcopenia in cognitively impaired patients. Acute hyperglycemia increases Aβ production, and altering
insulin signaling lead to changes in Aβ levels in the brain [32–34]. Increased levels of Aβ have been
also found in the skeletal muscle, which may cause impaired peripheral glucose metabolism [35,36].
In addition, glucose fluctuations are a greater trigger of oxidative stress than sustained hyperglycemia,
and independently contribute to the development of microvascular complications [37,38]. Because brain
tissue of AD show increased oxidative stress during the course of the disease [39], AD patients are
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more likely to be susceptible to the influence of glucose fluctuations on the brain. In fact, our previous
study showed that glucose fluctuations during postprandial periods were independently associated with
frontal white matter hyperintensity (WMH) in diabetic patients with AD but not in patients with normal
cognition [40]. Frontal WMH is known to play a predominant role in motor dysfunctions in AD/aMCI
patients [41,42]. Furthermore, an association between elevated 2 h post-load glucose levels evaluated
by the oral glucose tolerance test and brain atrophy has also been reported [43]. Thus, brain structural
changes associated with glucose fluctuations might further contribute to mobility disabilities in diabetes
patients with cognitive impairment.
In this study, the prevalence of sarcopenia was lower than previously reported [3], particularly
in the normal cognition group. This can be explained by differences in the measurement method for
muscle mass in the current study. Low muscle mass is an essential condition for the AWGS definition
of sarcopenia and was measured by calf circumference. A previous study showed that fat-free mass
decreases and fat mass increases with aging [44]. However, in older adult with diabetes, muscle mass
is even lower than in non-diabetic individuals [45]. Furthermore, higher level of insulin resistance has
been associated with low muscle mass and high fat mass [46]. A study using peripheral quantitative
computed tomography showed that diabetes patients have a larger intramuscular and intermuscular
adipose tissue in calf muscles than individuals without diabetes [47]. Therefore, diabetic patients are
considered to have deteriorated muscle quality compared to individuals without diabetes. It seems
likely that these muscle changes cannot be correctly measured with calf circumference. Although, calf
circumference is considered suitable for evaluating muscle mass, our observations suggest that calf
circumference may be difficult to accurately estimate the muscle mass of patients with diabetes.
We found no association between hypoglycemia and sarcopenia. Diabetes patients who
experienced hypoglycemic events had a high prevalence of comorbidities, disabilities, and malnutrition,
and were often treated with insulin therapy and use of polypharmacy [10]. However, in this study,
no difference was identified in these parameters between patients with and without hypoglycemia.
The study participants had relatively well-controlled glucose levels, and severe hypoglycemic events
were not observed. Therefore, we could not detect a sufficient impact of hypoglycemia. In fact,
hospitalization due to severe hypoglycemia can cause further deterioration in physical function [10].
Hypoglycemic symptoms in older patients are mild or asymptomatic, and episodes are less likely
to manifest [10]. We further addressed concerns about repeated mild hypoglycemia but found no
association of mild hypoglycemia with sarcopenia.
Currently, sarcopenia and frailty are considered a third category of diabetes-related complications in
addition to the traditional microvascular and macrovascular disease [4]. Because muscle weakness and
impaired physical function resulting from sarcopenia are major physiological components of frailty,
these conditions often overlap [3,48]. Some studies reported that frailty and cognitive decline are
reciprocally related and suggested that they share underlying pathophysiological mechanisms, including
AD pathology, chronic inflammation, mood disorder, and co-morbidities [49–51]. Thus, patients with
cognitive impairment are at high risk of vulnerability due to diverse extrinsic and intrinsic conditions.
Recently, some types of interventions, such as physical exercise, nutritional therapy, and multicomponent
interventions, to prevent frailty have been attempted [52]. Exercise training has benefits for physical
capacity and cognitive performance [53], improves skeletal muscle insulin sensitivity and increases muscle
mass in frail older adults [54]. Furthermore, the benefits of resistance training in improving glycemic
status and muscle strength have been reported [55]. Therefore, in addition to glucose management using
medications appropriately to avoid glucose fluctuations, multimodal interventions would be beneficial to
delay or prevent disability in older diabetic patients.
This study has several limitations. First, because this study had a cross-sectional design, causal
relationships should be carefully considered. Second, the sample size was relatively small. Nevertheless,
our results revealed the independent association between glucose fluctuations and sarcopenia, even after
adjusting for several confounding factors. Furthermore, our sample size was largely comparable to that of a
previous study that identified an association between altered glucose dynamics and frailty [56]. Additional
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studies with a large cohort estimated by calculation of the appropriate sample size are needed to confirm
our findings. Third, the cognitive impairment group was assigned based on the criteria of probable or
possible AD and aMCI [15,16], but biomarkers for AD pathology were not assessed in this study. A
biological definition based on neuroimaging with positron emission tomography and cerebrospinal fluid
biomarkers is necessary to achieve a precise diagnosis [57,58]. Fourth, SMBG was used evaluate glucose
levels, but continuous glucose monitoring (CGM) might more accurately represent the glucose profiles [59].
However, CGM in patients with cognitive impairment is difficult. Because we measured glucose levels on
8 separate days during the two-month period, our data could reflect the characteristics of glucose profiles
over this period. Finally, we did not use elaborate equipment to evaluate muscle mass and walking speed.
It is suitable to measure muscle mass using bioimpedance analysis [22]. Regarding walking speed, our
evaluation was based on self-reported answers related to road crossing. To safely cross the road while the
traffic signal is green, a pedestrian walking speed of 1.2 m/s is required [60]. This value is the same as the
cut-off for slow walking speed in Japanese elderly individuals [22].
5. Conclusions
The prevalence of sarcopenia was high in diabetes patients with cognitive impairment. Glucose
fluctuations were independently associated with sarcopenia, particular with low muscle mass, low
grip strength and slow walking speed. Our study described the characteristic glucose profiles in
older diabetes patients with sarcopenia. To maintain functional ability in older diabetes patients,
confirmation of our data in future longitudinal studies with a larger cohort is required.
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Appendix A
Figure A1. Daily glucose profiles based on sarcopenia in the cognitive impairment group. The figure shows
the average ± standard error (SE) glucose level. Average of the highest glucose level: the average of the
maximum glucose level of the day during the measurement period. Average of the lowest glucose level: the
average of the minimum glucose level of the day during the measurement period. The solid line represents
the sarcopenia group, and the dotted line indicates the no sarcopenia group. Fluctuation: the average of the
diurnal range from the minimum glucose level to the maximum glucose level. * p < 0.05.
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Figure A2. Daily glucose profiles based on the sarcopenia components in the cognitive impairment
group. The figures show the average ± SE glucose level based on the components of sarcopenia.
** p < 0.01, * p < 0.05.
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Abstract: Type 2 diabetic (T2D) subjects have a significantly higher risk of developing mild cognitive
impairment (MCI) and dementia than age-matched non-diabetic individuals. However, the accurate
evaluation of cognitive status is based on complex neuropsychological tests, which makes their
incorporation into the current standard of care for the T2D population infeasible. Given that the
ability to maintain visual gaze on a single location (fixation) is hampered in Alzheimer’s disease
(AD), the aim of the present study was: (1) To assess whether the evaluation of gaze fixation during
fundus-driven microperimetry correlated with cognitive status in T2D subjects; (2) to examine
whether the addition of fixational parameters to the assessment of retinal sensitivity increased the
predictive value of retinal microperimetry in identifying T2D subjects with MCI. For this purpose,
fixation parameters and retinal sensitivity were compared in three age-matched groups of T2D
subjects: normocognitive (n = 34), MCI (n = 33), and AD (n = 33). Our results showed that fixation is
significantly more unstable in MCI subjects than normocognitive subjects, and even more altered in
those affected by AD (ANOVA; p < 0.01). Moreover, adding fixation parameters to retinal sensitivity
significantly increases the predictive value in identifying those subjects with MCI: ROC (Receiver
Operating Characteristic) Area 0.68 with retinal sensitivity alone vs. ROC Area 0.86 when parameters
of fixation are added to retinal sensitivity (p < 0.01). In conclusion, our results suggest that fixational
eye movement parameters assessed by fundus-microperimetry represent a new tool for identifying
T2D subjects at risk of dementia.
Keywords: diabetes; dementia; microperimetry
1. Introduction
The American Diabetes Association recommends individualizing diabetes treatment by taking
into account the cognitive capacity of patients [1]. However, the accurate evaluation of cognitive
status is based on complex neuropsychological tests [2], which makes their incorporation into current
standards of care for the type 2 diabetic (T2D) population unfeasible. This is an important gap that
affects clinical practice because T2D patients have a significantly higher risk of developing Alzheimer’s
disease (AD) in comparison with age-matched non-diabetic subjects even after adjusting for other risk
factors [3–5]. These findings have been recently confirmed in a large nationwide population-based
study performed in Taiwan with a follow-up of 10 years, which clearly shows that the risk of developing
J. Clin. Med. 2019, 8, 59; doi:10.3390/jcm8010059 www.mdpi.com/journal/jcm141
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AD in the diabetic population is significantly higher than in the non-diabetic population with a hazard
ratio (HR) of 1.7 [6]. Similarly, other longitudinal population-based studies in T2D subjects have shown
an association with either an accelerated cognitive decline or an increased incidence of dementia [7].
Because of the increase of diabetes prevalence and the concomitant aging of populations, severe
cognitive impairment can be considered as an emerging long-time new “diabetic complication” with
dramatic consequences for the affected subjects and their families and with a significant impact on
healthcare systems. Mild cognitive impairment (MCI), which is also increased in diabetic patients,
consists of cognitive impairment on standard tests but no impairment in activities of daily living and
represents a transition state between normal cognitive function and dementia. The annual conversion
rate from MCI to dementia ranges between 10–30% in the general population [8–10], and we have
recently reported that T2D accelerates the conversion to dementia in patients with MCI [11]. Therefore,
strategies aimed at identifying T2D patients at risk of dementia are urgently needed. In this regard,
it has been estimated that interventions that delay the clinical onset of dementia by 1 year would
reduce its prevalence in 2050 by 9 million cases [12].
It could be argued that the benefits of the early diagnosis of dementia are questionable because
treatment is still unavailable. However, unrecognized cognitive dysfunction can affect treatment
adherence and diabetes self-management resulting in poor glycemic control, an increased frequency
of severe hypoglycemic episodes, diabetes-related complications, and hospital admissions [13,14].
In addition, the identification of those T2D subjects affected with MCI would allow the implementation
of a more personalized treatment. Hypoglycemic events increase the risk of dementia, therefore
treatments that do not increase this risk should be prioritized [15–17]. In addition, T2D patients with
cognitive impairment would be more prone to present an impaired self-management of diabetes. Thus,
the treatment of diabetes should be simplified in these patients in order to increase treatment adherence.
Interestingly, both AD and diabetic complications share common pathogenic pathways.
The impairment of insulin signaling, the presence of low-grade inflammation, and the pathways
directly related to chronic hyperglycemia, such as the accumulation of advanced glycation
end-products (AGEs) and the increase in oxidative stress play an essential role in the pathogenesis of
AD [18]. All these pathways have been implicated in diabetic complications and in particular with
diabetic retinopathy (DR). Moreover, several pathways involved in neurodegenerative diseases have
been identified in human retinas with early stages of DR [19]. These findings indicate that a common
etiology exists between the brain and retinal neurodegeneration in the setting of diabetes, which could
explain the increased risk of cognitive impairment that T2D subjects present.
Current strategies to screen for dementia are based on neuropsychological tests such as the
Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), and the Digit
Symbol Substitution Test (DSST) [20]. Both MMSE and MOCA are time-consuming (10 min each),
and DSST, which takes only 2 min, has low specificity [20,21]. Additionally, although these tests have
an important role as screening tools, they could be influenced by anxiety or depression which occurs in
a significant proportion of ageing T2D subjects [13]. Furthermore, when MCI is suspected, a complete
neuropsychological battery is needed, which is cumbersome and time consuming (at least 45 min) [22].
Given the high prevalence of T2D in the older population [23], the detection of MCI subjects based on
this battery is unfeasible for daily practice.
In clinical practice, there are no reported phenotypic indicators or reliable examinations for
identifying T2D patients at risk of developing dementia. In recent years, growing evidence has shown
that retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (DR) [24,25].
The retina is ontogenically a brain-derived tissue and it has been suggested that it may provide an
easily accessible and non-invasive way of examining the pathology of the brain [25,26]. Therefore,
it seems reasonable to propose that the evaluation of retinal parameters related to neurodegeneration
could be useful in identifying those T2D patients at a higher risk of developing cognitive impairment
and dementia. In this regard, we have recently demonstrated that retinal sensitivity assessed by
microperimetry significantly correlated with neuroimaging parameters and cognitive status [27].
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Apart from retinal sensitivity, microperimetry permits us to examine the capacity to maintain visual
gaze on a single location (fixation), which has been reported as being hampered in AD and other
neurodegenerative diseases [28–32].
Abnormalities in oculomotor function and gaze fixation have been previously reported in
subjects affected with AD. In fact, several eye movements like pro-saccades, anti-saccades, and
the micro-saccades and saccadic intrusions that occur during fixation are altered in subjects with
AD [28–30]. In addition, during fixation, subjects affected with AD present a greater frequency of
saccadic intrusions than normal subjects, causing instability in gaze maintenance [29]. Moreover,
micro-saccades that occur during normal fixation in AD are notably more oblique compared with
normal adults [30]. However, little is known regarding the potential usefulness of the assessment of
gaze fixation for identifying T2D patients at risk of AD. This is an important issue because the neural
circuits involved in gaze fixation are not the same as those participating in retinal sensitivity and,
therefore, complementary information could be obtained.
On this basis, we hypothesize that the assessment of retinal fixation by means of fundus-driven
microperimetry could be useful to identify those diabetic subjects with cognitive impairment.
For the first time we have analyzed data regarding fixational eye movement parameters assessed
by microperimetry with the following aims: (1) To assess whether gaze fixation abnormalities in
T2D diabetic subjects are related to cognitive status and, therefore, could be used as a biomarker
for identifying T2D subjects at risk of dementia, and (2) to determine whether fixation study is able
to increase the diagnostic reliability of retinal sensitivity in identifying subjects at risk of cognitive
impairment. Since in diabetic subjects with advanced diabetic retinopathy, both sensitivity and fixation
could be altered [33], those subjects with moderate non-proliferative or more advanced stages of
diabetic retinopathy were excluded from the study.
2. Materials and Methods
Data regarding fixation parameters obtained from the nested case-control study DIALRET
(ClinicalTrial.gov: NCT02360527) were analyzed. A total of 33 patients with AD, 33 with MCI,
and 34 with normal cognition in whom a full report of fixation parameters was available were included
in the study. All these patients were selected from 214 consecutive type 2 diabetic patients attending
a memory clinic (Fundació ACE, Barcelona, Spain). The study was conducted according to the
Declaration of Helsinki and was approved by the local Ethics Committee.
The main inclusion criteria were: (a) Age >65 years; (b) type 2 diabetes with a duration >5 years;
(c) written informed consent which included accepting participation in brain MRI (Magnetic Resonance
Imaging) and PET (Positron Emission Tomography), as well as a potential lumbar puncture.
The main exclusion criteria were: (a) Patients with other neurodegenerative diseases of the brain
or retina (i.e., glaucoma) or cerebrovascular diseases (Fazekas scale score ≤1) [34]; (b) HbA1c >10%
(86 mmol/mol). The exclusion of patients with poor control was because very high blood glucose
levels could affect retinal function [35]. (c) Moderate non-proliferative diabetic retinopathy (DR) or
more advanced stages of DR according to the International Clinical Diabetic Retinopathy Disease
Severity Scale [36]. The exclusion of patients with more advanced DR was based on the fact that severe
microvascular impairment could participate in neurodegeneration, and the aim of the study is to assess
retinal neurodegeneration regardless of the presence of overt microangiopathy.
All patients underwent complete neuropsychological, neurological, and psychiatric evaluations
as previously described [22] including Mini-Mental State Examination (MMSE) and Alzheimer’s
Disease Assessment Scale-Cognition subscale (ADAS-Cog). Higher values on MMSE and lower values
on ADAS-Cog evaluations indicate better cognition. A neuropsychologist and a neurologist from a
memory clinic performed the cognitive assessment and the diagnosis of MCI and AD. All patients
diagnosed with MCI fulfilled MCI Petersen’s diagnosis criteria [8,37]. In addition, a biochemical
analysis including HbA1c and a lipid profile was performed.
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Retinal sensitivity was evaluated by fundus driven microperimetry (MAIA 3rd generation,
Centervue®) after a previous papillary dilation of minimum 4mm. The standard MAIA test covers 10◦
diameter area with 37 measurement points and a red 1◦ radius circle was used as the fixation target.
For the evaluation of fixation, the MAIA microperimeter uses high-speed eye trackers (25 Hz).
The parameters that evaluate fixation are assessed by tracking eye movements 25 times/Sec
and by plotting the resulting distribution over the SLO (Scanning Laser Ophthalmoscope) image.
Each movement is represented by a point in the distribution which will constitute the fixation pattern
(Figure 1). All fixation positions during the examination are used by the instrument to calculate
the fixation indexes P1 and P2, which represent the percentage of fixation points inside a circle of 2
and 4 degrees of diameter from the total of fixation points, respectively. Subjects were classified as
having stable fixation if P1 was more than 75%, relatively unstable fixation if P1 was less than 75%
and P2 more than 75%, and unstable fixation if both P1 and P2 were below 75%. Microperimetry also
provides a more accurate estimation of the fixation pattern using the bivariate contour ellipse area
(BCEA). It calculates, by using two orthogonal diameters that describe the extent of the fixation points
(in degrees), the area and orientation of an ellipse encompassing a given proportion of the fixation
points. Lower BCEA values define better fixation stability. We have selected the BCEA corresponding
to 95% of the fixation points [38,39]. For retinal sensitivity and fixation, data corresponding to the right
eye were used, which was the first eye explored in all subjects. The duration of the measurements
varies from 1 min to 4 min approximately, depending on the subject.
The reliability index is assessed by measuring the number of stimuli reported as seen by the
patient when a stimulus is projected onto the optic nerve head (blind spot). A 100% of reliability means
that none of the stimulus projected onto the nerve head is reported as seen [39].
 
Figure 1. Microperimetry corresponding to a mild cognitive impairment (MCI) subject. The circles
in green, yellow, and purple are the 37 measurement points in which retinal sensitivity is assessed.
Different colors indicate different retinal sensitivity at each point (green being the best and purple the
worst). The blue dots are the fixation points detected during the whole examination (3.5 min).
Statistical Analysis
The categorical variables are presented as percentages. For the quantitative variables, the mean
and standard deviation (within the gaps) is displayed, except for BCEA95 in which the median
and range are used. Statistical significance was accepted at p < 0.05. To assess differences between
groups, the Chi-square test for qualitative variables and ANOVA followed by LSD (Least Significant
Difference) post-hoc tests for quantitative variables were used. For BCEA95, which does not have a
normal distribution (assessed by Shapiro Wilk test, cut-off p < 0.05), a non-parametric test was used to
compare between groups (Kruskal-Wallis). For the significant differences observed, post hoc pairwise
comparison analysis using the Duncan method was performed.
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To evaluate the correlation between BCEA95 and ADAS-Cog or MMSE, Spearman’s correlation
test and regression analysis were performed. Significance was accepted at the level of p < 0.05.
The Bonferroni correction was used for multiple comparisons.
Logistic regression analysis to predict MCI vs. normocognitive status was performed by using the
following variables: Age, sex, retinal sensitivity, fixation indexes P1 and P2, and BCEA95. All possible
equations were analysed and the two models that presented a highest AUC (Area Under the Curve)
were the following: (1) Retinal sensitivity + P1; (2) retinal sensitivity + P1 + BCEA95. Since the
purpose of the study was to evaluate fixation parameters, and as BCEA95 was one of the best fixation
measurements, we selected the second model. Multicollinearity was assessed by calculating the
Variance Inflation Factor (VIF). ROC curves and the Chi-squared test for ROC area comparison were
performed. Statistical analyses were performed with the Stata statistical package.
3. Results
The main clinical characteristics of subjects with type 2 diabetes included in the study are
summarized in Table 1. No differences were found among groups in terms of age, sex, hypertension,
dyslipidaemia, BMI (Body Mass Index), diabetes duration, or HbA1c. The mean reliability index of
the microperimetry test was above 90% in all groups and as expected, retinal sensitivity decreased in
the group with MCI and especially in those with AD (p < 0.01). The time taken for the examination
was longer in AD subjects or MCI (p < 0.01). This is because when retinal sensitivity is hampered,
the examination takes a longer time since more stimuli and different intensities are presented to the
patient. On the other hand, when retinal sensitivity is preserved, only the stimuli with the lowest
intensity are presented and the examination takes less time.






n = 34 p
Age (years) 79 (5.57) 77.03 (4.38) 75.53 (6.97) 0.06
Gender (males, %) 42.42 51.52 58.82 0.41
BMI 27.72 (3.79) 28.28 (4.48) 30.28 (4.45) 0.61
Hypertension (%) 78.79 75.76 73.53 0.88
Dyslipidemia (%) 63.64 66.67 71.43 0.81
Diabetes duration (years) 10.45 (6.23) 13.73 (10.64) 10.91 (6.12) 0.22
HbA1c (% of Hb, DCCT *) 6.79 (1.02) 6.99 (1.25) 7.5 (0.95) 0.37
Retinal sensitivity (dB) 16.95 (6.01) 21.05 (4.82) 23.39 (2.47) <0.00001
Fixation P1 (%) 45.03 (24.89) 58.21 (26.66) 88.52 (12.19) <0.00001
Fixation P2 (%) 70.2 (20.61) 81.03 (15.60) 96.09 (3.66) <0.00001
BCEA95 (degrees)
(median, range) 46.3 (12.5–187.7) 34.4 (1.2–155.1) 4.55 (0.3–23.5) <0.00001
Reliability 92.83 (14.49) 97.45 (7.04) 96.59 (13.59) 0.28
Duration of the
examination (minutes) 3.1 (1.14) 2.34 (0.83) 1.71 (0.42) <0.00001
* DCCT: Diabetes Control and Complications Trial was the reference method to calculate the HbA1c.
Fixation was more unstable, in terms of P1 and P2 percentages, in the group with MCI and
especially in the group with AD. Therefore, the lowest fixation capacity was found in patients with
AD and the highest in patients with normocognition, the differences between the groups being
statistically significant (p < 0.00001). To illustrate this point, representative examples of the fixation
graph, which describes the amplitude of eye movements in degrees versus time, of each group
(normocognition, MCI, and AD) are shown in Figure 2. In addition, we also found a significant
difference among groups BCEA95 (p < 0.00001). In the pairwise comparison analysis, the differences
were statistically significant among the three groups as shown in Table 2.
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Figure 2. Representative examples of the fixation graph close to the median BCEA95 value of a
normocognitive (a) (BCEA95 3.1◦), MCI (b) (BCEA95 34.7◦) and AD (c) (BCEA95 40.4◦) subject.
The green and the orange bands represent a circle of 1 and 2 degrees respectively.
Table 2. Pairwise comparison analysis (contrast and 95% confidence interval).
Normocognitive vs. MCI MCI vs. AD Normocognitive vs. AD
Retinal Sensitivity 4.10 (1.78, 6.41) 2.33 (0.08, 4.59) 6.43 (4.00, 8.87)
Fixation P1 13.18 (2.10, 24.26) 30.30 (19.49, 41.11) 43.48 (31.83, 55.14)
Fixation P2 10.83 (3.39, 18.27) 15.06 (7.80, 22.32) 25.89 (18.06, 33.72)
BCEA95 −23.27 (−41.23, −5.31) −35.11 (−52.93, −17.28) −58.37 (−77.13, −39.61)
A significant negative correlation was found between BCEA95 and MMSE (r = −0.5301,
p < 0.00001). In addition, BCEA95 also significantly correlated with the ADAS-Cog (r = 0.4716,
p < 0.00001). In other words, a more unstable fixation correlated with lower punctuation in the MMSE
test and a higher score in the ADAS-Cog, indicating that fixation instability is associated with a degree
of cognitive impairment (Figure 3a,b).
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(a) (b) 
Figure 3. Linear regression graphs between: (a) Mini-mental State Examination (MMSE) and BCEA95;
(b) Alzheimer’s Disease Assessment Scale-Cognition subscale (ADAS-Cog) and BCEA95.
Retinal sensitivity, BCEA95, P1, and P2 were also correlated among them, and the coefficients
(Spearman correlation) and their significance are displayed in Table 3. Interestingly, when analyzing
the same correlation within the normocognitive and MCI groups (excluding those with AD), fixation
P1 and P2 values no longer correlate with retinal sensitivity (Pearson correlation coefficients: 0.3199
and 0.311 respectively, p value > 0.05).
Table 3. Spearman correlation coefficients (and p values*) between retinal sensitivity and
fixation parameters.
Fixation P1 Fixation P2 BCEA95





Fixation P1 - 0.93* <0.00001
−0.93
* <0.00001
Fixation P2 - - −0.96* <0.00001
Finally, a comparison regarding the capacity to discriminate MCI subjects from normocognitive
subjects by using retinal sensitivity alone or by adding to the predictive model the parameters
of fixation BCEA95 and P1 was performed. The results are summarized in Table 4 and Figure 4.
The addition of fixation assessment to the results obtained by measuring retinal sensitivity significantly
increased the ROC area (p = 0.01), thus enhancing the capacity to discriminate between normocognitive
and MCI diabetic subjects. The optimal cut-off based for maximum efficiency (the cut-off point that
maximizes the percentage of correct classifications) was 0.494191 with a sensitivity of 72.7% (95% CI:
55.8 to 84.9%), specificity of 87.9% (95% CI: 72.7 to 95.2%), positive predictive value of 85.7% and a
negative predictive value of 76.3%. The VIF values (<10) showed that multicollinearity was not present
among the predictors (Table 5).
Table 4. ROC Area comparison between retinal sensitivity alone, and retinal sensitivity and fixation
parameters (P1 and BCEA95). The outcome is mild cognitive impairment (MCI) (reference = normal
cognition).
ROC Area Std. Err. 95% CI p-Value
Retinal Sensitivity 0.68 0.07 0.55–0.81
<0.01Retinal Sensitivity + BCEA95 + Fixation P1 0.86 0.05 0.77–0.95
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Figure 4. Comparison of two prediction models for MCI versus normal cognition, one based on retinal
sensitivity and fixation parameters P1 and BCEA95, and one with retinal sensitivity alone.
Table 5. Multicollinearity assessment: Variance inflation factor (VIF) for each predictor.
VIF 1/VIF
Retinal Sensitivity 1.15 0.87
BCEA95 4.45 0.22
Fixation P1 4.32 0.23
4. Discussion
Our findings indicate that fixational eye movement parameters assessed by microperimetry are
useful for identifying T2D subjects with MCI. Moreover, the addition retinal fixation parameters,
and more specifically P1 and BCEA95, to the assessment of retinal sensitivity significantly increase the
capability to identify those subjects with MCI. Therefore, the retinal functional assessment of ocular
movements as an objective method for identifying T2D patients with MCI opens up new feasible
clinical management procedures addressed to testing cognitive status, which could easily be added to
the routine ophthalmologic examination for the screening of DR.
Although there is evidence indicating that ocular movements are altered in AD, little is known
about the usefulness of the study of ocular movements to identify the prodromal stages of dementia.
Kapoula et al. [30] observed that MCI subjects present a major prevalence of oblique micro-saccades
during fixation compared with control subjects. Lagun et al. [40] demonstrated that the incorporation
of ocular movement information (i.e., duration of fixation, saccade length, and direction) was able
to increase the specificity and sensitivity of the measurements of the visual-paired comparison task
previously reported. Techniques used to evaluate ocular movements were based on electrodes placed
in the region around the eyes and usually incorporated support to restrict head movements [29,41].
New eye-tracking systems have been developed and are usually video-based techniques, which has the
advantage of being non-invasive [41–43]. One of their main limitations is head movement, because even
small movements may cause large errors in the estimation of a calibrated tracker [42]. Fundus-driven
microperimetry is a video-based technique with the advantage of incorporating a chin and forehead
bars that restrict head movements. However, the exact distance between the optical stimuli and the
eye could vary between subjects due to anatomical reasons and this could represent a limitation when
retinal fixation is being assessed.
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As previously mentioned, the presence of advanced DR could hamper the microperimetry results.
In this subset of subjects, the screening of cognitive impairment should be based on other methods
not based on retinal assessment (i.e., neuropsychological tests). However, it should be noted that
the vast majority of T2D subjects present no DR or just mild non-proliferative DR. In the present
study, given that the T2D patients included did not present signs of DR or other retinal disease,
the alterations in fixation detected in those patients with cognitive impairment could be attributed
to any neurodegenerative disease rather than an intrinsic eye disease. Marseglia et al. [44] showed
that the presence of T2D affects perceptual speed, attention, and primary memory in patients of
70–75 years. They postulate that these domains might be primarily affected by diabetes. It should be
noted that fixation eye movements are affected by attention and working memory [28]. For example,
micro-saccade rates transiently decrease during an attentional task [45]. Therefore, the evaluation
of fixation by fundus-driven microperimetry could be a biomarker of the first neuropsychological
abnormalities that occur in diabetes-related cognitive decline. The omnipause neurons (located in the
nucleus raphe interpositus of the paramedian pontine reticular formation) or the superior colliculus
(SC) are two of the main brain areas involved in fixation. It is possible that these areas are affected early
in the neurodegenerative process [46]. During microperimetry, the subjects are asked to maintain their
gaze fixated on a central target, while stimuli with different intensities are presented at 37 points in 3
concentric circles of 2, 6, and 10 degrees of diameter [47]. It could be hypothesized that subjects with
cognitive impairment are unable to inhibit the saccades triggered by the most eccentric stimuli and
maintain their gaze fixated on a central target. Furthermore, certain areas of the cerebral cortex, such as
the parietal and frontal cortex (frontal eye fields and the dorsomedial prefrontal cortex), show elevated
firing rates during fixation. These areas could contribute to the control of fixation through descending
projections to the SC and the omnipause region [46].
We observed statistically significant differences in P1, P2, and BCEA95 among the three groups.
Moreover, a correlation was found between BCEA95 and either ADAS-Cog or MMSE punctuations.
In addition, when BCEA95 and P1 were added to retinal sensitivity assessment, the capacity to detect
MCI by using microperimetry increased significantly. In fact, for a cut-off point of 0.49 of the model that
combines retinal sensitivity and fixation parameters (P1 and BCEA95), microperimetry has a sensitivity
of 72.7% and a specificity of 87.9% in identifying the subjects with MCI. Furthermore, we did not find
collinearity between parameters of retinal sensitivity and fixation. This would mean that this combined
test is examining different neural circuits, thus improving the performance of the examination. In this
regard, retinal sensitivity relies on the retina and the neural pathway of vision. The first station of the
optic tract is the lateral geniculate body of the thalamus, which is the first major visual processing
region in the brain and plays a crucial role in relaying information from the retinal ganglion cells to
the primary visual cortex [48]. By contrast, the superior colliculus and the parietal and frontal cortex
play an essential role in gaze fixation. There is evidence that both the geniculate body and the superior
colliculus are affected by AD [49–51]. Therefore, gaze fixation and retinal sensitivity are measuring
different neurological pathways and, consequently, can be considered complementary measurements
of neurodegeneration, thus enhancing the reliability of the retinal sensitivity assessment alone.
The main limitation of our study is that we have included patients without DR or only those
patients with mild non-proliferative DR. Since the presence of more advanced stages of DR, and in
particular diabetic macular edema, can alter fixation [52], our results are not representative for the
whole diabetic population. Furthermore, longitudinal studies examining retinal fixation in diabetic
subjects with and without DR should be performed in order to fully address the utility of fixation
assessment by microperimetry and guide its appropriate use.
In conclusion, our results indicate that the assessment of gaze fixation abnormalities in T2D is
related to cognitive status and could be a useful tool for identifying patients at risk of developing
dementia. In addition, the assessment of retinal sensitivity in combination with parameters of fixation
by using microperimetry could be a reliable method for detecting prodromal stages of dementia in the
T2D population.
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Abstract: Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical
studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results.
Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and
sulfonylureas (SU). Methods: Using a claims database called the Korean National Health Insurance
Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching
using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1
propensity score matching; average age 75.4; mean follow-up period: 1361.9 days). Survival analysis
was performed to estimate the risk of dementia. Results: The risk of all-cause dementia was lower in
the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66; 95% confidence interval (CI)
0.56–0.78; p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer’s disease
(HR 0.64; 95% CI 0.52–0.79; p < 0.001) and a lower risk, albeit non-significant, of vascular dementia
compared to SU use (HR 0.66; 95% CI 0.38–1.14; p = 0.139). Conclusion: Our findings suggest that
DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes
in a real-world clinical setting.
Keywords: dementia; dipeptidyl-peptidase IV inhibitors; diabetes mellitus; type 2; Alzheimer’s
disease; dementia; vascular
1. Introduction
Type 2 diabetes and dementia are prevalent in the elderly and have considerable impacts on public
health and patient quality of life. Recent estimates suggest that 382 million and 44 million individuals
worldwide are affected by type 2 diabetes and dementia, respectively [1,2]. Epidemiological evidence
indicates that diabetes is associated with an increased risk of dementia, including Alzheimer’s disease
and vascular dementia [3,4]. According to a recent meta-analysis of 28 prospective observational
studies, patients with diabetes have a 73% higher risk of dementia compared to those without
diabetes [5]. Although interventions to prevent and treat the classical macro- and microvascular
complications of diabetes have improved, cognitive dysfunction and dementia are emerging as
important complications in a rapidly aging society [6].
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Type 2 diabetes shares several pathophysiological components with dementia, such as
glucotoxicity, insulin resistance, inflammation, and oxidative stress [7]. These similarities suggest
that anti-diabetic medications may be effective against dementia. Preclinical and clinical studies have
investigated the effects of glucose-lowering agents on dementia and cognitive dysfunction but have
reported inconsistent results [8,9].
Dipeptidyl peptidase-4 inhibitors (DPP-4i) are widely used oral hypoglycemic agents associated
with a low risk of hypoglycemia and weight gain [10]. DPP-4is improve glucose metabolism by
increasing the bioavailability of active glucagon-like peptide-1 by inhibiting its degradation. DPP-4is
also have neuroprotective, anti-inflammatory, and anti-atherosclerotic effects. Moreover, DPP-4is
attenuated amyloid-β deposition and tau phosphorylation in streptozotocin induced Alzheimer’s
disease model [11,12]. A DPP-4i also improved memory and learning impairment, brain inflammation,
and endothelial dysfunction in a pancreatectomy-induced diabetes model [13].
In a recent cross-sectional study, higher DPP-4 plasma activity was associated with an increased
risk of mild cognitive impairment in elderly patients with type 2 diabetes [14]. This suggests that
DPP-4is may be effective against cognitive dysfunction in individuals with type 2 diabetes. However,
to our knowledge, no clinical study on the effect of DPP-4is on the incidence of dementia in type 2
diabetes has been reported. As long-term use of sulfonylurea (SU) was not associated with an increased
risk of Alzheimer’s disease in a population-based case-control study [15], we investigated the risk of
dementia in older patients on DPP-4is compared with SUs in a population-based cohort study using a
national health insurance database.
2. Methods
2.1. Study Design and Data Source
We conducted a population-based retrospective observational cohort study using the Korean
National Health Insurance Service Senior cohort (ver. 3.0, 1 January, 2002 to 31 December, 2015),
which comprises 550,000 (10%) individuals of the South Korean population >60 years of age as of
2002. The database was created using a stratified random sampling method with 1476 strata and
is thus representative of the Korean senior population. It contains information on demographic
characteristics, socioeconomic status, and claims, such as diagnosis (International Classification of
Diseases, 10th revision (ICD-10) code), drug prescriptions, and medical procedures. Socioeconomic
status was indirectly assessed using the annual medical insurance premium determined based on the
participant’s income and assets, such as property and automobile ownership. Socioeconomic status
was defined by dividing medical insurance premiums into 11 quantiles. This study was approved by
the Institutional Review Board of Ajou University Hospital (AJIRB-MED-EXP-18-033), which waived
the requirement for informed consent because all patient data were de-identified.
2.2. Inclusion and Exclusion Criteria
Patients were included in the cohort if they were aged >60 years with type 2 diabetes and started
taking a DPP-4i or SU from 1 November, 2008 to 31 December, 2015, regardless of whether they
were taking other hypoglycemic agents (DPP-4is were first approved in Korea on 1 November, 2008).
Patients who used both drugs were excluded. A 1-year wash-out period before the first prescription
of an SU or DPP-4i enabled identification of new users of each drug type. The prescribed drug and
date were defined as the index drug and index date, respectively. Patients who had been diagnosed
with type 1 diabetes mellitus or dementia before the index date or who had been prescribed donepezil,
memantin, rivastigmine, or galantamine for dementia were excluded. A flowchart of the patient
selection process is presented in Figure 1. The follow-up period was calculated from the index date to
the first occurrence of study outcomes or the study end date (31 December, 2015).
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Figure 1. Flow chart of the sample selection process. DM, diabetes mellitus; DPP-4i,
dipeptidyl-peptidase IV inhibitor; N, number; SGLT-2i, sodium-glucose co-transporter 2 inhibitor;
SU, sulfonylurea.
2.3. Study Outcome and Subgroup Analysis
The primary outcome was the first diagnosis of all-cause dementia (ICD-10 codes: F00, F01, F02,
F03, F04, F05, G30, or G31), and the secondary outcomes were the first diagnosis of Alzheimer’s
disease (F00, G30) or vascular dementia (F01). Subgroup analyses were performed according to sex,
age (<75 and ≥75 years), and the presence of DM microvascular or macrovascular complications.
DM microvascular complications were defined as at least one of DM nephropathy, neuropathy, or
retinopathy, and DM macrovascular complications as at least one of stroke, transient ischemic attack,
acute myocardial infarction, other ischemic heart disease, and peripheral artery occlusive disease.
155
J. Clin. Med. 2019, 8, 28
2.4. Statistical Analysis
R software (ver. 3.3.3; R Development Core Team, Vienna, Austria) and SAS (ver. 9.4; SAS
Institute, Cary, NC, USA) were used for statistical analyses. Data are expressed as means ± standard
deviation. The primary method of statistical adjustment was propensity score matching. Among the
patients who met the inclusion/exclusion criteria mentioned above, patients with similar characteristics
were selected at a ratio of 1:1 from both groups using propensity score matching. We used the
nearest-neighbor technique with a caliper of 0.1 on the probability scale, and replacement of the
control was not permitted. The following variables (Table 1): age, sex, socioeconomic status (index
date), diagnoses (1 year before the index date), and prescribed drugs (180 days before the index
date) were used to calculate propensity scores, and thus those variables were adjusted. Because the
claims database does not contain information on the duration of diabetes, we adjusted for several
variables that could indirectly reflect disease duration, such as diagnostic codes for DM triopathy, acute
myocardial infarction, other ischemic heart diseases, ischemic stroke, hemorrhagic stroke, transient
ischemic attack, and peripheral artery occlusive disease, as well as prescriptions for other hypoglycemic
agents, including insulin. The quality of correction of confounding variables between the two groups
was evaluated as a standardized difference. An absolute standardized difference between groups of
<0.1 was considered negligible. After propensity score matching, survival analyses were performed
among matched pairs to evaluate the effect of DPP-4is on dementia using the one minus survival
probability computed by the Kaplan-Meier approach. As several confounding variables were adjusted
for by propensity score matching, univariate Cox regression analysis was performed.
Table 1. Baseline characteristics of the matched pairs.
SU DPP-4i SMD
N 7552 7552
Age (SD) 75.42 (5.31) 75.39 (4.73) 0.007
Sex (Male, percent) 44.01 43.39 0.013
Socio-economic status (n, (%)) 0.060
1st to 4th of 11 quantiles 1892 (25.05) 1892 (25.05)
5th to 8th of 11 quantiles 2301 (30.47) 2378 (31.49)
9th to 11th of 11 quantiles 3359 (44.48) 3282 (43.46)
Hypertension 79.61 80.39 0.020
Dyslipidemia 74.13 74.44 0.007
Chronic kidney disease 5.77 5.61 0.007
End-stage renal disease 2.56 2.49 0.004
Any malignancy 12.47 12.27 0.006
Migraine 4.86 4.89 0.001
Asthma 21.93 22.30 0.009
Chronic obstructive pulmonary disease 13.55 13.85 0.009
Connective tissue disease 6.50 6.46 0.002
Atrial fibrillation 4.97 4.67 0.014
Heart failure 8.74 8.91 0.006
Osteoporosis 25.08 25.52 0.010
Cerebrovascular disease
Ischemic stroke 11.30 11.40 0.003
Hemorrhagic stroke 0.91 0.91 <0.001
Transient ischemic attack 3.42 3.34 0.004
Acute myocardial infarction 2.65 2.78 0.008
Other ischemic heart disease 25.20 25.77 0.013
Other heart disease 18.18 18.68 0.013
Peripheral artery disease 1.44 1.44 <0.001
Microvascular complications of diabetes
Neuropathy 10.88 10.58 0.010
Nephropathy 5.79 5.75 0.002
Retinopathy 10.05 10.45 0.013
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Table 1. Cont.
SU DPP-4i SMD
Alcohol use † 3.48 3.15 0.018
Tobacco use † 0.05 0.07 0.005
Obesity † 0.08 0.08 <0.001
Hypoglycemia 2.73 2.32 0.026
Medication use
Anti-diabetic medicine
Metformin 93.98 93.95 0.001
Thiazolidinedione 5.27 5.08 0.008
Alpha-glucosidase inhibitor 15.21 15.39 0.005
Meglitinide 8.33 8.10 0.008
SGLT2i 0.54 0.87 0.039
Insulin 37.45 37.01 0.009
Anti-hypertensive agent
Calcium channel blocker 69.95 70.21 0.005
ACEI 32.56 32.94 0.008
ARB 72.64 72.91 0.006
Beta blocker 47.96 48.34 0.008
Alpha blocker 13.33 13.04 0.009
Diuretics 67.00 66.71 0.006
Aspirin 73.38 73.90 0.012
P2Y12 inhibitor 32.79 32.93 0.003
Warfarin 5.95 5.55 0.017
Other antiplatelet 25.73 25.45 0.006
NOAC 3.30 3.63 0.018
Lipid-lowering agent
Statin 72.22 73.20 0.022
Fibrate 15.28 15.04 0.007
Ezetimibe 7.79 8.00 0.008
Data are presented as frequencies or means (SD). † Confirmed by diagnosis code (International Classification of
Diseases, 10th revision). Less than 0.1 (10%) in absolute value of standardized mean difference (SMD) between
groups was considered negligible. The mean (SD) standardized difference of all covariates was 1.04% (1.03%). ACEI,
angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor antagonists; DPP-4i, dipeptidyl peptidase-IV
inhibitor; NOAC, novel oral anticoagulant; SD, standard deviation; SGLT2i, sodium-glucose co-transporter 2
inhibitor; SMD, standardized mean difference; SU, sulfonylurea.
3. Results
The cohort comprised 18,445 new SU users and 7754 new DPP-4i users, for a total of 12,833
person-years. After propensity score matching, 7552 pairs remained. The mean follow-up period of
the matched pairs was 1361.9 days. Approximately 94, 37, and 15% of patients were already prescribed
metformin, insulin, and alpha-glucosidase inhibitors, respectively. Table 1 lists the other baseline
characteristics of the matched pairs. The standardized differences of all variables were less than 10%,
and the mean standardized difference was 1.04% (1.03%). Thus, the baseline characteristics of the
matched pairs were well adjusted.
During the study period, 565 patients had newly developed dementia, among whom 367 had
Alzheimer’s disease and 54 vascular dementia. When dementia was defined by diagnosis codes, the
risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (Figure 2A and
Table 2; hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.56–0.78; p < 0.001). Additionally, the
risk of Alzheimer’s disease was significantly lower in the DPP-4i group (Figure 2B, Table 2; HR 0.64;
95% CI 0.52–0.79; p < 0.001). The DPP-4i group also had a lower risk, albeit non-significant, of vascular
dementia (Figure 2C, Table 2; HR 0.66; 95% CI 0.38–1.14; p = 0.14). Furthermore, when dementia was
defined using both diagnosis codes and medications, similar trends were observed; that is, the DPP-4i
group also had a lower risk of all-cause dementia and Alzheimer’s disease (Figure 2D–F and Table 2;
HR 0.54; 95% CI 0.40–0.73; p < 0.001 for all-cause dementia, HR 0.54; 95% CI 0.39–0.75; p < 0.001 for
Alzheimer’s disease, HR 0.46; 95% CI 0.14–1.46; p = 0.18 for vascular dementia).
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Figure 2. Kaplan-Meier plots for dementia-free survival in new users of DPP-4i and SU. (A–C) Dementia
was defined by diagnosis codes; all-cause dementia (A), Alzheimer’s disease (B), vascular dementia
(C). (D–F) Dementia was defined by both diagnosis codes and medications; all-cause dementia (D),
Alzheimer’s disease (E), and vascular dementia (F). DPP-4i, dipeptidyl peptidase-4 inhibitor; N, number
of patients; SU, sulfonylurea; y, year(s).
Table 2. The risk of dementia in DPP-4i use compared with SU use.
N Events HR Lower CI Upper CI p-Value
Event defined with diagnosis codes
All-cause dementia 15,104 565 0.66 0.56 0.78 <0.001
Alzheimer’s disease 15,104 367 0.64 0.52 0.79 <0.001
Vascular dementia 15,104 54 0.66 0.38 1.14 0.14
Event defined with diagnosis codes and medication
All-cause dementia 15,104 184 0.54 0.40 0.73 <0.001
Alzheimer’s disease 15,104 164 0.54 0.39 0.75 <0.001
Vascular dementia 15,104 14 0.46 0.14 1.46 0.18
CI, 95% confidence interval; DPP-4i, dipeptidyl-peptidase IV inhibitor; HR, hazard ratio; N, number of patients;
SU, sulfonylurea.
Subgroup analyses were performed to determine whether age, sex, and DM complications
influenced the protective effect of DPP-4i against dementia (Table 3). DPP-4i use was significantly
associated with a lower risk of dementia in males and females. DPP-4i use was associated with a lower
risk of dementia in patients aged ≥75 years (HR 0.61; 95% CI 0.50–0.76; p < 0.001) but not in those
aged <75 years (HR 0.77; 95% CI 0.58–1.03; p = 0.08), compared to SU use. Patients without diabetic
microvascular complications had a significantly lower HR for dementia in the DPP-4i group compared
to the SU group (HR 0.64; 95% CI 0.52–0.78; p < 0.001). Among patients with diabetic microvascular
complications, DPP-4i use was not significantly associated with an improvement in dementia (HR 0.74;
95% CI 0.53–1.03; p = 0.07). However, compared with SU use, DPP-4i use was associated with a lower
risk of dementia irrespective of diabetic macrovascular complications.
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Table 3. Subgroup analyses according to sex, age, and presence of diabetic microvascular or
macrovascular complications.
N Events HR Lower CI Upper CI p-Value
Male 6601 202 0.60 0.45 0.80 <0.001
Female 8503 363 0.69 0.56 0.85 <0.001
Patients aged ≥75 years 7662 376 0.61 0.50 0.76 <0.001
Patients aged <75 years 7442 189 0.77 0.58 1.03 0.08
Patients with
DM microvascular complication 3418 144 0.74 0.53 1.03 0.07
Patients without
DM microvascular complication 11686 421 0.64 0.52 0.78 <0.001
Patients with
DM macrovascular complication 5487 227 0.67 0.51 0.87 0.003
Patients without
DM macrovascular complication 9617 338 0.65 0.52 0.81 <0.001
CI, 95% confidence interval; HR, hazard ratio; N, number of patients; DM, diabetes mellitus.
4. Discussion
This population-based study demonstrated that use of DPP-4i was associated with a 34% lower
risk of all-cause dementia compared with use of SUs in older patients with type 2 diabetes. Indeed,
DPP-4i use was related to a significantly lower risk of Alzheimer’s disease, but not vascular dementia,
compared with SU use.
To our knowledge, this is the first report that DPP-4i use is associated with a lower risk of dementia
in older patients with type 2 diabetes. Our cohort was large and representative of the Korean senior
population, enabling propensity score-matched analyses. We also used a new-user design with a
one-year washout period to reduce the bias inherent in retrospective nonrandomized comparative
effectiveness studies.
Insulin resistance and impaired insulin signaling due to chronic hyperglycemia in the brain
may induce hyperphosphorylation of tau protein and accumulation of amyloid-β protein, which are
hallmarks of Alzheimer’s disease [8,16]. In addition, cerebrovascular diseases such as stroke, which
are prevalent in diabetes, are closely associated with the development of vascular dementia and the
progression of Alzheimer’s disease. Because there are interactions between diabetes and dementia
and there is no curative treatment for dementia, the effects of antidiabetic medications on cognitive
function are of interest.
Our findings support previous reports of a neuroprotective effect of DPP-4is. Research has
shown that in human neurons, linagliptin alleviates amyloid-β-induced impaired insulin signaling
and neurotoxicity [17]. Long-term sitagliptin treatment attenuated memory impairment and reduced
inflammation, nitrosative stress, and amyloid-β protein and amyloid precursor protein accumulation
in the brains of transgenic mice with Alzheimer’s disease [18]. Vildagliptin and sitagliptin reversed
mitochondrial dysfunction in the brain by decreasing mitochondrial reactive oxygen species production
and insulin signaling, and improved the learning and memory deficits induced by high-fat-diet
consumption [19,20]. In addition, sitagliptin treatment improved memory impairment in mice fed
a high-fat diet by enhancing hippocampal neurogenesis and reducing oxidative stress [21]. In a
streptozotocin-induced rat model of Alzheimer’s disease, saxaglitpin and vildagliptin decreased
amyloid-β deposition and tau phosphorylation by increasing hippocampal glucagon-like peptide-1
levels, which reversed the cognitive deficits [11,12]. However, DPP-4is reportedly increases the risk of
Alzheimer’s disease by aggravating tau phosphorylation and insulin resistance in the hippocampus
and primary neurons of OLEF (Otsuka Long-Evans Tokushima Fatty) rats [22].
Few clinical studies have addressed the association between DPP-4is and cognitive function in
type 2 diabetic patients. In a prospective pilot study, 10 older patients with type 2 diabetes treated
with vildagliptin together with metformin exhibited no cognitive decrements after a 1-year follow
up [23]. Furthermore, some previous studies have shown that DPP-4i not only protects against
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cognitive impairment, but also acts as a cognitive enhancer. Rizzo et al [24]. reported that DPP-4is
improved cognitive function compared with SUs, independently of sustained chronic hyperglycemia
and glucose variability, in 240 older patients with type 2 diabetes and mild cognitive impairment. In
addition, sitagliptin treatment for six months was associated with an increase in the Mini-Mental State
Examination score (independent of the change in HbA1c level) compared with metformin treatment in
older diabetic patients with or without Alzheimer’s disease [25]. These results suggest that DPP-4is
could be a cognitive enhancer or protect against cognitive impairment while also functioning as an
anti-diabetic agent, which may explain its effects on the risk of dementia. However, these studies
had limitations due to a small sample size and short duration of follow-up. The current results are
consistent with previous clinical research that reported the beneficial effects of DPP-4is on cognitive
function. As our study included a large older population with type 2 diabetes (mean age 75 years)
who had a high risk of dementia in a real-world clinical setting, we believe that these findings provide
evidence of the protective effects of DPP-4i on the incidence of dementia.
DPP-4i use was associated with a lower risk of Alzheimer’s disease, but not vascular dementia,
compared with SU use. This finding implies that the efficacy of DPP-4is varies among the types of
dementia. Meta-analyses of three large cardiovascular outcome trials of DPP-4i (the SAVOR-TIMI
53, EXAMINE, and TECOS trials) as well as a pooled analysis of small randomized clinical trials
showed no significant difference in the risk of stroke between DPP-4i and placebo treatments [26].
Considering these neutral effects of DPP-4i on the risk of stroke, which is a predisposing factor for
vascular dementia, DPP-4is may not protect against vascular dementia.
In our subgroup analysis, the association between DPP-4i use and a decreased risk of dementia
was not evident in patients aged <75 years or in those with diabetic microvascular complications.
Although DPP-4i use was related to a lower risk of dementia in subjects with and without diabetic
macrovascular complications, the association was weaker in those with diabetic macrovascular
complications. Therefore, the protective effect of DPP-4is against dementia may be greater in older
patients and those without diabetic complications.
This study had several limitations. This study was a retrospective analysis, and the claims
database lacked information on patient medical histories (most notably, DM duration and body mass
index (BMI)), education, lifestyle variables, and laboratory measurements (such as HbA1c); therefore,
confounding factors may have influenced the results. Randomized clinical trials on how DPP-4is
affects the incidence of dementia are needed to confirm our results. The ongoing CAROLINA-cognition
sub-study is exploring whether DPP-4is are superior to SUs in terms of preventing cognitive decline in
patients with type 2 diabetes [27]. Additionally, we calculated the incidence of dementia according to
diagnosis codes; thus, discrepancies between the medical diagnosis and the diagnosis in the claims
data may have reduced the accuracy of the analysis [28]. According to a previous study reporting
the accuracy of dementia diagnosis code in Medicare claims data in regard to clinically-diagnosed
dementia, the sensitivity and specificity of dementia diagnosis codes in the claims database were 0.85
and 0.89, respectively [29]. When we performed additional survival analyses for dementia defined by
both diagnosis codes and prescriptions for dementia, the results showed similar trends. In particular,
patients with mild cognitive impairment are less detectable in retrospective observational studies
performed using claims databases. Finally, only Koreans were analyzed in this study; therefore, caution
should be used when generalizing our results to other ethnicities.
In conclusion, compared with SU use, DPP-4i use was associated with a lower risk of dementia
in older Koreans with type 2 diabetes. Further research in other populations using dementia as an
endpoint is needed to further assess the neuroprotective effects of DPP-4is.
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Abstract: Background: Glucose is one of the constituents in hemodialysates and peritoneal dialysates.
How the dialysis associates with the incident diabetes mellitus (DM) remains to be assessed. Methods:
The claim data of end-stage renal disease (ESRD) patients who initiated dialysis from and a cohort of
matched non-dialysis individuals from 2000 to 2013 were retrieved from the Taiwan National Health
Insurance Research Database to examine the risk of incident DM among patients on hemodialysis
(HD) and peritoneal dialysis (PD). Predictors of incident DM were determined for HD and PD
patients using Fine and Gray models to treat death as a competing event, respectively. Results: A total
of 2228 patients on dialysis (2092 HD and 136 PD) and 8912 non-dialysis individuals were the study
population. The PD and HD patients had 12 and 97 new-onset of DM (incidence rates of 15.98 and
8.69 per 1000 patient-years, respectively), while the comparison cohort had 869 DM events with the
incidence rate of 15.88 per 1000 patient-years. The multivariable-adjusted Cox models of Fine and
Gray method showed that the dialysis cohort was associated with an adjusted hazard ratio (HR) of
0.49 (95% CI 0.39–0.61, p value < 0.0001) for incident DM compared with the comparison cohort. The
adjusted HR of incident DM was 0.46 (95% CI 0.37–0.58, p value < 0.0001) for HD and 0.84 (95% CI
0.47–1.51, p value = 0.56) for PD. Conclusions: ESRD patients were associated with a lower risk of
incident DM. HD was associated with a lower risk of incident DM, whereas PD was not.
Keywords: burnt-out diabetes; chronic kidney disease (CKD); dialysis; end-stage renal disease
(ESRD); incident diabetes mellitus (DM); insulin resistance
1. Introduction
The increasing prevalence of chronic kidney disease (CKD) has a global impact on healthcare
management and socioeconomic systems worldwide. Similarly, the prevalence of diabetes mellitus
has also been trended high in the general population, especially in the obese and aging [1]. Both of
these two entities share many common cardiovascular morbidities and may influence each other in an
enhancing manner.
Uremia occurs as a result of enormous retention of various substances when the kidney function is
worsening progressively. The acceptable renal replacement therapy includes hemodialysis (HD),
peritoneal dialysis (PD), and kidney transplant. Glucose is used as one of the constituents in
hemodialysates and peritoneal dialysates [2,3]. Thus, one may expect the higher incidence rate
of diabetes mellitus (DM) for dialysis patients owing to the more glucose uptake from the dialysate.
However, the epidemiological data on the association of glucose load with incident DM have concluded
contradictory results [4,5].
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Insulin resistance (IR) is one of the key determinants in the development and progression of
DM. IR has existed across all the CKD spectrums and gets exacerbated with the deterioration of
renal function as uremia toxins contribute to IR [6,7]. Metabolic acidosis, even of a slight degree, can
suppress insulin release and induce IR in CKD [8]. Once non-DM end-stage renal disease (ESRD)
patients undergo dialysis treatment, the reduction of uremia toxin and alleviation of metabolic acidosis
by dialysis may partially alleviate the degree of IR, thus mitigating the diabetic risk. DM is the leading
cause of ESRD worldwide and about 40% of ESRD patients were attributed to diabetic nephropathy [9].
How the dialysis associates with the incident diabetes remained to be assessed. Taiwan has the highest
prevalence and incidence rates of ESRD in the world. Therefore, we conducted a retrospective national
cohort study using the Taiwan National Insurance Research Database (NHIRD) to compare the risk of
incident DM between ESRD patients undergoing PD or HD and non-dialysis patients. In addition, we
also determined the risk factors associated with incident DM.
2. Materials and Methods
2.1. Data Source and Study Population
This nationwide retrospective study was conducted using the data retrieved from the Longitudinal
Health Insurance Database (LHID), which was randomly selected from the Taiwan National Health
Insurance Research Database (NHIRD) and contained the entire claim data for one million beneficiaries.
The Taiwan NHIRD was released by the Taiwan National Health Research Institute for scientific
research. The Taiwan National Health Insurance (NHI) program has been launched since 1995 and all
citizens are enrolled in the program, except prisoners, with a coverage rate of >99%. Therefore, The
Taiwan NHIRD can represent the utilization conditions of medical resources for the 23 million residents
and is one of the largest databases universally. The NHI adopted the International Classification of
Diseases-9th revision, Clinical Modification (ICD-9-CM) for medical payments applications. Patients
with ESRD who underwent dialysis treatments will be issued a related catastrophic illness card and the
copayment was waived. The Bureau of NHI audits the computerized claim data for medical expenses
regularly and those contracted institutions with improper charges or malpractice will face heavy
penalties, thus ensuring accurate medical coding. Many high-quality researches have been published
using the Taiwan NHIRD [10–12]. This study was exempted from informed consents because the
personal identification data were encrypted and transformed in the NHIRD. The Institution Review
Board of Changhua Christian Hospital reviewed and approved all the study proposals.
2.2. Study Design
This study was conducted using the inpatient and outpatient claim data from the LHID from 1996
to 2013. Patients who were at the age of 18–100 years and had started maintenance dialysis therapy for
at least 90 days between the periods from 2000 to 2013 were enrolled in the dialysis cohort. The date of
the first ESRD diagnosis was referred to as the index date. Patients who had undergone dialysis for
ESRD from 1996 to 1999, received kidney transplant before the index date, type 2 DM before the index
date or type 1 DM throughout the entire period, or incomplete demographics were excluded. Dialysis
patients were further categorized as PD and HD groups according to their initial dialysis modality.
The reference non-dialysis cohort was recruited from the same dataset with four controls matched to
each one dialysis patient by age, gender, and the index year after excluding enrollees with CKD, ESRD,
or renal transplant throughout the study period or DM before the index date. Follow-up data for the
cohorts was reviewed from the index date until the date of incident DM, the end of 2013 or censored
due to death, whichever occurred first.
2.3. Definition of ESRD, DM and Other Comorbidities
The inpatient and outpatient reimbursement data from LHID were linked to define the baseline
demographic features and clinical conditions for both cohorts. Individuals were having any
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comorbidity if they fulfilled the following rules: One diagnostic code at discharge or at least two
diagnostic codes in outpatient claims. To minimize the accidental miscoding in the outpatient
reimbursement data, the diagnosis from outpatient encounters also required that the first and last
diagnoses within one year were at least 30 days apart. ESRD on dialysis was ascertained from the
catastrophic illness certificates with the code 585. DM was diagnosed only when there were both DM
codes (ICD-9 code 250) and the use of anti-diabetic agents.
Aside from demographic data (e.g., sex, age, and residency area), we also collected information
about comorbidities and drug treatments from the LHID. The baseline comorbidities included
hypertension (ICD-9 codes 401–405), ischemic heart disease (ICD-9 codes 410–414), congestive
heart failure (CHF) (ICD-9 code 428), cerebrovascular disease (ICD-9 codes 430–438), rheumatoid
disease (ICD-9 codes 446.5, 710.0–710.4, 714.0–714.2, 714.8, 725.x), gout (ICD-9 code 274), and
chronic obstructive pulmonary disease (ICD-9 codes 491, 492, 496). We also obtained information
on pharmacotherapy regarding statins, anti-hypertensive drugs, analgesics, and glucocorticoids for
multivariate adjustment.
3. Statistical Analysis
Summary descriptive data were shown as mean ± standard deviation (SD) and frequency with
percentage for continuous and categorical covariates, respectively. The distributions of variables
between the case cohort and matched reference cohort were compared using Student’s test, or
Mann-Whitney test and the Chi-square test or Fisher’s exact test, as appropriate.
The outcome of interest in this study was incident DM event. The incidence rate was calculated
as the number of new-onset DM cases divided by the follow-up time and expressed as the number
of events per 1000 person-years for the dialysis and comparison groups. As death, a competing
risk for the development of incident DM, was censored, we ran the Fine and Gray competing risk
models with hazard ratio (HR) and 95% confidence interval (CI) to compare the DM risk between the
cohorts. We also compared the risk of mortality (non-DM death), death without DM, between the
cohorts. The association was further examined by stepwise cause-specific Cox proportional hazard
models with SLENTRY = 0.15 and SLSTAY = 0.15. The HRs of incident DM for dialysis cohort versus
comparison cohort were adjusted for all the baseline variables. The propensity score was calculated by
logistic regression analysis and was used to adjust in the Cox regression model to reduce bias from
unmeasured confounding factors. Four levels of sensitivity tests was performed as (1) adjusted for
propensity score; (2) kidney transplant as a censored covariate; (3) change of renal replacement therapy
as a time-dependent covariate; and (4) change of dialysis mode or kidney transplant as a censored
event. The associations were also assessed in subgroups stratified by gender, age, income, and the
number of medical visits in one year after study entry. Risk factors for incident DM were determined
in the entire study population, comparison cohort and ESRD dialysis cohort, respectively. Statistical
analyses were done using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY,
USA). A two-sided p-value was set to < 0.05 with statistical significance.
4. Results
4.1. Patients’ Baseline Characteristics
The enrollment flowchart was depicted in Figure 1, demonstrating that after the matching
processes a total of 2228 dialysis cases (2092 HD; 136 PD) and 8912 control cases were recruited
from 2000 to 2013 for the analysis. The differences of the baseline patient characteristics between the
dialysis and comparison cohorts were compared in the Table 1. As expected, the ESRD dialysis cohort
had more medical visits, higher prevalence of most comorbidities, and higher proportion of patients
taking medication than the comparison cohort.
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Figure 1. Flowchart of patient selection processes for the end-stage renal disease (ESRD) cohort and
the comparison cohort.
4.2. Prevalence of Incident DM and Mortality Rate in the Dialysis and Comparison Cohorts
During the follow-up period of around five–six years, the dialysis cohort had lower rate of DM and
higher death rate compared to the comparison cohort (4.89% vs. 9.75%, p value < 0.001 for DM; 30.12%
vs. 14.03% for death, p value < 0.001, Table 1). The cumulative incidence rate of DM was significantly
lower in the dialysis cohort than in the comparison cohort, while the mortality rate was higher in the
dialysis cohort than in the comparison cohort (Figures 2 and 3; log-rank test, p value < 0.001 and p
value < 0.001, respectively). The PD and HD patients had 12 and 97 DM events (incidence rates of 15.98
and 8.69 per 1000 patient-years, respectively), while the comparison cohort had 869 DM events with
the incidence rate of 15.88 per 1000 patient-years (Table 2). The multivariable-adjusted Cox models of
Fine and Gray method showed that dialysis cohort was associated with an adjusted HR of 0.49 (95%
CI 0.39–0.61, p value < 0.0001) for incident DM compared with the comparison cohort. The reduced
diabetic risk in dialysis cohort was attributed to the lower diabetogenic effect of HD (adjusted HR 0.46,
p value < 0.0001) rather than that of PD (adjusted HR 0.84, p value = 0.56). The significant associations
were also consistently found when running stepwise Cox models. Regarding mortality, PD, and HD
cohorts had significantly higher mortality risk in both Cox models.
4.3. Sensitivity Analysis
Table 3 showed the results of the four sensitivity analyses to corroborate the previous models.
In all assessments, a significant negative correlation between dialysis patients and DM events
further confirmed the finding that dialysis is a protective factor in the development of DM. HD was
significantly associated with a reduced risk of incident DM compared to the comparison cohort, while
the risk between PD and comparison cohort did not differ in the four sensitivity analyses. Regarding
non-DM death, dialysis cohort was associated with higher mortality risk than the comparison cohort.
4.4. Association of Dialysis with Incident DM Stratified by Sex, Age, Year of Enrollment, Numbers of Medical
Visits, and Economic Incomes
Dialysis cohort was associated with a lower risk of incident DM than the comparison cohort in
all the subgroup analyses, while a significantly higher mortality risk was seen in the dialysis cohort
(Table 4).
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Figure 2. Cumulative incidence rate of diabetes mellitus between the end-stage renal disease (ESRD)
cohort and the comparison cohort (p-value < 0.001, Log-rank test).
 
Figure 3. Cumulative incidence rate of mortality between the end-stage renal disease (ESRD) cohort
and the comparison cohort (p-value < 0.001, Log-rank test).
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Table 1. Baseline characteristics and clinical outcomes between the dialysis and comparison cohorts.
No. of Patients
Frequency Matched by Age, Gender, Index Year (1:4)
p-Value
ESRD Dialysis Patient Comparison Cohort
2228 8912
Demographics
Age 60.29 ± 16.43 60.29 ± 16.43 1.000
Gender, Male 1096 (49.19%) 4384 (49.19%) 1.000
The year of diagnosis
2000 223 (10.01%) 892 (10.01%) 1.000
2001 122 (5.48%) 488 (5.48%) 1.000
2002 138 (6.19%) 552 (6.19%) 1.000
2003 139 (6.24%) 556 (6.24%) 1.000
2004 159 (7.14%) 636 (7.14%) 1.000
2005 168 (7.54%) 672 (7.54%) 1.000
2006 176 (7.9%) 704 (7.9%) 1.000
2007 159 (7.14%) 636 (7.14%) 1.000
2008 167 (7.5%) 668 (7.5%) 1.000
2009 157 (7.05%) 628 (7.05%) 1.000
2010 172 (7.72%) 688 (7.72%) 1.000
2011 162 (7.27%) 648 (7.27%) 1.000
2012 174 (7.81%) 696 (7.81%) 1.000
2013 112 (5.03%) 448 (5.03%) 1.000
Geographic location
Northern Taiwan 958 (43%) 3846 (43.16%) 0.912
Central Taiwan 428 (19.21%) 1643 (18.44%) 0.418
Southern Taiwan 796 (35.73%) 3208 (36%) 0.832
Eastern Taiwan and islands 46 (2.06%) 215 (2.41%) 0.372
Monthly income, NTD 14,054.51 ± 13,083.05 14,383.13 ± 13,818.97 0.310
Number of medical visits in 1 year after study entry 35.62 ± 19.28 26.34 ± 18.42 <0.001
Pre-existing comorbidities
Hypertension 1757 (78.86%) 6986 (78.39%) 0.628
Gout 473 (21.23%) 1337 (15%) <0.001
Ischemic heart disease 400 (17.95%) 1373 (15.41%) 0.003
Congestive heart failure 430 (19.3%) 835 (9.37%) <0.001
Cerebrovascular disease 181 (8.12%) 691 (7.75%) 0.561
Chronic obstructive pulmonary disease 297 (13.33%) 1051 (11.79%) 0.047
Rheumatoid disease 83 (3.73%) 280 (3.14%) 0.165
Charlson’s comorbidity index score 3.95 ± 1.84 2.55 ± 1.84 <0.001
Long-term medication use
Anti-hypertensive drugs 1563 (70.15%) 5419 (60.81%) <0.001
ACEIs/ARBs 1085 (48.7%) 3418 (38.35%) <0.001
Diuretics 873 (39.18%) 2306 (25.88%) <0.001
Beta-blockers 946 (42.46%) 3219 (36.12%) <0.0001
NSAIDs 231 (10.37%) 737 (8.27%) 0.002
Analgesic drugs other than NSAIDs 320 (14.36%) 875 (9.82%) <0.001
Statin 437 (19.61%) 1186 (13.31%) <0.001
Corticosteroid 245 (11%) 499 (5.6%) <0.001
Outcome
New-onset DM 109 (4.89%) 869 (9.75%) <0.001
Death 671 (30.12%) 1250 (14.03%) <0.001
Follow-up time (years) 5.35 ± 3.92 6.14 ± 3.95 <0.001
Values are expressed as mean ± SD or number (percentage). Abbreviations: ACE inhibitor, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, Non-Steroidal Anti-Inflammatory Drug; NTD, New
Taiwan Dollar.
4.5. Risk Factors for Incident DM among Dialysis Patients
We further determine the contributing factors to incident DM in the study population (Table 5).
Among the entire study population, the factors contributing to the occurrence of incident DM consisted
of hypertension, gout, and the user of statins with the presence of hypertension having the greatest risk
being adjusted HR of 1.95 (95% CI 1.62–2.35, p value < 0.0001). The risk factors were not exactly the
same among the whole study population, dialysis population and comparison population. In dialysis
cohort, age was the only contributing factor for incident DM with an adjusted HR of 1.02 (1.01–1.04).
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5. Discussion
To the best of our knowledge, our study is the first one using a representative nationwide data,
to quantify the incidence rate of DM in patients undergoing dialysis compared with a non-dialysis
reference cohort. Strikingly, ESRD patients were associated with a lower risk of incident DM (aHR 0.49;
95% CI 0.39–0.61, p < 0.0001), which was attributed to HD (aHR 0.46; 95% CI 0.37–0.58, p < 0.0001),
not to PD (aHR 0.84, 95% CI 0.47–1.51, p = 0.56). The contributors to incident DM in the entire study
cohort included hypertension, gout, and the use of statins.
Our findings were consolidated by the following reasons. First, we attempted to mitigate the
impact of different patient’s characteristics distributions on the measured outcomes in the study cohorts
by adjusting the propensity scores. Second, all established confounding factors for DM, including age,
gender, comorbidities, and some pharmacotherapies were adjusted in competing- risk Cox models,
and thus these covariates could not explain the reduced risk of incident DM in relation with dialysis.
Third, the number of medical visits was also adjusted in the multivariate Cox models, so the detection
bias, possibly caused by more frequent visits in dialysis patients, was minimized. Fourth, in our study,
ESRD is, as expected, to associate to higher mortality risk, but surprisingly relate to lower incident DM
risk when compared with non-ESRD. One may attribute those observations of our study to the higher
death rates occurring in the ESRD patients, thus preventing them from developing DM. In order to
resolve this issue, Fine and Gray method of competing risk analysis was chosen in our investigation,
which more substantiated our findings.
The practice of dialysis procedures is very complex and various aspects related to dialysis per se
and patients have different or even oppose effects on the pathogenesis of DM. Most of the available
data suggested the liability of ESRD patients to develop DM. For example, intake of foods with
high glycemic index is believed to predispose to postprandial hyperglycemia and higher insulin
levels. The results from epidemiological studies on glycemic load in association with incident DM were
contradictory. Villegas et al. reported that high intake of foods with a high glycemic index and glycemic
load, especially rice, may increase the risk of type 2 DM in Chinese women, but this association was
not found in the Whitehall II study [4,5]. Regardless, two meta-analyses, one of prospective cohort
studies and the other of retrospective studies, reported a positive association of both dietary glycemic
index and glycemic load and risk of type 2 DM [13,14]. The glucose content in the dialysate is another
source of caloric supply in the dialysis patients. Based on our findings, the association between ESRD
and incident DM could not be solely explained by glucose load.
Tremendous contributors to the development of DM have been identified with IR being
one of the most important factors. IR exists in every stage of CKD and the etiologies are
multifactorial, including vitamin D deficiency, erythropoietin deficiency, uremia milieu, inflammation,
and hyperparathyroidism [15]. In addition, many comorbid factors, not related to CKD itself,
contributing to IR, include old age, obesity, dyslipidemia, and hypertension, and so forth. IR has
been shown to increase in ESRD patients, but dialysis treatment was reportedly capable of alleviating
resistance. Using the euglycemia hyperinsulinaemic glucose clamp technique, Kabayashi et al. reported
that both HD and PD can improve IR observed in uremia milieu [6]. Similar findings were also
documented by Satirapoj et al. who reported decreased IR after five weeks of HD and PD in the same
patient group [16]. However, no significant difference was found between predialysis and dialysis
groups in a later investigation [17]. Therefore, once CKD patients do not develop DM before reaching
ESRD, dialysis treatments may have positive effects on IR, thus reducing the incident DM risk.
Of the risk factors for type 2 DM, increasing body weight has been reported to one of the most
important contributors to impaired glucose tolerance or even type 2 DM. Body mass index (BMI)
was the greatest contributor among the three covariates (age, race/ethnicity, BMI) to the increase
in diabetes prevalence after adjustments in a study of five NHANES involving 23,932 participants
aged 20 to 74 years [18]. The nutritional parameters showed a longitudinal decline with dialysis
vintage in dialysis patients. In an analysis of 17,022 patients commencing PD or HD, the BMI trajectory
changed in a non-linear fashion, where mean BMI initially decreased, followed by increment and then
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stabilization at three years [19]. Afterwards, it dropped gradually. The protein-energy wasting (PEW)
in ESRD patients on dialysis is caused by uremic toxins, inadequate dietary intake due to anorexia,
and inflammation, and is closely associated with mortality [20]. Therefore, PEW or malnutrition may
contribute to both lower incidence rate of DM and higher mortality rate. However, we did not have
the BMI values for the present study.
Patients with DM and CKD have been found to require reduced or even discontinued of
antidiabetic medication with the progression of CKD, initiation of dialysis therapy and gradual
loss of residual renal function with time [21]. “Burnt-out diabetes” refers to the situation where
diabetic patients can attain appropriate glycemic control, e.g., HbA1C < 6%, without any antidiabetic
agents. A great number of mechanisms contributing to this phenomenon consist of loss of dietary
intake due to diabetic gastroparesis and uremia, diminished renal and hepatic clearance of insulin
with prolongation of insulin half-life, impaired renal gluconeogenesis, protein-energy wasting,
disrupted counter-regulation of hypoglycemia, imposed dietary restriction, and hypoglycemia effects
of dialysis [22,23]. Burnt-out diabetes was reported in 20.7% and 5.4% of Japanese diabetic patients
undergoing HD by using glycated hemoglobin and glycated albumin, respectively [21]. Therefore,
considering these effects underlying “burnt-out diabetes” on glucose homeostasis among non-diabetic
patients at the initiation of dialysis, dialysis procedure per se might prevent those from developing DM.
In dialysis modalities (HD or PD), no consistent conclusion was drawn on which one is preferable
to the other in terms of clinical outcomes. Typically, uremic toxins and excessive fluid have been
removed intermittently in HD and continuously in PD. While higher inflammation was observed
in oxidative stress and IR in ESRD, the influence of PD and HD on them were not exactly the
same. Initiation of dialysis can improve IR and glucose tolerance. However, glucose load and
absorption was also different. Glucose load is continuous in the PD patients throughout the day,
whereas approximately 15–25 g of glucose may be removed during HD with the net absorption of
glucose determined by the concentration of glucose-containing hemodialysates [24,25]. The glucose
concentrations used to achieve appropriate ultrafiltration range from 1360 to 3860 md/dL and the
glucose load delivered by PD can be as much as 10% to 30% of a patient’s total energy intake [26,27].
Burnt-out diabetes was only evidenced in HD, not in PD. Therefore, the effects of PD and HD on the
occurrence of incident DM were different and the reduced risk of DM was only documented for HD.
CKD was shown to complicate IR, mainly due to post-receptor defect of insulin action, and may
be prone to the development of incident DM in some reports. The aim of our study was to address
whether the dialysis per se would increase or reduce the incidence of DM, so those pre-dialysis CKD
patients developing DM in their CKD period ahead of ESRD requiring dialysis were excluded from
our case cohort. We proposed that the remaining ESRD patients without developing DM in the CKD
period may have some protective factors in the environmental and genetic aspects that mitigate the
pro-diabetic tendency. Those protective factors may continue or even amplify once they progress to
ESRD. This can partially explain why ESRD was associated with a lower risk of incident DM, although
their influence cannot be comprehensively addressed in this study.
As with other nationwide studies using Taiwan NHRID, there are several limitations in our
study. First, some known contributing factors to incident DM, such as body mass index, physical
activity, family history of DM, smoking, alcohol consumption, quantity and quality of sleep and dietary
patterns, were not available in the NHRID. Those factors usually lead to cardiovascular comorbidities,
which were controlled in our study, so we believe the bias caused by un-adjustment of those factors
could be minimized. Second, four types of peritoneal dialysis solution (PDS) have been available
in Taiwan: (1) The conventional glucose-based PDS; (2) neutral- pH PDS with low concentration of
glucose degradation products; (3) icodextrin-based PDS; and (4) amino acid- containing PDS [28]. Many
studies reported that biocompatible PDS led to less inflammation as compared to bio-incompatible
PDS. Long-term online hemodiafiltration with ultrapure solution reportedly caused less inflammation
via enhanced clearance of middle molecules than low-flux hemodialysis [29]. We cannot compare the
influence of the four types of PDS and these two HD modes on glucose homeostasis due to technical
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limitations. Third, the number of patients on PD was relatively small, which may lead to the over-
or underestimation of incident diabetic risk with PD. Therefore, the risk of diabetes in PD should be
interpreted with caution. Fourth, the lack of laboratory data in our study is one limitation of NHRID.
However, in order to avoid mis-coding problems, the use of DM’s ICD-9 code and anti-diabetic drugs
is a prerequisite for diagnosing DM to improve diagnostic accuracy.
In conclusion, this study highlights the significant reduction in the risk of developing diabetes in
patients undergoing dialysis and this association was attributed to HD rather than PD. In addition to
Cox models of Fine and Gray’s method, stepwise cause-specific hazard models and sensitivity tests
further corroborated this paradoxical relationship. Large-scale prospective studies on the underlying
mechanisms of this phenomenon are urgent.
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Abstract: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the
developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD
was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers. However, this strategy only partially covered the DKD progression.
Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed.
In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and
glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms
of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients.
In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression
and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors,
has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part,
the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic
experimental models suggest that these drugs may exert their reno-cardiovascular protective effect
by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated
strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change
diabetes management algorithms.
Keywords: diabetes; diabetic kidney disease; reno-cardiovascular protection; sodium-glucose
co-transporter 2 inhibitors; glucagon-like peptide-1 receptor agonists; dipeptidyl peptidase 4 inhibitors
1. Introduction
Diabetic kidney disease (DKD) is the first cause of chronic kidney disease, leading to premature
death and end-stage renal disease (ESRD) in the developed and developing world. In response,
multiple potential therapeutic agents have been tested, focusing on the treatment of hyperglycaemia
and hypertension, mainly directed at the renin-angiotensin system blockade [1–4]. However, these
therapies only partially delay the progression of DKD to ESRD, so there is an urgent need for additional
effective treatments. In this context, sodium-glucose co-transporter 2 (SGLT2) inhibitors and the
glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently emerged as new potential strategies
for both diabetic type 2 and 1 patients [5–7].
The SGLT2 is expressed in the proximal tubule of the kidneys and is responsible for 90% of renal
glucose reabsorption. SGLT2 inhibitors promote the urinary excretion of glucose and, consequently,
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lower blood glucose levels. Interestingly, these drugs scarcely provoke hypoglycaemia, as their effect
is not related to beta cell function or modifications in insulin sensitivity [8]. SGLT2 inhibitors were
first approved by the U.S. Food and Drug Administration (FDA) in 2013 for patients with type 2
diabetes, and the first study that demonstrated their beneficial effects in terms of delaying DKD
progression was published in 2016 [5]. Glucagon-like peptide-1 (GLP-1) is an endogenous incretin
peptide released from intestinal L cells in response to ingested nutrients. GLP-1 is rapidly inactivated
by the enzyme dipeptidyl-peptidase-4 (DPP-4) and cleared by the kidneys. GLP-1 stimulates pancreatic
insulin synthesis and insulin secretion in a glucose-dependent manner, slows gastric emptying,
inhibits glucagon release, and promotes satiety. GLP-1 receptor agonists are structurally similar to
GLP-1 but resist dipeptidyl peptidase 4 (DDP-4) degradation [8]. Exenatide was the first GLP-1RA
approved by the FDA in 2005 for patients with type 2 diabetes, and in 2016, liraglutide was the first
that demonstrated beneficial effects in terms of decreasing albuminuria [9]. DPP-4 inhibitors are
a class of oral hypoglycaemics that block the DPP-4 enzyme and subsequently neutralise several
incretin peptides, including the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 [8].
Thus, DPP-4 inhibitors increase GLP-1 and reduce blood glucose by inhibiting glucagon release and
stimulating insulin secretion. Sitagliptin was the first DPP-4 inhibitor approved by the FDA in 2006,
followed by linagliptin, saxagliptin, and alogliptin. More recently, in 2019, linagliptin demonstrated
beneficial effects in reducing the progression of albuminuria in DKD [10].
In this review, we describe the new strategies for reno-cardiovascular protection in patients with
type 2 diabetes and their potential mechanisms. We cover the most important studies focused on the
renoprotection exerted by SGLT2 inhibitors, GLP-1RAs, and DPP-4 inhibitors in DKD patients.
2. Classical Pharmacological Reno-Cardiovascular Approaches in Diabetes
Patients with diabetes have a higher prevalence of cardiovascular morbidity and mortality
compared to the general population [11]. It is well known that diabetes is associated with accelerated
atherosclerosis, affecting the coronaries, which increases the risk for myocardial infarction, heart failure,
and may cause diabetic cardiomyopathy independent of coronary artery disease, hypertension, and
valvular complications [12]. According to some authors, during the early stages of diabetes, there is an
increase in plasma renin activity, mean arterial pressure, and renal vascular resistance [13], suggesting
that renin-angiotensin-aldosterone system (RAAS) activation plays a major role in the development of
cardiovascular disease (CVD) [14]. Therefore, angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin II receptor blockers (ARB) have been, for many years, the first line therapy for secondary
CVD prevention in patients with diabetes [15].
In the late 80’s to early 90’s, an ACEi, enalapril, demonstrated its effectiveness in reducing
mortality in patients with heart failure [16,17]. Later, the heart outcomes prevention evaluation (HOPE)
trial included subjects with high cardiovascular risk, such as diabetic patients, and demonstrated that
another ACEi, ramipril, significantly reduced the rates of death, myocardial infarction, and stroke
in patients with vascular disease or diabetes [14]. Similarly, the losartan intervention for endpoint
reduction (LIFE) trial showed that Losartan was more effective than Atenolol in reducing cardiovascular
morbidity and mortality in patients with hypertension, diabetes, and ventricular hypertrophy [17].
In 2001, two seminal studies demonstrated the nephroprotective effect of RAAS blockades in patients
with type 2 diabetes [2,3]. A subsequent metanalysis supported the use of ACEi in patients who have
diabetic kidney disease (DKD) with significant albuminuria [18]; however, the beneficial effect of RAAS
inhibition as a primary prevention in diabetic patients has not been demonstrated. The beneficial
effect of RAAS blockade in patients with advanced chronic kidney disease (estimated glomerular
filtration rate (eGFR) < 30 mL/min/1.73 m2) is unknown, given the fact that those patients have been
systematically excluded from clinical trials [1,19].
After the previously mentioned results, and based on preliminary studies demonstrating an
added effect on decreasing albuminuria with a dual RAAS blockade [18], later research was focused
on studying the effect of the combination of ACEi and ARB in high risk DKD patients [20]. During
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this period, the ongoing telmisartan alone and in combination with ramipril global endpoint trial.
(ONTARGET) evaluated whether the combination of an ACEi (ramipril) with an ARB (telmisartan)
was better than the full dose of either drug. This study showed that there was no superiority of the
ACEi versus the ARB and that the dual blockade did not confer greater cardiovascular protection.
Moreover, the combination of ACEi and ARB increased the risk of adverse events, namely hyperkalemia,
hypotensive symptoms, and the over declined eGFR, more than monotherapy [20]. Similar results were
obtained from the aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE), which
compared the effect of a direct renin inhibitor aliskiren to placebo in high-risk type 2 diabetic patients
on top of an ACEi or an ARB. The ALTITUDE trial, just like the ONTARGET study, demonstrated
that the simultaneous administration of aliskiren with an ACE inhibitor or an ARB should be avoided.
The study was halted early because an increased incidence of hypotension, hyperkalemia, renal
complications, and non-fatal stroke (HR = 1.25; 95% CI 0.98–1.60; p = 0.07) was observed in the
aliskiren arm during the follow-up of approximately 2.7 years [21]. Consequently, Novartis (Basel,
Switzerland) immediately suspended all promotional and educational programs related to aliskiren
and its combinations.
3. Reno-Cardiovascular Protection of SGLT2 Inhibition
SGLT2 inhibitors enhance renal glucose excretion by inhibiting renal glucose reabsorption in the
renal proximal tubule. Consequently, SGLT2 inhibitors reduce plasma glucose in an insulin-independent
manner and improve insulin resistance in diabetes [22]. SGLT2 inhibitors were shown to reduce glycated
haemoglobin (HbA1c) by approximately 0.6%–1.2%, with a lower rate of hypoglycaemia [23]. Four
recent major trials have shown that SGLT2 inhibitors are superior to other anti-diabetic medications in
the prevention of cardiovascular events and renal protection [5,24–26]. The empagliflozin cardiovascular
outcome event trial in type 2 diabetes mellitus patients (EMPA REG OUTCOME ) was the first clinical
trial examining the effects of empagliflozin compared to placebo on cardiovascular morbimortality in
patients with type 2 diabetes and at a high risk for cardiovascular events [27]. EMPA REG included
7020 patients, all of them with established cardiovascular disease and an eGFR ≥ 30 mL/min/1.73 m2,
randomly assigned to receive empagliflozin at −10 or 25 mg or a placebo on top of standard care.
Death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke was decreased
in the empagliflozin group (10.5%) compared to the placebo group (12.1%) (HR 0.86; 95% CI 0.74–0.99;
p = 0.04). Interestingly, this benefit was higher in older patients (>65 years) and with HbA1c ≤ 8.5%.
Empagliflozin more significantly decreased cardiovascular death (3.7% vs. 5.9%) and death from any
cause (5.7% vs. 8.3%) compared to placebo (HR 0.62; 95% CI 0.49–0.77; p < 0.001 and HR 0.68; 95% CI
0.57–0.82, p < 0.001), as well as hospitalization for heart failure (HR 0.65; 95% CI 0.50–0.85; p = 0.002).
HbA1c levels were similar in both groups. In contrast, in previous studies, empagliflozin was associated
with a decrease in HbA1c levels in patients with type 2 diabetes [28,29]. In the EMPA REG study, patients
receiving empagliflozin showed a decrease in weight, waist circumference, uric acid level, blood
pressure, and increased cholesterol levels. 2250 out of 7020 patients (32%) included in the EMPA REG
OUTCOME trial had chronic kidney disease (eGFR < 60 mL/min/1.73 m2 and/or macroalbuminuria) [5],
and 1896 patients (27%) presented microalbuminuria and eGFR ≥ 60 mL/min/1.73 m2. Treatment
with empagliflozin showed benefits in terms of incident or worsening nephropathy (12.7% vs. 18.8%
in placebo group) (HR 0.61; 95% CI 0.53–0.70; p < 0.001) and progression to macroalbuminuria
(11.2% vs. 16.2%) (HR 0.62; 95% CI 0.54–0.72; p < 0.001). Patients receiving empagliflozin demonstrated
a decrease in the doubling of serum creatinine compared to the placebo group (HR 0.56; 95% CI
0.39–0.79; p < 0.001), as well as a lower rate of renal replacement therapy initiation (0.3% vs. 0.6%)
(HR 0.45; 95% CI 0.21–0.97; p = 0.04) (see Table 1). eGFR decreased in the empagliflozin group within
the first weeks of treatment, but at the end of follow up, eGFR remained stable with empagliflozin
compared to a decrease in the placebo group [30].
The Canvas Program studied the cardiovascular and renal effects of canagliflozin (100 mg or
300 mg) versus placebo in 10,142 type 2 diabetic patients with a previous history of cardiovascular
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disease or two or more cardiovascular risk factors and eGFR > 30 mL/min/1.73 m2. The mean eGFR was
76.5 ± 20.5 mL/min/1.73 m2; 22.6% presented microalbuminuria and 7.6% presented macroalbuminuria.
Canagliflozin administration significantly decreased HbA1c levels, as well as blood pressure and body
weight. In the canagliflozin group, deaths from cardiovascular cause, non-fatal myocardial infarction,
and non-fatal stroke were significantly decreased by 14% (26.9 vs. 31.5 patients, with an event per 1000
patient-years) [24]. Regarding renal outcomes, canagliflozin reduced the risk of the composite outcome
of a sustained 40% reduction in eGFR, renal replacement therapy initiation, and death from renal
causes. Canagliflozin reduces albuminuria progression (HR 0.73; 95% CI 0.67–0.69), and the regression
of albuminuria occurred more frequently in canagliflozin treated patients (HR 1.7; 95% CI 1.51–1.91).
The dapagliflozin effect on cardiovascular events (DECLARE-TIMI 58) evaluated the effects of
dapagliflozin (SGLT2 inhibitor) versus placebo on cardiovascular and renal outcomes in patients who
had, or were at risk for, cardiovascular disease. Eligible patients were older than 40 years old, had type
2 diabetes, a history of cardiovascular disease or more than two classical cardiovascular risk factors,
and an eGFR ≥ 60 mL/min/1.73 m2. The study included 17,160 patients, 40.6% with cardiovascular
disease and 59.4% with multiple cardiovascular risk factors. The mean eGFR was 85.2 mL/min/1.73 m2
and only 7% of patients had an eGFR <60 mL/min/1.73 m2. Dapagliflozin significantly decreased
HbA1c levels, body weight, and blood pressure [25]. There were no differences in cardiovascular
death, myocardial infarction, and ischemic stroke between the two groups. Dapagliflozin reduced
the risk of this composite outcome by 17% due to a significantly lower rate of hospitalization for
heart failure in the dapagliflozin group (HR 0.73; 95% CI 061–0.88). It also reduced the composite
renal outcome (a decrease of 40% or more in eGFR, end-stage renal disease, or death from renal
or cardiovascular cause) risk by 24% (HR 0.76; 95% CI 0.67–0.87). Interestingly, the renoprotection
observed with dapagliflozin was independent of the presence of established CVD [25].
The renoprotective effect of SGLT2 inhibition has become evident in the last 3 years. However,
until now its use has been limited to patients with eGFR > 45 mL/min/1.73 m2 (Table 2). A recent paper
published by Vlado Perkovic clearly demonstrated the beneficial effect of canagliflozin in patients
with moderate–advanced DKD (CREDENCE trial) [26]. This trial studied the effect of canagliflozin
compared to placebo in patients with eGFR= 30–90 mL/min/1.73 m2 and a urinary albumin-to-creatinine
ratio > 300–5000 mg/g creatinine, receiving a stable dose of an ACE or ARB. It included 4401 patients
with a mean eGFR of 56.2 mL/min/1.73 m2 and a mean albumin-to creatinine ratio of 927 mg/g. Of note,
31% of patients had an eGFR < 45 mL/min/1.73 m2. The trial was halted early because the number
of primary outcome events in the placebo group required to trigger analysis was reached sooner
than estimated. Canagliflozin decreased the risk of end-stage kidney disease, doubling of the serum
creatinine level, or renal or cardiovascular death by 30% compared to placebo [26]. Patients in the
canagliflozin group also showed a 30% reduction in the risk of cardiovascular death or hospitalization
for heart failure (HR 0.69; 95% CI 0.57–0.83; p < 0.001), a 20% reduction of cardiovascular death,
myocardial infarction or stroke (HR 0.80; 95% CI 0.67–0.95), and a 29% reduction of hospitalization
for heart failure (HR 0.61; 95% CI 0.47–0.80). Canagliflozin group showed a decreased eGFR slope
compared with the placebo group (−3.19 ± 0.15 vs. −4.71 ± 0.15 mL/min/1.73 m2 per year), which
means a difference of 1.52 mL/min/1.73 m2 per year. Rates of adverse events were similar in both
groups. In conclusion, the use of canagliflozin in type 2 diabetic patients with established kidney
disease on top of renin-angiotensin system blockade was safe and decreased the risk of kidney failure
and cardiovascular events [26].
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4. Reno-Cardiovascular Protection of GLP1 Receptor Agonists
GLP-1RAs are glucagon-like peptide-1 (GLP-1) molecule analogues. GLP-1 is an incretin secreted
by intestinal enteroendocrine L-cells in response to food intake, which increases insulin secretion in
a glucose-dependent manner [31]. GLP-1 Ras have been shown to improve glycaemic control and
reduce glycated haemoglobin (HbA1c) by approximately 1%–1.5% in short-term treatments with a
lower rate of hypoglycaemia [9,32]. The reduction of hypoglycaemic events is important in diabetic
patients with chronic kidney disease (CKD), where GLP-1RAs have proven to be safe while many other
antihyperglycemic drugs require dose adjustment as insulin or are simply contraindicated (Table 2).
These new drugs have also been shown to reduce weight during treatment, which seems to be a class
effect and an interesting outcome when it comes to treating overweight type 2 diabetic patients [9,32–34].
However, their most significant impact is that GLP-1RAs were demonstrated to reduce major adverse
cardiovascular events (MACEs), liraglutide, semaglutide, and albiglutide [9,33,35], and delay DKD
progression liraglutide, semaglutide, and dulaglutide [6,32,33].
In the liraglutide effect and action in diabetes: evaluation of CV outcome results (LEADER) trial,
Liraglutide was shown to decrease three-point MACEs and death from cardiovascular causes in a
3.8 year follow-up when compared to the placebo added to standard care (HR 0.87; 95% CI 0.78–0.97;
p < 0.001) [9]. Moreover, death from any cause was lower in the Liraglutide group and, although there
were no statistically significant differences in the occurrence of myocardial infarction or stroke between
both groups, there was a trend toward a reduced incidence of both events. In the subgroup analyses,
these protective effects were more evident in patients with kidney disease and an eGFR rate below
60 mL/min/1.73 m2, as well as in patients with cardiovascular disease at baseline. In concordance,
semaglutide also reduced the MACE composite outcome when compared to placebo during a follow-up
period of 2.1 years in the trial to evaluate cardiovascular and other long-term outcomes with semaglutide
in subjects with type 2 diabetes (SUSTAIN-6) (HR 0.74; 95% CI 0.58–0.95; p < 0.001) [33]. There was
a significant reduction in the incidence of non-fatal stroke and a non-significant trend for a lower
incidence of non-fatal myocardial infarction in the semaglutide group. However, and in contrast to
the results displayed in the LEADER trial, the rates of death from cardiovascular causes, and death
from any cause, were similar in both groups. This could be, in part, explained by the larger number
of patients recruited in LEADER and the longer observation time. In the randomized, double-blind,
placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with
type 2 diabetes mellitus (HARMONY), albiglutide also reduced the incidence of three-point MACEs
compared to placebo during a follow-up of 1.6 years (HR 0.78; 95% CI 0.68–0.90; p < 0.0001) [35]. This
decrease was mainly driven by a reduction in the incidence of myocardial infarction, but rates of stroke
and death from cardiovascular causes were similar in both treatment groups.
Conversely, other GLP-1RAs did not demonstrate clear cardiovascular benefits. In the evaluation
of lixisenatide in acute coronary syndrome (ELIXA) trial, lixisenatide exhibited non-inferiority when
compared to a placebo added to standard care during a 25 month follow-up in patients with established
cardiovascular disease, but did not reduce the incidence of the composite cardiovascular outcome [36].
Nonetheless, all patients included in the ELIXA were at high cardiovascular risk, with a recent previous
history of myocardial infarction or unstable angina, while 81.2% of patients in LEADER had established
cardiovascular disease, without previous ischemic heart disease [9], and 60.5% in SUSTAIN-6 [33], and
71% of patients in HARMONY [35] had a previous history of ischemic heart disease. Another trial, the
exenatide study of cardiovascular event lowering (EXSCEL), showed a non-significant trend to reduce
the incidence of three-point MACEs compared to placebo, where 73.1% of the trial population had
previous cardiovascular disease [34].
When it comes to evaluating the renoprotective effects of GLP-1RAs, trials usually examine a
composite outcome of new-onset persistent macroalbuminuria, persistent doubling of serum creatinine,
end-stage renal disease, or death due to renal causes. A secondary renal outcome analysis of LEADER
showed a reduced incidence of this composite outcome in patients receiving liraglutide (HR 0.78;
95% CI 0.67–0.92; p = 0.003) [6]. This reduction was mainly driven by a lower incidence of persistent
183
J. Clin. Med. 2019, 8, 864
macroalbuminuria, but there were no differences in the doubling of serum creatinine, end-stage renal
disease, or death due to renal causes between the groups. New-onset microalbuminuria incidence was
lower in the treated group. The effect of Liraglutide appeared to be independent in a subgroup analysis
by baseline albuminuria or eGFR. A slightly slower decline of eGFR was also observed in the treated
group. In the SUSTAIN-6 trial, semaglutide also reduced the secondary composite renal outcomes
of new or worsening nephropathy (HR 0.64; 95% CI 0.46–0.88; p = 0.005) [33]. Recently, secondary
renal outcomes analysis of the dulaglutide versus insulin glargine in patients with type 2 diabetes
and moderate-to-severe chronic kidney disease (AWARD-7) trial revealed that dulaglutide therapy in
patients with moderate-to-severe CKD (stages 3 and 4) reduced the glomerular filtration rate decline
in the short-term when compared to insulin glargine during a 1 year follow-up [32]. This finding
was especially significant in participants who seemed to have a more severe disease with a baseline
urine albumin-to-creatinine ratio (UACR) higher than 300 mg/g. In addition, albuminuria reduction
was more pronounced in this subgroup (AWARD-7). Interestingly, the AWARD-7 is an randomized
clinical trial (RCT), where dulaglutide was compared to insulin glargine, and both treatments were
combined with insulin lispro. There were little to no differences in glycaemic control between groups,
which may indicate that protective renal effects could be mediated by other mechanisms related to this
pharmacological class [32]. Whether cardiovascular protection is a class effect or a specific outcome
of certain GLP-1RAs is still controversial and future trials like the dulaglutide and cardiovascular
outcomes in type 2 diabetes (REWIND) will give us more information on this matter. Furthermore,
although it seems that GLP-1RAs exert renoprotective effects, specific trials should be designed to
evaluate this aspect.
5. Combination of SGLT2 Inhibitors and GLP1 Receptor Agonists in Diabetes
Despite their promising cardiovascular and renal protective effects, there are still very few trials
that verify the positive outcomes of SGLT2 inhibitors and GLP-1RAs used in combination. In the
randomized controlled trial 104-week results—once-weekly exenatide plus once-daily dapagliflozin
vs. once-weekly exetanide or dapagliflozin alone (DURATION-8), patients with type 2 diabetes
inadequately controlled by metformin were randomly assigned to receive exenatide plus dapagliflozin,
exenatide alone, and dapagliflozin alone [37]. During a 28 week follow-up, there was a significant
reduction of HbA1c in the combined therapy, compared to exenatide or dapagliflozin, and a considerably
higher proportion of patients achieved a glycated haemoglobin ≤7%. Exenatide plus dapagliflozin also
exhibited a significant weight reduction compared to dapagliflozin or exenatide alone, and systolic
blood pressure (SBP) reduction was slightly higher in the combined treatment. It is worth mentioning
that no episodes of hypoglycaemia were described and only one case of ketoacidosis was reported in the
exenatide group. In the dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately
controlled type 2 diabetes (AWARD-10) trial, two different doses of dulaglutide (0.75 or 1.5 mg) or
placebo were assigned to patients previously receiving SGLT2 inhibitors with or without metformin [38].
Dapagliflozin and empagliflozin were the most used SGLT2 inhibitors during the 24 week follow-up. A
higher proportion of patients in both dulaglutide groups also achieved the goal of HbA1c ≤ 7%. Only
the dulaglutide dose of 1.5 mg provided a significant weight and SBP reduction when compared to
placebo. Similar to DURATION-8, the reported adverse effects were mainly gastrointestinal and were
more frequently described with high doses of dulaglutide. There were no differences in hypoglycemic
events between groups, and the described rates were low. In another recent trial, the superior efficacy
of insulin degludec/liraglutide vs. insulin glargine (IGlar U100) as add-on to SGLT2 inhibitors ± oral
antidiabetic drug therapy in patients with type 2 diabetes (DUAL IX) trial, patients already receiving a
SGLT2 inhibitor with or without other oral antidiabetic drugs were randomized to be treated with
an injectable combination of insulin degludec and liraglutide (IDegLira) or insulin glargine (IGlar)
alone [39]. After 26 weeks of treatment, the group receiving IDegLira had a significant reduction in
HbA1c compared to IGlar (treatment difference −0.36%; 95% CI −0.5, −0.21; p < 0.0001). However, no
changes in body weight were found with the IDegLira treatment. Hypoglycaemic episodes, although
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were rarely described, were more frequent when compared to the rates displayed in DURATION-8
and AWARD-10, which may be related to the addition of insulin.
Considering the evidence, the combination of the SGLT2 inhibitor and GLP-1RAs has proven to be
safe and well tolerated. The rates of adverse effects are similar to those described in monotherapy and
of a mild to moderate intensity. Hypoglycaemic episodes were barely described, although no trials have
evaluated their safety in populations with established chronic kidney disease, where there is a higher
risk of antidiabetic treatment related hypoglycaemia. Greater reductions of HbA1c, body weight, and
blood pressure were observed in combined treatments. Despite these results, cardiovascular outcomes
and/or DKD progression with add-on therapy have not been analyzed in the previous trials. Therefore,
more studies are needed to evaluate these events.
6. Potential Nephroprotective Mechanisms of SGLT2 Inhibitors and GLP1 Receptor Agonists
Blood glucose level and the reduced blood pressure produced by SGLT2 inhibitors and GLP-1RAs
have undeniable beneficial effects in terms of cardio-renal protection. However, other independent
pathways have also been described and may potentially be relevant to explain their renoprotective
effects. Both drugs have natriuretic properties that produce hemodynamic effects on the kidneys. In
healthy subjects, glucose and sodium (Na+), among other metabolites and electrolytes, are reabsorbed
by the tubular cells, mainly in the proximal portion (98% of the total glucose and 67% of the Na+).
Glucose is absorbed together with Na+ by sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2)
located at the apical membrane of the tubular cells. Although both transporters are expressed in
the tubular cells, the major part of the glucose (90%) is reabsorbed by SGLT2 [40,41]. Na+ is further
reabsorbed by other transporters, of which the Na+/H+ exchanger isoform 3 is the most important
(NHE3) [42]. Glucose is transported to the blood stream by the glucose transporters (GLUT) -mainly
GLUT2- [40,41] and Na+ via the Na+/K+ ATPase [42], both located at the basolateral membrane
of the tubular cells. This active transport of glucose and Na+ contributes importantly to glucose
homeostasis and to the maintenance of the intraglomerular tone. In diabetic patients, due to glomerular
hyperfiltration, glucose and Na+ levels are increased in the lumen of the tubules. In response, the
tubular reabsorbing mechanisms are upregulated both by an increase in the activity or expression of
the transporters mentioned above [43] and by a translocation of GLUT2 to the apical membrane [44,45].
Therefore, glucose and Na+ blood levels rise, contributing to hyperglycaemia and hypertension. In
addition, the enhanced reabsorption in the proximal tubule, decreases Na+ flow to the distal tubule
and activates the macula densa. Both SGLT2 inhibitors and GLP-1RAs increase natriuresis, leading to
the restoration of the tubuloglomerular feedback, which results in afferent arteriole vasoconstriction
and, finally, in a reduction of the intraglomerular pressure. SGLT2 inhibitors have a more important
natriuretic effect than GLP-1RAs, most probably related to the direct blockade of the tubular Na+
uptake mediated by SGLT2 and/or the impairment of the Na+/H+ exchanger isoform 3 (NHE3) activity,
which is glucose-dependent and seems to be indirectly blocked by SGLT2 inhibition [46] (see Figure 1).
It has recently been described that treatment with empagliflozin decreases NHE3 expression in the
kidneys of diabetic otsuka long-evans tokushima Fatty (OLETF) rats, as well as the expression of
Na+-K+-2Cl− cotransporters and epithelial Na+ channels, when compared to untreated littermates,
suggesting that SGLT2 modulates the Na+ reabsorption of several tubular transporters [47]. GLP-1RAs
only seem to decrease NHE3 activity [48–50], a fact that would explain the difference in the natriuretic
potential of these two drugs [51]. It is unclear whether GLP-1RAs inhibit NHE3 activity through
interaction with the GLP-1 receptor or extrarenal mechanisms, such as the renin–angiotensin system or
atrial natriuretic peptide modulation [52,53].
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Figure 1. Mechanisms of glucose reabsorption and intraglomerular pressure control in healthy
individuals and in diabetic patients. (A) In healthy individuals, approximately 90% of glucose is
reabsorbed by SGLT2 that is located at the apical membrane of the proximal tubular cells and transported
back to the blood stream by the basolateral glucose transporter 2 (GLUT2) transporter. Na+ is reabsorbed
by the apical transporters SGLT2 (with glucose) and the Na+/H+ exchanger isoform 3 (NHE3) and
returned to the circulation via several basolateral Na+ transporters: sodium bicarbonate transporters,
Na+ channels, and the Na+/K+ ATPase. Tubular glucose and Na+ reabsorption mechanisms contribute
to glucose homeostasis and glomerular tone control thanks to the tubuloglomerular feedback controlled
by the macula densa. (B) In diabetic patients, glucose and Na+ reabsorption mechanisms are increased
secondary to the hyperfiltration. This fact contributes importantly to the hyperglycaemia and raises the
intraglomerular pressure. (C) Both SGLT2i and GLP-1RAs produce natriuresis that leads to a decrease
of the glomerular pressure. In the case of SGLT2 inhibitors, the natriuretic effect is due to the direct
blockade of SGLT2 and the collateral inhibition of NHE3, which has an SGLT2 dependent activity.
Regarding GLP-1RAs, these drugs impair only NHE3 activity by an unknown mechanism. Moreover,
SGLT2 inhibition contributes to blood glucose level control. : Basolateral Na+ transporters.
Interestingly, SGLT2 inhibitors and GLP-1RAs probably have other effects on the kidneys,
independent of the glycaemic control and the natriuresis produced by both drugs. As mentioned
before, SGLT2 is clearly expressed in the tubular compartment [54]. However, the glomerular cells
can also express SGLT2 under protein overload conditions [55], suggesting that this transporter can
be upregulated in a non-diabetic context. In addition, SGLT2 is overexpressed in human tubular
cells in a culture (HK-2) treated with transforming growth factor beta 1 (TGF-β1). In this model, the
effects of TGF-β1 are reverted by empagliflozin most probably by nuclear factor kappa B/toll-like
receptor 4 (NF-κB/TLR4) pathway inhibition [56]. Moreover, non-diabetic murine and rat models
of kidney injury have shown that treatment with SGLT2 inhibitors decreases kidney fibrosis and
inflammation markers [55,57,58]. In a similar way, GLP-1RAs seem to have beneficial effects on the
kidneys beyond natriuresis. In a high-fat-diet-induced obesity mice model with renal impairment,
liraglutide treatment likely protected subjects from kidney injury through lipid and mitochondrial
metabolism regulation via the sirtuin/AMP-activated protein kinase/peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (Sirt1/AMPK/PGC1α) pathways [59]. The results obtained in
diabetic and non-diabetic experimental models using SGLT2 inhibitors and GLP-1RAs clearly highlight
the possibility that these drugs have a direct protective effect on the kidneys.
7. Current Role of DPP-4 Inhibitors in Patients with Type 2 Diabetes and CKD
The indications for Dipeptidyl Peptidase 4 Inhibitors in patients with type 2 diabetes and CKD
have been analyzed over the last 10 years. In early 2010, diverse studies involving a small number
of patients demonstrated the safety and efficacy of an adjusted dose of vildagliptin in patients with
advanced CKD in hemodialysis and peritoneal dialysis [60,61]. In agreement with these studies, clinical
trials performed with alogliptin and sitagliptin demonstrated the safety and efficacy of these DPP-4
inhibitors in type 2 ESRD patients receiving dialysis [62,63]. Later studies by Laakso et al. showed
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that no dose adjustment was needed when linagliptin was used in patients with moderate to severe
renal impairment [64]. Drug dosage adjustments based on renal function of the currently available
DPP-4 inhibitors are depicted in Table 2. Three important randomized clinical trials assessed the
protective effect of DPP-4 inhibitors on renal functions. The first published study, the saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes mellitus (SAVOR-TIMI 53) trial, demonstrated
that treatment with saxagliptin was associated with a reduction in UACR compared with placebo
(median observation time, 2.1 years) in patients with T2D at a high cardiovascular risk with diverse
baseline renal characteristics, including a substantial number of patients with renal dysfunction and/or
albuminuria. Interestingly, decreased UACR in saxagliptin-treated patients seemed to be independent
of its effect on glycemia. This was observed in patients with normoalbuminuria, microalbuminuria, and
macroalbuminuria, irrespective of their eGFR at baseline. However, the positive effect of saxagliptin
on UACR was not accompanied by a reduction of other renal outcomes [65]. The second study, the
linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and
renal dysfunction (MARLINA-T2D) trial, was aimed at investigating the glycaemic and renal effects
of linagliptin added to the standard-of-care in patients with type 2 diabetes and albuminuria [66].
Previous studies by the same group retrospectively included four completed studies with 217 patients
with type 2 diabetes and prevalent albuminuria, randomized to either linagliptin 5 mg/day (n = 162) or
placebo (n = 55). They found that linagliptin significantly reduced albuminuria from baseline by 28%,
compared to placebo, after 24 weeks of treatment. Of note is that an effect on albuminuria was already
seen after 12 weeks of treatment [67]. In the MARLINA trial, linagliptin improved glycaemic control in
type 2 diabetes patients and those with early stages of diabetic kidney disease but did not improve
renal damage, as estimated using the surrogate endpoint of albuminuria, although significantly more
of the participants in the linagliptin group than those in the placebo group experienced a meaningful
improvement in albuminuria [66]. The last recently published clinical trial, the cardiovascular and
renal microvascular outcome study with linagliptin (CARMELINA) study, aimed to test the long-term
(median observation time, 2.2 years) effect of linagliptin on hard renal outcomes. This study included
adults with type 2 diabetes and high cardiovascular and renal risk (74% of patients had prevalent
chronic kidney disease, 43% had an eGFR below 45 mL/min/1.73 m2, and 15.2% had an eGFR below
30 mL/min/1.73 m2). Linagliptin reduced the progression of the albuminuria category (i.e., a change
from normoalbuminuria to microalbuminuria/macroalbuminuria or a change from microalbuminuria
to macroalbuminuria) by 14% (HR 0.86; 95% CI 0.78–0.95; p = 0.003), although the composite renal
endpoints of sustained ESRD, death due to renal failure, or a sustained decrease of 50% or more were
not different [10].
8. Conclusions
Diabetic kidney disease is the leading cause of premature death and end-stage renal disease in the
developed world. Until 2016, the only treatment that demonstrated to be able to attenuate DKD was
a renin-angiotensin system blockade, either by ACEi or ARB. However, the partial effectiveness of
these agents means that new therapeutic strategies are still needed to delay or prevent progression to
ESRD. In recent years, the reno-cardiovascular safety profile of SGLT2 inhibitors and GLP-1RAs has
been demonstrated [6,9,68–70]. These new drug classes offer reno-cardiovascular protective effects
in diabetic patients. Thus, cardiologist and nephrologists should consider the administration of
SGLT2 inhibitors or GLP-1RAs for renovascular protection in their type 2 diabetic patients. Recent
studies published by endocrinologists, nephrologists and/or cardiologist all recommend the use of
SGLT2 inhibitors or GLP-1RAs as a second line treatment in type 2 diabetic patients when it is not
contraindicated [71–74].
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